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Synthesis and Evaluation of C10 Nitrogenated Aporphine Alkaloids at Serotonin and Dopamine 
Receptors   
by 
Anupam Karki 
Advisor: Dr. Wayne W Harding 
Aporphine alkaloids, belonging to the isoquinoline class of compounds, have been investigated as a 
potential source of ligands for Central Nervous System (CNS) receptors. Previous research indicates that 
the aporphine scaffold may be manipulated to synthesize selective ligands for serotonin and dopamine 
receptors.  Novel aporphine alkaloids containing C10 nitrogen substitutions were synthesized, and their 
affinities were evaluated at serotonin (5-HT1A, 5-HT1B, 5-HT2A, 5-HT7A) receptors and dopamine (D1, D2, D3, 
D4, and D5) receptors. Two series of racemic aporphine compounds with C10 nitrogenous functionalities 
were synthesized and analyzed at the aforementioned receptors.  
 
The first series of aporphine alkaloids contain C10 nitro, amine, amide, and methanesulfonamide motifs. 
Compounds in this C10 monosubstituted series displayed higher affinity at 5-HT1AR and 5-HT7AR and 
lacked affinity at 5-HT1BR and 5-HT2AR.  This series contained compounds with an N6-methyl group and 
compounds with and N6-propyl group. The N6-methyl substituted C10 nitrogen functionalized aporphine 
analogs had higher binding affinities at 5-HT7AR versus 5-HT1AR.  In contrast the N6-propyl sub-set of 
compounds exhibited a reversal of this selectivity. Compound 103a was the most potent compound and 
behaved as an antagonist at 5-HT7AR (Ki = 4.5 ± 0.6 nM, IC50 = 1.25 µM), with 10-fold selectivity over 5-
HT1AR (Ki = 49 ± 6.3 nM). These monosubstituted analogs lacked significant binding among all dopamine 
receptor subtypes. C10 analogs with a benzofused aminothiazole moiety showed higher affinity and 
selectivity for serotonin receptors as compared to the C10 monosubstituted compounds. These compounds 
displayed high binding affinities for 5-HT1AR and 5-HT7AR; analogs containing an N6-methyl substitution 
v 
 
favor binding at 5-HT7AR. Among the benzofused aminothiazole analogs compound 108a had the best 
binding affinity at 5-HT7AR (Ki = 6.5±0.8 nM) and functions as an antagonist (IC50 = 0.26 µM). These 
benzofused aminothiazole analogs also lacked affinity for dopamine receptors. Unlike analogs in the C10 
monosubstituted subset, compounds with the benzofused aminothiazole moiety with an N6-methyl 
substitution displayed moderate affinity for 5-HT1BR.         
 
The second series of compounds contained a C1,2,10-trisusbtitution pattern on the aporphine core. The 
1,2,10-trisusbtituted series of compounds as a group displayed weak binding affinity at 5-HT1AR and 
considerably higher binding affinity at 5-HT1BR. These compounds provided moderate affinity at 5-HT2AR 
and 5-HT7AR. At dopamine receptors, most of the trisubstituted series of compounds failed to show affinity 
towards D5 receptors suggesting a lack of tolerability at D5R receptors for C10 N substituted aporphines 
with moderate to low affinity at D1R, thus attaining D1R versus D5R selectivity. Compound 128e was the 
most potent D1R ligand (Ki = 58 nM) and lacked binding affinity at all other dopamine receptor subtypes.  
 
Compounds 103a, 108a, and 128e have been identified as three new lead compounds with promising 
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GPCRs: Classes, Activation and Subtypes    
 
G-Protein-Coupled Receptors (GPCRs) have an important role in the pathogenesis of various psychiatric 
disorders (e.g. depression, bipolar disorder, schizophrenia) and neurodegenerative diseases (e.g. 
Parkinson’s disease (PD), Alzheimer’s disease (AD))1. GPCRs are localized in the central nervous system 
(CNS) and mediate key physiological processes such as cognition, mood, appetite, and pain. The function 
of GPCRs is regulated by neurotransmitters such as serotonin and dopamine acting as endogenous ligands 
on their respective GPCRs to elicit a myriad of cellular responses. Thus, alteration in the normal function 
of GPCRs in the CNS is responsible for eliciting symptoms shown during psychiatric and neurodegenerative 
disorders.2–5  The well-established interest in GPCRs as drug targets is evident with nearly 30% of currently 
approved drugs targeting GPCRs.6 
 
GPCRs are the largest family of cell membrane proteins. On a fundamental level, all GPRCs contain a 
seven-transmembrane domain (7-TM) forming the core of the structure. The structure of a typical GPCR 
includes seven counterclockwise connected transmembrane α-helixes, extracellular N-terminus and an 
intracellular C-terminus.7 The GPCRs differ among different classes based on their sequence homology 
and functional characteristics (fingerprinting) and are classified into A-F class system. The A-F class system 
(Figure. 1.1) includes GPCRs from both vertebrates and invertebrates. The GPCR classes include: Class 
A) “Rhodopsin-like” Rs; this GPCR family consists of the more than 80 % of currently known GPCRs; B) 
Secretin Receptor family (7 %) ; C) Metabotropic/ Glutamate Receptors (3.8 %) ; D) Fungal mating 
Receptors (0.5 %)  ; E) Cyclic nucleotide Receptors (0.4 %) and F) Frizzled/smoothened Receptors (2.8 
%).7–9 Another system of classification uses phylogenetic relationship and is known as “GRAFS” system; 
Glutamate (G), Rhodopsin (R), Adhesion (A), Frizzled/Taste2 (F), and Secretin (S).  
 
Rhodopsin-like receptors (Class A) are the largest family of GPCRs and are the most targeted GPCRs for 
therapeutic purpose. The rhodopsin-like receptors are distinguishable from others by a short extracellular 
amino terminal and highly conserved hydrophobic residues within each transmembrane helix. Class A 
3 
 
GPCRs are further divided into 19 different sub-families (most prominent sub-families are shown in Figure. 
1).8,10 Analytical studies of class A of GPCRs have shown that regardless of having receptors with different 
architecture, function, and ligand preference there is a common, conserved underlying activation pathway 
that correlates the ligand binding site to G-protein coupling region. This conserved activation pathway is 
mediated by 34 amino acid pairs which upon receptor activation by a ligand connects spatially and 
structurally disconnected but known motifs spanning across the transmembrane structure.2,11,12  
 
 
Activation of heterotrimeric G-protein, with α, β and γ subunits (Figure 1.3), is primarily responsible for the 
signal transduction produced by the rearrangement of receptor protein. Receptor activation facilitates the 
displacement of GDP from the inactive phase of heterotrimer and its subsequent replacement by GTP. 
Conformational changes along Gα produced by exchange of nucleotide leads to disassociation of Gα from 
Figure 1.1: GPCR family tree 
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the βγ-complex; both of these fragments act as secondary messengers for modulation of downstream 
pathways. The βγ-fragments are involved in interactions with intracellular or membrane effectors such as 
ion channels. There are 23 different Gα subunits which have been divided broadly into 4 different families 
based on the primary function produced by them under activation. The first family Gα i/ Gαs modulates 
adenyl cyclase (AC) activity, Gαo activates ERK activity, Gαq activates phospholipase C, and the last family 
Gα12/13 activates small GTPases. Gα subunits also has intrinsic GTPase property with which it hydrolyses 
GTP into GDP, inactivating itself and increasing affinity for βγ-complex.10–12  
 
Figure 1.2: Signaling and classification of G-proteins3 
 
The other and non-canonical mode of signal transduction utilized by GPCRs is through G-independent-
recruitment of β-arrestin protein by the receptor. Initially, the function of β-arrestin was understood to 
modulate signal transduction by internalization of GPCRs after prolonged activation.2 Further research 
provided evidence that β-arrestin also played an important role in signal transduction, ion-trafficking, 
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ubiquitination of receptors, and even mediate nuclear signaling.2,13,14 This new role of β-arrestin has led to 
the concept of ‘biased ligands’, in which different ligands are able to stabilize different receptor 
conformations leading to preference for one pathway versus another by preferentially enabling either G-
protein or β-arrestin signal transduction.  
 
Involvement of GPCRs in different physiological functions has made several sub-classes of rhodopsin-like 
receptors including peptide and amine sub-families a prominent target for therapeutics (Figure 1.4). 
Currently, approximately 70% of FDA approved non-olfactory drugs are targeted towards aminergic 
receptors.6 This immense ‘bulls-eye’ among aminergic subfamily receptors in part is due to the involvement 
of the aminergic receptors in neurological disorders..  Among the sub-subfamily of aminergic receptors, 
serotonin and dopamine receptors have been implicated in depression, dementia, anxiety, obesity, 
addiction, Parkinson’s disease, and Alzheimer’s disease. As such, serotonin, and dopamine receptors are 
important drug targets among GPCRs for treatment of neurological diseases.  
 
       
 
Figure 1.3: Aminergic GPCRs as drug targets15  
 




Serotonin or 5-Hydroxytryptamine (5-HT) is a monoamine neurotransmitter which produces various 
biophysical changes by modulating activity of serotonin receptors localized inside and outside CNS. Inside 
CNS, serotonin receptors are distributed across the forebrain region and have been associated with 
neurological functions including cognition, sleep-wake cycle, thermoregulation, food intake and mood 
regulation.16–19 Outside CNS serotonin receptors are involved in gastro-intestinal movements, platelet 
aggregation and smooth muscle contraction. These neural activities are controlled by different classes of 
serotonin Rs found in different parts of an organism. To date, 7 different families (5-HT1-7) of serotonergic 
receptor have been identified and these are divided into 16 distinct subtypes.4,16,20 The subtypes are defined 
by modes of signal-transduction pathways, sequence homology and pharmacological characteristics of the 
receptors (Table 1-1).21 Except for the 5-HT3 subtype, which is an ion-channel, all other serotonin receptor 
subtypes modulate CNS functions via activation and inhibition of different pathways depending on activation 
of different Gα proteins. The 5-HT1 family activates Gαi/o protein which is responsible for inhibition of cAMP 
production, the 5-HT2 family activates Gαq which in turn activates PLC (phospholipase C), and 5-HT4-7R 
activation proceeds through recruitment of Gαs which activates cAMP production. Along with G-protein 
based pathway, some serotonin receptors also utilize a G-protein-independent β-arrestin pathway for signal 
transduction.20 Elucidated and identified pathways of signal transduction of different subtypes of serotonin 
receptors are mentioned in Table 1-1.4,16,20,22  
 






5-HT1A Gαi/o  Inhibit AC → reduced cAMP → inhibit PKA 
5-HT1B Gαi/o Inhibit AC → reduced cAMP → inhibit PKA 
5-HT1D Gαi/o Inhibit AC → reduced cAMP → inhibit PKA 
5-HT2A 
Gαq/11 Activate PLC → increase IP3 → increased intracellular Ca+, Activate PKC  
β-arrestin  Activate PI3K → activate Src →activate Akt  
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5-HT2B Gαq/11 Activate PLC → increase IP3 → increased intracellular Ca+ 
5-HT2C 
Gαq/11 Activate PLC→ increase IP3→ increased intracellular Ca+, Activate PKC  
β-arrestin Activate Calmodulin → increase ERK signaling 
5-HT4 
Gαs Activate AC → increase cAMP→ activate PKA 
β-arrestin Inhibit Src →reduced ERK signaling 
5-HT5A 
Gαi/o  Inhibit AC → reduced cAMP→ inhibit PKA22 
Gq Activate PLC → increase IP3→ increased intracellular Ca+22 
5-HT6 Gαs Activate AC → increase cAMP → activate PKA 
5-HT7 Gαs Activate AC → increase cAMP → activate PKA 
5-HT3 
Ion channel 




  Serotonin Receptors: Clinical Implications 
 
Serotonin receptors are involved in major neurological pathways and are implicated in the development of 
cognition deficit and neuropsychiatric symptoms shown during Alzheimer’s disease, dementia, and mood 
disorders.1 Several therapeutics have been developed targeting different subtypes of serotonin receptor for 
alleviating symptoms of neuropsychiatric disorders. Examples of serotonin receptor targeting agents that 
have been examined in clinical studies as well as their functional activity and potential therapeutic use are 




Table 1-2: Serotonin subtype ligands and related clinical studies in humans 
Serotonin subtypes and ligands 
Subtype Ligand Function Major clinical implication Ref 
5-HT1A 
8-OH-DPAT Agonist Sleep Disorder 23 
Buspirone Partial Agonist Anxiety 24 
Lecozotan antagonist Alzheimer’s Disease 25 
 
5-HT1B 
Zolmitriptan Agonist Migraine 26 
Sumatriptan Agonist Migraine 27 
 
5-HT1D PNU142633 Agonist Addiction 28 
 
5-HT2A 
Psilocybin Agonist Schizophrenia 29 
Ketanserin Antagonist Hypertension 30 
Sarpogrelate Antagonist Claudication 31 
Nelotanserin Inverse Agonist Insomnia 32 
Pimavanserin Inverse Agonist Parkinson's Disease 33 
 
5-HT2C 
Agomelatine Agonist Major depressive disorder 34 
Lorcaserin Agonist Obesity 35 
 
5-HT3 
Ondansetron Antagonist Motion sickness 36 





Tegaserod Partial Agonist  Constipation 38 
 
5-HT6 Idalopirdine Antagonist Memory Impairment 39 
 
5-HT7 JNJ-18038683 
Antagonist Depression  40 
Antagonist Bipolar Disorder .41 
 
Obtaining ligands that are highly selective (specific) for particular serotonin receptor subtypes is challenging 
due to the structural similarities among receptor subtypes (discussed later).  
 
 5-HT2A Receptor: Currently Available Ligands and Clinical Indications  
 
5-HT2ARs are widely distributed in the CNS. This receptor is mainly localized in cerebral cortex, forebrain, 
olfactory bulb, neocortex, hippocampus, and thalamus regions of the brain. In these regions, 5-HT2ARs are 
responsible for learning and memory, cognition, sleep-wake cycle, and thermoregulation.42–44 This 
extensive localization relates to the implication of 5-HT2ARs in various psychiatric and mental disorders 
such as schizophrenia,45,46 depression,47 anxiety,44 Alzheimer’s disease,17 addiction,43,48 insomnia,49 and 
memory loss.50 Interest in 5-HT2AR antagonists has been ever-growing due to the role of 5-HT2AR in 
development of symptoms in neuropathological diseases. Several non-selective and selective 5-HT2AR 
antagonists have undergone clinical trials towards identification of treatments for schizophrenia, 
Parkinson’s disease, and addiction. 
 





One of the major symptoms shown during etiology of schizophrenia is the development of psychosis. 5-
HT2AR antagonism has shown potential to ameliorate psychosis along with other symptoms. The atypical 
antipsychotic risperidone (1) (Figure 1.4) has been shown to improve negative symptoms of schizophrenia 
through serotonergic antagonism.51–53 Recent clinical trials of another 5-HT2AR antagonist roluperidone (2) 
, demonstrated a novel mechanistic pathway for treatment of schizophrenia by targeting negative symptoms 
and increasing cognitive function in almost all of the participants.54 These two studies with risperidone - a 
5-HT2AR/D2R dual antagonist and roluperidone – a 5-HT2AR / sigma2R dual antagonist together shows the 
importance of 5-HT2AR antagonists in producing anti-psychotic effects. Other atypical antipsychotics used 
to treat schizophrenia such as zotepine (3) have shown similar effectiveness as risperidone in reducing 
agitation of acutely ill schizophrenic patients.51  Perospirone (4), another 5-HT2AR/D2R dual antagonist was 
effective among 75% of participants with schizophrenic in phase II and phase III trial study.55 
 
Figure 1.4: 5-HT2AR ligands with clinical utility for Schizophrenia 
 
Parkinson’s disease: 
Pruvanserin (5, Figure 1.5) , a 5-HT2AR antagonist with high selectivity was able to alleviate prevalent 
dyskinesia and psychosis in primates with Parkinson’s disease56.   Pimavanserin (6), a selective 5-HT2AR 
inverse agonist, in a six-week study, was able to reduce psychosis in 200 adults suffering from Parkinson’s 
disease.33  Ritanserin (7) which is a highly selective 5-HT2A/2CR-dual antagonist was also able to ameliorate 
11 
 
the symptoms of Parkinson’s disease including tremors shown during idiopathic and drug-induced 
parkinsonism.57  
 




Figure 1.6: 5-HT2AR ligands in clinical trials for depression 
 
5-HT2AR antagonism is also implicated in depression. Figure 1.7 lists 5-HT2AR antagonists that have 
undergone clinical evaluations in humans. Although most anti-depressants act on the serotonin transporter 
(SERT), nefazodone (8, Figure 1.6) also has 5-HT2AR antagonism and has shown effectiveness in treating 
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major depression.58 Atypical antipsychotics have 5-HT2A antagonist properties and this feature can 
contribute to their anti-depressant property. For instance, risperidone (1) was able to alleviate psychotic 





Figure 1.7: 5-HT2AR ligands studied for their anti-addiction potential 
 
5-HT2AR has been associated with memory and drug-associated stimuli. Activation of 5-HT2AR is postulated 
to increase drug-seeking behavior and subsequent relapse among abstinent addicts. The highly selective 
5-HT2AR antagonist volinanserin, (9, Figure 1.7), was able to induce lower levels of cocaine-seeking 
behavior under self-administrative condition.48,59 In another study which looked at self-administration of 




5-HT2AR antagonism has been related to sleep-cycle and has been identified as a treatment for insomnia. 
Studies have shown that 5-HT2AR antagonism of mirtazapine (11, Figure 1.8 ) and quetiapine (12) has 
potential to cure insomnia even at low dosage.61 Eplivanserin, (13, Figure 1.8), Pruvanserin (5), Ritanserin 
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(7), and ketanserin,(10 , Figure 1.7), have also been investigated as pharmacotherapies to reduce 
insomnia.32  
 
Figure 1.8: 5-HT2AR ligands studied for their anti-addiction potential 
 
 5-HT7A Receptor: Currently Available Ligands and Clinical Indications 
 
5-HT7 R is one of the newest members of serotonin receptor to be added to subtypes of serotonin receptors. 
There are four isoforms of 5-HT7R and only three isoforms are found in humans: 5-HT7A, 5-HT7B and 5-
HT7C. 5-HT7D is the fourth isoform that has been identified in rat. 5-HT7Rs are most abundant and expressed 
broadly throughout CNS with localization in the hypothalamus and thalamus, cerebral cortex, spinal cord, 
prefrontal cortex, and amygdala. 62–64 5-HT7Rs hence have been implicated in cognition enhancement, 
sleep pattern, circadian rhythm, neuropathic pain, learning and memory and thermoregulation. 5-HT7R 
knockout (KO) experiments conducted on mice have shown mixed results regarding psychiatric disorders; 
the collection of studies is inconclusive as some studies shows the potential role of 5-HT7R in diseased 
state while other doesn’t show significant differences between WT and KO mice models.65–67 Even though 
there are gaps in the exact role of 5-HT7Rs in psychiatric condition, there seems to be a vital function of 5-
HT7Rs in depression,68–70 sleep pattern,66,68,69 cognition66,71–73,40, Alzheimer’s disease,71,74–76 and 




 5-HT7 Receptor Ligands: Clinical Indications 
Neuroprotection:  
 
Figure 1.9: 5-HT7AR agonists and their clinical implications in neuroprotection 
 
5-HT7R agonists are scarcer than antagonists. In a 5-HT7R knockout (KO) study conducted on mice, non-
selective agonist 5-CT was only able to produce significant hypothermic effect than wild-type. This study 
implied that 5-HT7R is involved in producing hypothermic effect.78 5-HT7R agonists have also been 
investigated as neuroprotective agents. Systemic administration of AS-19 (14, Figure 1.9), to rats which 
had drug-induced amnesia (cholinergic and NMDA antagonists) enhanced memory formation in these rats. 
This effect was reversed by SB-269970 but not by 5-HT1AR antagonist showing that 5-HT7R played a role 
in memory formation.75,76 In a separate study AS-19 improved synaptic dysfunctions in a rat model of AD 
through reduction of apoptosis in the hippocampus.74 5-HT7R agonist LP-12, (15, Figure 1.9) was able to 
prevent NMDA induced cell death in hippocampal cells by upregulating PDGFβ expression.79,80 
 
Memory:  
Analysis of the functional profile of non-selective serotoninergic ligands including ritanserin (7), ketanserin 
(10), and clozapine (16, Figure 1.10) at 5-HT7AR expressed in HEK293 cells revealed that these compounds 




Compound SB 258719 (17, Figure 1.10), a 5-HT7AR selective compound from a series of 5-HT7R ligands 
synthesized by Glaxo SmithKline was also analyzed for its functional preference at 5-HT7R. Albeit less 
active than other tested antagonist, SB-258719 (18), displayed partial inverse agonist profile at 5-HT7AR.66 
In a separate study, the role of compound SB-269970 was investigated in relation to working and reference 
memory in rats. The study showed that SB-269970 was able to antagonize 5-HT7AR which improved 
reference memory but did not affect working memory in rats.37 
 








Studies in rat models show that the 5-HT7R antagonism of amisulpride, (19, Figure 1.11), is responsible for 
reduction of cognitive impairment related to stress and schizophrenia.72,73 The only selective 5-HT7R 
antagonist that has been undertaken for clinical study is JNJ-18038683.69,81 JNJ-18038683, (20, Figure 
1.11), is currently being investigated as therapeutic for cognitive impairment shown during bipolar disorder.  
 
Sleep Impairment: 
In a separate clinical study, JNJ-18038683 was also able to increase drug-induced REM sleep suppression 
in humans.40 A clinical study investigating the sleep effects of lurasidone (21, Figure 1.12) on human 
showed that 5-HT7R antagonistic property of lurasidone was able to induce a sleep maintenance effect 
without affecting sleep onset, REM, or slow wave sleep70,82. 
 
Figure 1.12: 5-HT7R antagonist, lurasidone in sleep impairment 
 
There is a scarcity of selective agonists and antagonists for 5-HT7R. The interest in 5-HT7-antagonists is 
evident as blocking or reducing activity of 5-HT7R has shown to improve symptoms and complications 
associated with several neuropsychiatric conditions.  
 
Dopamine Receptors and Function 
 
Dopamine was chemically synthesized in 1910 and first gained acknowledgement as a therapeutic to lower 
blood pressure in 1950. Dopamine receptors gathered more attention during the mid-1960s wherein a 
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correlation between levels of dopamine in the brain and Parkinson’s disease was demonstrated. Dopamine 
is involved primarily in the CNS and is responsible for the regulation of behavior, motor activity, cognition, 
learning and reward.83–86 The activity shown by dopamine is modulated by dopamine Rs which falls under 
the aminergic sub-family of GPCRs.  
 
The mechanisms of signal transduction of dopamine receptors after its activation can be classified into two 
broad pathways. Most prominent among them is the G-protein dependent pathway in which the ligand-
binding site interaction leads to activation of G-proteins, as previously discussed for serotonin Rs. The Gα 
fragment (Gαs and Gαi) modulates activation of PKA by regulating adenyl cyclase (AC) activity.87  The other 
pathway of signal transduction for dopamine receptors is G-protein-independent pathway and consists of 
recruitment of β-arrestin. β-arrestin initiates signal transduction by activation of β-arrestin2-mediated protein 
kinase B (Akt) which in turn activates glycogen synthase kinase (GSK3) to create a downstream signaling. 
Another less understood of signaling by dopamine concerning activation of D1-D2-like heteromeric receptor 
complex, promotes activation of Gαq and/or promote β-arrestin signal transduction pathways.3,14,87 
 







Gαs/olf, Activate AC→ increase cAMP→ activate PKA87–89 
β-arrestin Activate Calmodulin → increase ERK signaling89 
D5 Gαs/olf Activate AC→ increase cAMP→ activate PKA88 
D2 
Gαi/o Inhibit AC→ reduced cAMP→ inhibit PKA87 
β-arrestin Inhibit Akt → inhibit GSK387 
D3 
Gαi/o Inhibit AC→ reduced cAMP→ inhibit PKA87 
β-arrestin Inhibit Akt → inhibit GSK387 
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D4 Gαi/o Inhibit AC→ reduced cAMP→ inhibit PKA87 
  
The development of molecular biology and cloning led to many dopamine receptors being identified and 
classification of dopamine receptors into D1R/D2R classification with reference to sequence homology, 
adenyl cyclase response and pharmacology.85 Dopamine receptors are divided into two main families. D1-
like receptors (D1R and D5R subtypes) function by upregulating adenylyl cyclase increasing the cAMP level 
whereas D2-like dopamine receptors (D2, D3, and D4 subtype) downregulates adenylyl cyclase cause 
reduction of cytosolic cAMP levels (Table 1-4). From a therapeutic perspective there has been more focus 
on D2-like receptors due to its involvement in neuropathological conditions and various psychiatric 
disorders.  
 
 Dopamine Receptors: Clinical Indications: 
 
Dopamine receptors are localized primarily in the CNS and play an active role in a myriad of functions. 
Their dysfunction is evident in the pathophysiology of various neurological disease and psychiatric disorders 
including Parkinson’s disease,90–92 Alzheimer’s disease,84,93,94 schizophrenia,52,95,96 depression,1,87,97 and 
addiction,98,99 among others. As such these dopamine receptors have been targeted for treatment of 
symptoms in various neurological and psychiatric diseases.  Depletion of dopamine levels has been 
implicated as the cause of Parkinson’s disease. The modulation of dopamine receptors has been implicated 
in schizophrenia, where dopamine antagonists have shown to reduce the extent of psychosis and agonists 
to increase psychosis.95 Addiction is directly correlated with dopamine receptors as addictive agents are 
shown to induce rewarding effects by increasing dopamine receptor activation by acting as agonist or via 
increasing dopamine levels through different cellular mechanisms. 100 
Table 1-4: Dopamine receptor subtype, ligands, and related clinical studies in humans 
Dopamine receptor subtypes and ligands 
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Subtype Ligand Function Major clinical implication Reference 
D1/D5 
Fenoldopam Agonist Hypertension  101 
Dihydrexidine Agonist Schizophrenia  95 
 
D2 
Bromocriptine Agonist Parkinson's Disease  102 
Brexpiprazole Agonist Schizophrenia  96 
Haloperidol Antagonist Schizophrenia and Mood disorder  103 
   
D3 
Pramipexole Agonist Parkinson's disease, Bipolar disorder  102,104 
Chlorprothixene Antagonist Schizophrenia  105 
   
D4 Ropinirole Agonist Parkinson’s Disease  90 
 
The involvement of dopamine receptors in various neuropathological disorders has led to discovery and 
usage of various dopamine receptor targeting agents as therapeutics for different disorders. Table (1-4) 
has a list of different ligands and diseases mentioning the same. One of the major issues with most of these 
therapeutics is selectivity. For instance, apomorphine which has been used as a primary therapeutic against 
Parkinson’s disease shows activity at most of the dopamine receptors, Pramipexole has activity on all D2-
like receptors. Offsite binding can lead to side effects such as nausea, vomiting and hypotension.  
  
 D1 Receptor: Clinical Indications: 
 
The localization of two classes of DA receptors - D1-like and D2-like, varies among tissue types and among 
various organisms. Among all the five subtypes, D1R and D2R subtypes are in abundance and have been 
the target of several studies. The D1R subtype is the most widespread and is found mostly in striatum, 
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nucleus accumbens, olfactory bulb, and to a lesser extent in hippocampus and amygdal.87,100,106–110 In the 
CNS, D1Rs have a special role in maintaining higher cognitive functions including working memory, 
attention, and executive functions. Given the role of D1R in various cognitive functions different D1R ligands 
have been investigated for its clinical significance and as therapeutic for neurological disorders including 
Parkinson’s disease,91,111–114 Tourette’s syndrome,115 addiction,99,116 narcolepsy,91,117 Alzheimer’s 
disease,93,94 and Lesch Nyhan syndrome. 118 
 
Parkinson’s Disease:  
 
Figure 1.13: D1R agonists implicated in Parkinson’s disease 
 
D1R have a well-recognized function in working memory.87,94,119 Parkinson’s disease is associated with 
impairment in cognitive function and motor function associated with lower level of dopamine receptor action. 
There is a major interest in dopamine receptor agonists which are able to increase dopamine receptor 
activation as a treatment of PD. In a primate study with drug-induced impairment in cognition and minor 
parkinsonian motor signs, D1-like receptor agonist dihydrexidine, (22, Figure 1.13), was able to improve 
cognition and reduce mistakes during task performance and motor function by increasing task 
persistence.120 A selective D1R agonist pro-drug ABT-431 (23), displayed significant efficacy in the 
treatment of parkinsonian motor defects.. In a clinical study on patients with Parkinson’s disease ABT-431 
was able to produce full antiparkinsonian effect while minimizing dyskinesia induction.113,116 D1R partial 
agonist CY-208-243 (24) was subjected to human clinical studies for therapeutic use against Parkinson’s 
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disease where it displayed improved motor functions via D1R stimulation. However, the study was 
discontinued due to safety concerns.113  
 
Psychosis and motor function: 
In a clinical trial, injection of D1R selective agonist dihydrexidine, (22, Figure 1.13), increased activity of the 
brain in the frontal and pre-frontal region. This finding underlines the potential of D1R ligands in modulation 
of prefrontal dopaminergic function.95 This study falls in line with a previously conducted study on D1R 
antagonist NNC 01-0687 (26, Figure 1.14).  Compound 26 was able to reverse symptoms shown during 
psychosis such as being less social and being emotionally withdrawn.119,121  
 
Orphan Diseases: 
Studies conducted on the D1R selective antagonist SCH-23390 (27, Figure 1.14), showed no antipsychotic 
effects but was able to reduce involuntary movements in choreic patients, which is one of the symptoms 
shown by Huntington’s disease patients.122 Clinical trials conducted with another D1R antagonist ecopipam 









Pfizer have developed a series of non-catechol D1-like ligands that can be used as therapeutics against PD 
such as PF-06419751 (29) and PF-06669571 (30) (Figure 1.14). These non-catechol D1R agonists have 
completed phase I clinical trials. PF-06419751 however was terminated during phase 2 after it showed 
fluctuations in motor activity in patients.123  
 
Figure 1.15: D1R agonists: Non-catechol agonists 
 
Alzheimer’s Disease: 
Alzheimer’s disease progression is associated with increased localization and expression of D1R. This 
altered receptor levels of D1R is indicative of a depletion of cognitive behavior present in AD patients.93 D1R 
have also been linked to mediation of epileptic effect of amyloid-Aβ1-42. D1R are associated with many 
clinical conditions and a selective and potent ligand can be utilized to understand mechanisms and can be 
developed as a therapeutic for various neurological diseases, including Alzheimer’s disease.94 
 
 D5 Receptor: Similarity to D1 Receptor and Selectivity 
As mentioned previously, the D1-like subfamily consists of D1R and D5R subtypes of dopamine receptors. 
The D1R is highly localized in the CNS and has been studied with interest as stated above. Although less 
abundant than D1R, the D5R has recently been of interest due to the fact that activity of D5Rs is subtle but 
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not negligible. Rat knockout (KO) experiments of D5R have shown that disruption of function of D5 results 
in hypertension.124 D5Rs have also been shown to play a role in female sexual pathway.125  
 
There are several D1-like ligands primarily targeted for D1R, however only a handful of ligands that 
selectively target D1R are currently known. For all the ligands that are involved in clinical significance of 
D1R, the major problem in selectivity between these receptors comes from the underlying fact that these 
receptors share 80% sequence homology among themselves. The binding affinities and selectivity between 
the two members of D1-like subfamily between some previously discussed ligands and additional ligands 
(31- 35) represented in Figure 1.15 is illustrated in Table (1-6) below.133,126 
 
 
Figure 1.16: Different D1R/D5R catechol ligands and their selectivity 
 
Table 1-5 Lack of selectivity between D1R and D5R among different ligands: 
Ligand 
Ki(nM) 
D5R/D1R D1R D5R 
Dopamine 2340 228 0.1 
Ecopipam, 28 1.2 2.0 1.7 
Dihydredexine, 22 2.2 14.0 6.4 
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SCH23390, 26 1.4 2.0 1.4 
SKF38393, 35 1.0 0.5 0.5 
CY208-243, 24 417 40 0.1 
A-86929, 31 51.0 15.0 0.3 
Apomorphine, 32 372.0 14.8 0.0 
Dinapsoline, 33 5.5 10.0 1.8 
Dinoxyline, 34 3.9 3.8 1.0 
 
Clozapine, 16 (Figure 1.10), is an atypical antipsychotic and has small preference for D1R over D2R. SAR 
study of substitution on diazepine ring nitrogen with various amidic side chain has shown up to 28-fold D1-
subtype selectivity over D5-subtype. This SAR has shown potential usage of amide functionality that can 
be utilized to further investigate to achieve significant D1R selectivity.126 
 
Overall, GPCR modulation has been involved in a myriad of vital physiological function specially in CNS 
where it is responsible for cell signaling resulting in controlling cognition, memory, psychosis, self-
administrative behavior among other. Several clinical studies conducted on serotonin and dopamine ligands 
has shown potential to alleviate symptoms shown during neurological diseases and some of these ligands 
have been developed into full therapeutics. However, there persists problem with side-effects due to 
selectivity/specificity among these ligands at various aminergic receptors. The problem has been 
exacerbated by the lack of crystal structures of some GPCRs which can be useful to direct ligand design 
and development. As such, a detailed understanding of structure activity relations (SARs) of various 
adducts formed by modifications on scaffolds (e.g :- tetrahydroisoquinoline, benzazepines, and piperidine) 
is essential for ‘fine-tuning’ of previously identified ligands towards synthesis of novel drug molecules 




 Aporphines: A Privileged Scaffold 
 Naturally Occurring Aporphines 
 
There are more than 500 known structures of naturally occurring aporphine alkaloids. Aporphine alkaloids 
are a group of tetracyclic alkaloids which consists of an isoquinoline core (ring A and B), a biaryl subunit 
(ring A and D), and a stereogenic center (C6a) (Figure 1.16, aporphine core). Aporphines form the largest 
group of isoquinoline with several groups including proaporphines, secoaporphines, oxaporphines, 
dehydroaporphines, 7-hydroaporphines, aporphine dimers and aristolactams.127,128 These alkaloids are 
also known to show a variety of bio-pharmacological activities including dopaminergic,86 anti-oxidant,  
cytotoxicity, anticancer,129 anti-HIV,130 antiplatelet,131 and anticholinesterase.132,133  
 




 Aporphines as Multi-Receptor Selective Ligands 
 
Aporphine alkaloids are a privileged template capable of producing a wide range of biological responses at 
neuroreceptors.134–139 Aporphines have shown high affinity for central nervous system (CNS) receptors and 
have been extensively studied as ligands for dopamine (e.g.:- D1R, D2R and D3R),140–143 serotonin (e.g.:-5-
HT1AR, 5-HT2AR, 5-HT2BR).144–149 These receptors are implicated in expression of typical tendencies 
manifested in neuropsychiatric disorders and drug abuse. Several studies have also suggested that 
aporphine derivatives are able to selectively target different subtypes of receptors. Recent studies have 
also shown the capability of aporphine derivatives towards biased signaling among these subtypes, 
particularly at D1R and D2R. Herein, the activity of aporphines historically used as lead compounds for CNS 




Nantenine (42, Figure 1.17), is a naturally available 1,2,9,10-tetra-oxygenated-aporphine derivative 
commonly found in fruit of Nandina domestica. Multiple studies on nantenine have shown that it shows 
moderate dual affinity and antagonism at 5-HT2AR and α1AR.150,151,152 A study conducted by Indra et al. in 
2002 analyzed activity of (±) nantenine on mice-serotonin receptor showed that (±) nantenine was able to 
antagonize drug induced head-twitch movement by blocking 5-HT2AR.153 The results from another study by 
the same group suggested that methoxy substitutions at C1, and methyl substitution at N-6 of nantenine 
may play a vital role in antagonistic affinity and activity at serotonin (5-HT2A) receptor (Table 1-8).151  
Fantegrossi et al. in 2004 established the capability of racemic nantenine to antagonize the effects produce 
by MDMA in mice.152 Study by the  same group discovered that nantenine was able to block MDMA-induced 
head-twitch movement in mice in a similar manner to 5-HT2AR antagonist M100907. 152 This established 
nantenine as a lead of choice for 5-HT2AR. 




Table 1-6: Affinity of nantenine at CNS receptors- data from PDSP 
 
Receptor Ki (nM) Receptor Ki (nM) Receptor Ki (nM) Receptor Ki (nM) 
5-HT1A NA α1A AR 2 D1 895 DOR >10000 
5-HT1B 100 α1B AR 1191 D2 858 MOR >10000 
5-HT1D 49 α1D AR 340 D3 309 KOR 7265 
5-HT2A 832 α2A AR 1288 D4 262 H1 >10000 
5-HT2B 543 α2B AR 252 D5 2397 H2 672 
5-HT2C 1069 α2C AR 181 DAT >10000 H3 >10000 
5-HT5A 2224 β1 AR 8565 SERT 244 H4 >10000 
5-HT6 257 β2 AR >10000 NET >10000 Sigma 2 >10000 
5-HT7A 67 β3 AR >10000 









1.1.11.1. Nantenine at 5-HT2A Receptor: SAR Studies on Nantenine Analogs at 5-HT2A Receptor 
 
 
Figure 1.18: Structures of serotonin, MDMA and nantenine 
 
SAR studies conducted via variation of sterically and electronically different attachments at C1, C2, 
C3, C4 and N6 have increased our understanding of important structural features pertaining to binding and 
selectivity of nantenine at the 5-HT2AR.  
 
C1: Nantenine substitutions at C1-O with small alkyl chains (n < 5) were tolerated at the binding pocket and 
increase binding of nantenine, suggesting presence of a hydrophobic pocket near C1 in the binding 
pocket.154 Bulky sidechains were unfavorable to the binding resulting in reduced affinity. C1-O-allyl and C1-
O-allyl provided significantly improved binding, with both of these attachments with a similar electronic 
distribution could explain this favored binding behavior.154,155 p-Bromobenzyl substitution at C1 led to the 
identification of most potent 5-HT2A ligand.156   
 
C2: Only small C2-O-alkyl substitutions (n ≤ 3) provided a slight improvement of binding; other longer alkyl 
chains were detrimental to 5-HT2A binding.  These findings suggest that C1-subtitutions but not C2-
substituions play a vital role in 5-HT2A affinity.154,156 Molecular docking studies suggested that hydrophobic 
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substitutions at C1 were able to push the molecule into a more favorable position allowing for formations of 
hydrogen bond with Ser242 inside the binding pocket.157  
 
C3: C3-halogen substitution resulted in higher affinity; a modeling study showed a different binding 
orientation of the halogenated molecules as compared to nantenine. 158 
 
N6: N6-methyl substitution was vital for binding affinity of nantenine at 5-HT2A. The nitrogen atom is involved 
in forming the vital salt-bridge with Asp155 residue inside the binding pocket and substitution are sensitive 
to the nature of salt bridge and in turn affinity.157,159 A brief summary of major SAR finding of nantenine 
analogs along 5-HT2AR has been posted in Table 1-7. 
 
Table 1-7: Summary of nantenine derivatives at 5-HT2AR 
## Nantenine Derivatives Major SAR finding Reference 
1 
 
C1-O-methyl and N6-Methyl were 
vital to binding affinity of 
nantenine analogs to 5-HT2A. 





C1-O-alkyl chains were tolerated 
at 5-HT2A and increased binding 
affinity. C1-O-CH2cyclopropyl 
increased the binding affinity 
more than 12-fold (Ki = 68 nM)  
Chaudhary 








substitutions were not tolerated at 
5-HT2A.  C1-O-allyl had the highest 
binding affinity, Ki = 70 nM   
Chaudhary 
et al., 2011 
4 
 
Only small linear alkyl 






All substitutions except N6-methyl 
resulted in reduction of binding 
affinity  
Chaudhary 
et al., 2011 
5 
 
There was not much difference in 
binding affinity among (R)/(S)-
isomers and racemic nantenine. 
Although S-isomer had slightly 
higher binding affinity 
S.Ponnala 






binding affinity at 5-HT2A. C2-O-
methyl and C3 bromo had the 
highest binding affinity (Ki = 48 
nM). 
N.Kapadia 
et al., 2014 
7 
 
C4-phenyl substitution displayed 
improvement in overall binding at 
5-HT2A with small C1-O-alkyl 
groups   
N.Kapadia 
et al., 2014 
8 
 
Lead to the identification of 
highest binding aporphine alkaloid 
at 5-HT2A, when X= Br (Ki = 9.2 
nM).  
S.Ponnala 
et al., 2015 
 
1.1.11.2. SAR of Nantenine Analogs at 5-HT7A Receptor: 1,2,9,10-tetraoxygenated Aporphines 
 
Our lab has synthesized and analyzed boldine derivatives at 5-HT7R and 5-HT1AR (Table 1-8). C9 
substitutions improved binding affinity at 5-HT7R and provided selectivity over 5-HT1AR. The highest affinity 
was shown by compound (46, Ki = 15 nM) with C9-O-butyl substitution.  However, a clear SAR trend could 








Apomorphine is the oldest drug for Parkinson’s disease. Apomorphine is a naturally available aporphine 
alkaloid found in bulbs and roots of Nymphaea species.161 The use of apomorphine in medicine started 
after it was discovered as the product of dehydration of morphine in hydrochloric acid.161 Apomorphine was 
initially recognized for its emetic property and in later years has been used as treatment for various 
psychiatric disorders including schizophrenia, mania, depression, and sleeplessness. In 1884, 
apomorphine was first hypothesized to be useful for patients with PD. Apomorphine’s binding profile (Table 
1-9) has been evaluated and analyzed at various mono-aminergic receptor due to desirable and 
undesirable actions of its use as antiparkinson drug.161,162 
 
## R1 
Ki (nM) 5-HT1A 
5-HT7 5-HT2A 5-HT1A 5-HT7 
43 H NA 314 20 15.7 
44 Me 966 171 43 4.0 
45 Et 818 506 69 7.3 
46 n-butyl 268 153 15 10.2 
47 n-pentyl 239 179 24 7.5 
48 n-hexyl 570 273 58 4.7 
33 
 
Table 1-9: Affinity of apomorphine (32) at monoaminergic receptors - Millan et al.163 
Receptor Ki (nM) Receptor Ki (nM) Receptor Ki (nM) 
5-HT1A 117 α1A AR 1995 D1 372 
5-HT1B 2951 α1B AR 676 D2 35 
5-HT1D 1230 α1D AR 65 D3 26 
5-HT2A 120 α2A AR 141 D4 4 
5-HT2B 132 α2B AR 66 D5 15 
5-HT2C 102 α2C AR 36 H1 >10000 
5-HT5A NA β1 AR >10000 
  
5-HT6 NA β2 AR >10000 
  
5-HT7A NA β3 AR NA 
  
 
 SAR of Apomorphine Analogs at 5-HT7AR: 
1.1.13.1.  Aporphine Alkaloids: C11-N-Methyleneaporphine analogs 
 
Studies conducted on aporphine derivatives has focused primarily on (R)-apomorphine due to its clinical 
significance. Herdberg et al. discovered that replacement of the C11 hydroxyl group of (R)-apomorphine 
with a C11 phenyl substituent decreased DR affinity while increasing 5-HT1AR affinity (Table 1-11).164 T. 
Linnanen extended this finding and discovered that C11 phenyl substituted aporphine not only targeted 5-
HT1AR but also 5-HT7R. Expansion of this finding to include di-ortho substituted phenyl derivative at C11 
lead to identification of potent and selective 5-HT7R ligands. Compound 56 was the most potent compound 
with binding affinity (Ki) of 3.79 nM and 38-fold selectivity over 5-HT1A and has been characterized as a 5-





Table 1-10: C11-phenyl-N-methyleneaporphine analogs at 5-HT7AR and 5-HT1AR165 
 
1.1.13.2. Aporphine alkaloids: C1-11-Steric Constrained Aporphine Analogs 
Steric constraint was introduced into the aporphine ring by introducing a novel ring system, (R)-1,11-
methyleneaporphine (59, Table 1-11). Although, a generalized SAR could not be established, this new 
strained ring substitution allowed interactions between the binding pocket, above and below the plane of 
 
## R1 R2 
Ki (nM) 5-HT1A 
5-HT7 
ref. 
5-HT7 5-HT1A D2 
49 - - 88 80 527 1 165,164 
50 H H 9.78 1.8 233 0.2 165,164 
51 OMe H NA 26.9 1330 - 164 
52 OH H NA 28.5 1570 - 164 
53 OMe OMe 13.5 554 2030 41 165 
54 OH OH 36.2 139 1000 4 165 
55 Me CN 20.8 778 2470 37 165 
56 CN Me 3.79 142 3350 38 165 
57 Me OH 43.1 319 3350 7 165 
58 OH Me 23 48.8 2500 2 165 
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the tetracyclic aporphine ring. 166 Disubstituted C12 compounds had improved binding affinity with methoxy 
and hydroxy group substitution giving highest binding affinity at 5-HT7R. Monosubstituted (6aR,12S) amino-
NH2 derivative had better affinity and selectivity than similar (6aR,12S) hydroxy substitution whereas 
acetamide derivatives were not tolerated at 5-HT7R (Table 1-11).    
Table 1-11: C1-11-steric constrained aporphine analogs at 5-HT7R and 5-HT1A R 166 
 
 
Compound R1 R2 
Ki (nM) 5-HT1AR 
5-HT7 R  5-HT7R 5-HT1AR D2R 
(R)-59 H H 6.9 40.7 83.2  6 
(6aR,12R)-60 OH H 13.5 31.0 23.8 2 
(6aR,12S)-61 H OH 103.0 1210.0 215.0 12 
(6aR,12R)-62 OH Me 27.7 315.0 182.0 11 
(6aR,12S)-63 Me OH 4.3 61.5 26.0  14 
(6aR,12R)-64 NHAc H 538.0 204.0 3650.0 0.4 
(6aR,12S)-65 H NHAc 1320.0 716.0 7980.0 0.5 
(6aR,12R)-66 NH2 H 13.4 142.0 261.0 11 
(6aR,12S)-67 H NH2 18.0 355.0 2250.0 20 
(6aR,12R)-68 OMe Me 1.1 17.3 7.1 16 
(6aR,12S)-69 Me OMe 1.1 16.9 71.0 15 
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Overall, the aporphine scaffold has shown preference towards 5-HT7R. Despite having ligands with good 
binding affinity at 5-HT7R, there has been lack of distinct SAR features that can improve selectivity of 
aporphine alkaloids for 5-HT7R over 5-HT1AR. In the absence of crystallographic structures of the receptor, 
new SAR studies can help improve our understanding towards development of a selective ligand.   
 
 Apomorphine at Dopamine Receptor 
 
Currently available dopamine receptor agonists such as apomorphine (32) and levodopa (71) (Figure 1.18) 
suffer from short half-life due to the susceptible catechol moiety. Dopamine and apomorphine both (Figure 
1.18) contain a β-phenylethylamine motif and a catechol moiety. The catechol moiety is important for 
forming hydrogen bonds between the hydroxy groups of catechol and serine and threonine residues in 
dopamine receptors binding site.167 However, this necessary catechol moiety also raises major 
pharmacokinetic problems for apomorphine as a therapeutic. Firstly, apomorphine is removed from the 
body as a “bound” residue (glucuronides and sulfated compounds) and is also susceptible to spontaneous 
oxidation by air at body pH and autoxidation, thus reducing its bioavailability168,169. Also, the metabolites 
formed after the action of catechol-O-methyltransferase on the catechol moiety can interact with different 
pathways before being released from the body.170  
 
An onset of motor fluctuations and dyskinesia signals the progression from early to advanced Parkinson’s 
disease. In animal models of PD, the development of dyskinesia has been attributed to a shorter half-life of 
such therapies.171 A continuous subcutaneous infusion of apomorphine or levodopa (71) can improve the 
plasma concentration to avoid dyskinesia- “wearing off” effect.172 This  comes with a cost of independence. 
A second more viable approach for PD treatment is the identification of long-acting agonists which has 




Figure 1.19: Dopamine receptor agonists 
 
1.1.14.1. SAR Analysis of N6-methyl Apomorphine Analogs at Dopamine Receptor 
 
Most of the apomorphine derivative synthesis has focused on modifications to the metabolically labile 
catechol moiety. During SAR studies with various apomorphine analogs it was noticed that along with the 
chiral center at C6a, the C10-OH group of the catechol moiety was vital for agonistic property shown by 
apomorphine at D1R.174 Apomorphine derivatives that contain a C11-OH group possessed affinity for D1R 
however they lacked significant agonistic property at D1R (Table 1-12). 174 
 
Table 1-12: Binding affinity and activity of apomorphine analogs at D1R and D2R 
 
Compound R1 R2 
Kia (IC50b) nM D1R-adenylate cyclase (%) b 
D1R D2R Agonism Antagonism 




(S)-APO, 72 OH OH (3620) (680) na 43.2 




(58) ns 87.8 
(S)-11-OH-APO, 74 H OH (5061) (2242) ns 38 
(R)-75 Br OH (171) (664) ns 87.8 
(S)-76 Br OH (3340) (2930) na 54.2 
a data derived from Si et al175, bdata derived from Schhaus et al. 174 ns → not significant activation, na → 
not available 
 
1.1.14.2. SAR Analysis of N6-propyl Apomorphine (NPA) analogs at Dopamine Receptor 
Table 1-13:Binding affinity of N-propylnoraporphine derivatives binding at D1R and D2R and selectivity l175 
 
Compound R1 R2 R3 
Ki (nM) 
D1R D2R 
(R)-NPA, 77 OH OH H 730 10 
(R)-11-OH-NPA, 78 H OH H 699 28.5 
79 OH OH OMe 1800 0.17 




As mentioned before, most of the apomorphine derivative synthesis have focused on the important yet 
labile catechol moiety of apomorphine. Neumeyer et al. observed that despite showing reduced binding 
affinity at dopamine receptors C11-OH-NPA (78), was able to reproduce similar antinociceptive effect 
produced by NPA (77), in rats (Table 1-13).176 C2-hydroxy and methoxy substitutions were detrimental to 
D1R binding and increased D2R binding and D2R selectivity. 175  
 
1.1.14.3. SAR Analysis of C1-susbtituted Apomorphine Analogs at Dopamine Receptor 
 
A recently published study of C1 substituted apomorphine analogs revealed increased binding affinity at 
D1R (84 , Ki = 40 nM), while retaining affinity at D2R, and efficacy at both D1R and D2R among the analogs.143 
These C1 analogs did not show any selective binding towards D1R and functionally were more active at 
D2R when compared to D1R (Table 1-14). This shows that the C1 aporphine position is sensitive to ligand-
binding site interaction at D1R and can be utilized to improve D1R binding affinity. 
 
Table 1-14: Binding affinity and potency of C1-apomorphine derivatives at D1R and D2R143  
 
Compound R1 
Ki (nM) EC50 nM (efficacy, %) 
D1R D2R D2R/D1R D1R D2R D2R/D1R 
Apomorphine, 32 H 492 53 0.18 25.7 (100) 4.0 (100) 0.16 
81 CH3 187 54 0.11 21.9 (109) 5.1 (97) 0.23 
82 Benzyl (Bn) 168 77 0.29 78 (97) 49 (98) 0.63 
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83 OH-CH2 980 43 0.04 117 (102) 3.4 (95) 0.03 
84 4-OH-Bn 40 47 1.18 10.5 (95) 2.7 (102) 0.25 
 
1.1.14.4. Apomorphine Analogs: D1R/D2R Biased Ligands  
 
One major problem related to Parkinson’s disease treatment using a dopamine agonist strategy is the 
production of dyskinesia as a side effect, generally as a wearing off effect of the dopamine receptor agonist. 
Apomorphine does not provide an exception to this trend. Interest in biased pathways has updated our 
understanding to be able to avoid dyskinesia by synthesis of biased ligands. Along those lines, the 
production of dyskinesia is associated with uncontrolled activation of the G-protein based cAMP pathway.177 
Therefore, D1R agonists with -arrestin biased signaling are particularly appealing as novel anti-Parkinson’s 
disease drugs, as they are not expected to induce dyskinetic side effects. 
 
Recent studies of bias in apomorphine analogs have shown a slight increment of bias by 
propylnorapomorphine (NPA, 77) compared to apomorphine. (R)-Apomorphine shows a high G-protein bias 
at D1R with approximately 42-fold more activation of G-protein vs β-arrestin pathway. NPA is able to 
improve β-arrestin bias at both D1R and D2R, and at higher dosage NPA induced β-arrestin pathway 
overtakes cAMP activation (Table 1-15).177    
 
Table 1-15: Selective bias shown by apomorphine and N-propylnoramorphine at D1R, D2R 
 
-arrestin c-AMP 
G-Bias EC50 pEC50 Emax (%) EC50 pEC50 Emax (%) 
D1R 
APO, 32 520.8 6.3 13.02 3.77 8.4 94.92 41.5 
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NPA, 77 1884 5.73 72.23 1.1 8.96 84.87 19.32 
D2R 
APO, 32 10.1 8 75 1.61 8.8 60 2.16 
NPA, 77 1.18 8.93 93.83 0.04 10.4 94.38 0.885 
        
 
1.1.14.5. Aporphine Analogs: 1,2,9,10-tetraoxygenated Aporphine 
 
Modifications on aporphine alkaloids enabled the identification of D1R selective ligands. Boldine is a 
naturally available 1,2,9,10-tetraoxygenated aporphine. Methoxy substitutions of C9 decreased activity at 
either one or both receptors. However, C3 mono-halogenated boldine derivatives provided improved 
binding affinity at D1R thus improving selectivity. C3-Iodide-boldine derivative (88) provided one of the 
highest binding affinity among any aporphine alkaloids at D1R (Ki = 2 nM) with 34-fold selectivity over the 
D2R (Table 1-16).178 Highest selectivity was achieved by C9-methoxy and C3-I-substitution (90) with 139-
fold selectivity over the D2R.179 
 
Table 1-16: Binding affinity of C3-halogennated boldine derivatives at D1R and D2R178,179 
 
COMP R1 R2 X 
Ki (nM) 
D2R/D1R D1R D2R 
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Boldine, 85 H H H 294 366 1 
Predicentrine, 86 H CH3 H 243 761 3 
87 H H Br 49 740 15 
88 H H I 2 68 34 
89 H CH3 Br 15 613 41 
90 H CH3 I 6 831 139 
 
The C3 substitution of boldine with halogens increased binding affinity at D1R with less electronegative 
iodine substitution increasing D1R-binding dramatically. This increase in binding has been attributed to three 
major factors; hydrophobic interaction of the halogen, electronegativity of halogens to form favorable 
aromatic stacking and distortion to the tetrahydro-isoquinoline ring produced by C3 halogen substitution.  
 
Summary and Outlook 
 
Neuropsychiatric disorders have a unique etiology and it has been shown that effectiveness of compounds 
increases when multiple receptors are targeted selectively.142,145,149,180 The previous studies mentioned 
above demonstrate that the tetracyclic template of aporphines provides an opportunity for optimization and 
development of new CNS receptor ligands that are mono- or multi-receptor selective.  In particular 
aporphines are valuable as ligands that target serotonin and dopamine receptor subtypes.   
 
The SARs of aporphine alkaloids have been well studied at some CNS receptors. However, a similar 
thorough analysis is yet to be undertaken at a broader set of CNS receptors. Most previous studies have 





This thesis focuses on the introduction of a C10 nitrogen functionality and its diversification into various N-
based functionalities (e.g.: - aniline, amides, and sulfonamides) concurrently with alkyl substitution at C1 O 
and/or N-6 to create a new library of aporphine analogs. This study seeks to use nantenine (a 
tetrasubstituted naturally occurring aporphine with preference for serotonin receptors) and apomorphine (a 
dopamine receptor preferring ligand) as templates to improve the affinity shown by these compounds at 
serotonin and dopamine receptors. These analogs will be tested at various serotonin and dopamine 
receptors with the anticipation that the novel substituted aporphines will target different monoaminergic 
CNS receptors, leading to identification of novel selective ligands with potential as therapeutic leads.  These 
newly discovered ligands may also be useful as chemical tools to elucidate the role of receptor modulation 
in neurological and psychiatric disorders in which the targeted receptors are implicated e.g., Alzheimer’s 








2. SYNTHESIS AND EVALUATION OF C10 MONOSUBSTITUTED AND 
C10 BENZOFUSED AMINOTHIAZOLE APORPHINE ANALOGS AT 
SEROTONIN AND DOPAMINE RECEPTORS 






Various scaffolds have been investigated to achieve selective 5-HT7R ligands, however there are only a 
handful of known 5-HT7R ligands that have achieved selectivity against the closely related 5-HT1A subtype.  
To date, JNJ-1803863 (20,  Figure 1.11), is the only selective 5-HT7R ligand that has undergone clinical 
trials (as a therapeutic agent against cognitive impairment and depressive symptoms in bipolar disorder).41 
Selective and potent 5-HT7R ligands have demonstrated promise as effective treatments for 
neuropsychiatric conditions and as useful pharmacological tools. Thus, identification of potent and selective 
5-HT7R ligands are of interest.  
 
Structural modifications on the aporphine scaffold have led to the identification of ligands with high affinity 
at 5-HT7R and moderate selectivity over 5-HT1AR (Figure 2.1). However, SAR studies at 5-HT7R have been 
relatively sparse compared to 5-HT1A receptors. Johannson et al have described a number of 
atropoisomeric C11 phenyl aporphines and C1,11-methylene aporphines with 5-HT7R binding affinity and 
selectivity over 5-HT1AR. Our lab has previously also identified N-methylaurotenanine analogs with high 
affinity at 5-HT7AR and modest selectivity over 5-HT1A receptors. 
 
 





Rationale for analog design 
Hypothesis:  We hypothesize that aporphines that contain C10 nitrogen functionalities with hydrogen bond 
donor or acceptor capabilities will exhibit binding affinity at 5-HT7R. 
 
Figure 2.2: Target analogs 
 
We targeted the synthesis and evaluation of various C10 N-substituted analogs (amides, 
methanesulfonamides, N, N-dialkylated, and urea). These functionalities have HBA or HBD capabilities 
which we anticipated may lead to strengthened interactions at 5-HT7R (Figure 2.2).  C10 benzo-fused 
aminothiazoles were also targeted for synthesis and evaluation as representative heterocycles containing 
both HBA and HBD groups. Since N6-alkyl substitutions (methyl and propyl) have featured prominently in 
obtaining selectivity at different serotonin and dopamine receptors, we were curious about the effect of 
these substitutions on 5-HT7R binding and selectivity.  Thus, analogs also contain alkyl group variations at 
N6.  Previously conducted SAR studies on aporphines have not examined the effect of C10 nitrogen 
substituents at 5-HT7R or other receptors.  Thus, this is the first study that has been performed in order to 
understand the tolerance for C10 nitrogen substitutions in that regard.  
47 
 
Results and Discussion 
 Synthesis: 
 
C10 monosubstituted analogs were synthesized utilizing Scheme 2-1 shown below. Readily available 2-
(2-bromo-4-nitrophenyl) acetic acid (91) was coupled with phenethylamine (92) to obtain amide 93.  The 
obtained amide 93 was cyclized under Bischler-Napieralski conditions to give an intermediate imine which 
was subsequently reduced to afford an intermediate tetrahydroisoquinoline.  The secondary amine 
functionality of this intermediate was Boc-protected and the aryl bromide 94 thus produced was cyclized 
via palladium-catalyzed direct arylation to afford aporphine 95.  After cyclization, the Boc group of 95 was 
deprotected with acid and the resulting secondary amine 96 was then subjected to reductive amination with 
various aldehydes to obtain N-alkylated analogs 97a-b. Reduction of the nitro group of 97a-b gave anilines 
98a-b.  
 
Scheme 2-1: Reagents and conditions: (a) HBTU, DIPEA, THF, rt, 96%; (b) POCl3, ACN, reflux, 12h;  (c) 
NaBH4, MeOH, 0 °C; (d) (Boc)2O, K2CO3, ACN, rt, 60% over 3 steps; (e) Pd(OAc)2, tris(4-
fluorophenyl)phosphine, K2CO3, (CH3)3CCOOH, DMA, 100 °C, 70%; (f) TFA, CHCl3, rt, 2h, 78%; (g) HCHO 





Scheme 2-2: Reagents and conditions: (a) Ac₂O, DCM, 2h, rt, (40-65%) (b) (CH₃CH₂CH₂CO)₂O, DCM, 2h, 
rt, (50-60%) (c) (CH3SO2)2O, Et3N, DCM, rt, 14h, (35-40%) (d) HCHO, NaBH(OAc)3, DCM, rt, 18h, (75-
80%) (e) KCN, AcOH, water, 1h, rt, (40-60%) (f) HCOOH, reflux, 2h, (30-40%) (g) TFAA, DCM, rt, 2h, (60-
80%); (h) (C₆H₅CO)₂O, DCM, rt, 8 hrs, (30-60%) 
 
Anilines 98a-b were utilized as key intermediates to synthesize C10 monosubstituted aporphine analogs 
and C9/10 and C10/11 benzofused aminothiazole derivatives. Various C10-N-amide derivatives 99-101, 
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105,106 were synthesized via reaction of the anilines 98a-b with their respective anhydrides. The C10 
formamide derivative 104a was obtained by refluxing aniline 98a with formic acid in a solvent free condition 
(NMR analysis of C10 formaides showed that they existed as rotamers). C10 N, N-dimethylated analogs 
(102a-b) were synthesized by reductive amination. For synthesis of the C10 urea-containing analogs (103a-
b), compounds 98a-b were reacted with KCN in acid.  
 
 
Scheme 2-3: Reagents and conditions: KSCN, Br2, AcOH, 0 ˚C - rt, 12h, 60-75% 
 
Benzofused aminothiazoles were synthesized by reacting the respective C10 amines 98a-b with potassium 
thiocyanate and bromine. Two regioisomers, C10/11 (107a-b) and C9/10 (108a-b), were obtained for each 
amine precursor.  In both cases, a 1:1 ratio of regioisomers was obtained after purification. The identity of 
the regioisomers was confirmed by NMR. Compounds 107a-b had a pair of doublets, whereas compound 
108a-b displayed two distinct singlets in the aromatic region corresponding to the ring D protons. We also 







 SAR of C10 Monosusbtituted Aporphine Analogs at Serotonin Receptors: 
 
Table 2-1: Affinity of C10 monosubstituted analogs at 5-HT receptors 
 
    
Ki (nM)a,b,c 
Comp# R1 R2 R3 5-HT1AR 5-HT2AR 5-HT6R 5-HT7AR 1A/7A 
96 H -- -- 350 ± 45 na nd nd - 
97a Me -- -- 100 ± 13 na nd nd - 
98a Me H H 269 ± 0.35 672 ± 87 nd nd - 




93 ±12 1062 ± 140 
nd nd - 
99b Pr 
 
H 21 ± 2.7 




H 83 ± 1.1 na nd nd - 
100b Pr 
 
H 15 ± 2.0 na na 311 ± 40 0.05 
101a Me  H 133 ± 17 
na na 
27 ± 3.5 4.9 
101b Pr  H 23 ± 3.0 
na na 
199 ± 26 0.1 
102a Me Me Me 458 ± 59 566±73 1588±200 17 ± 2.2 26.9 
102b Pr Me Me 256 ± 33 na na 984 ± 130 0.3 
103a Me 
 
H 49 ± 6.3 
na na 










H 62 ± 11 nd nd 9.0 ± 0.25 6.9 
105a Me 
 
H 17 ± 3.5 nd nd nd - 
105b Pr 
 
H 9.1 ± 1.1 nd nd nd - 
106a Me 
 
H 22 ± 5.0 nd nd nd - 
106b Pr 
 
H 16 ± 6.0 nd nd nd - 
8-OH 
DPAT 
   0.8 ± 0.01   
  
Clozapine     3.0 ± 0.4 4.0 ± 0.5 11.4 ± 1.5  
aExperiments carried out in triplicate; b[3H]WAY100635 used as radioligand; c[3H]Ketanserin used as 
radioligand; d[3H]LSD used as radioligand; fna – not active (compounds displayed < 50% inhibition in a 
primary assay), nd – not determined 
 
2.1.2.1. SAR at 5-HT1A Receptor: 
 
Data for evaluation of the C10 nitrogenated analogs are shown in Table 2-1. The C10 aniline derivative 98a 
had lower affinity than the nitro precursor 97. Among all investigated C10 nitrogenated analogs at the 5-
HT1AR, N6-propyl substituted compounds 98b-106b displayed higher binding affinity (lower Ki) compared 
to their N6-methyl congeners 98a-106a for all C10 nitrogenous functionalities except C10 urea. Compound 
98b with an N-propyl group displayed a high affinity for the 5-HT1AR (Ki = 30 nM) with 9-fold higher affinity 
than its N6-methylated congener, 98a (Ki = 269 nM).  
 
The binding affinities of the analogs containing C10 amide and C10 sulfonamide moieties ranged from 9.1 
nM to 133 nM. All acylated and sulphonylated products of the C10 aniline 98a-b into C10 amide 
functionalities acetamide 99a-b, butyramide 100a-b, methanesulfonamide 101a-b, formamide 104, 
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trifluoroacetamide 105a-b, and benzamide 106a-b resulted in an improvement of 5-HT1AR binding affinity 
as compared to their respective aniline precursor.  Compound 99b was the most selective compound with 
binding affinity of 21 nM at 5-HT1AR and lacking affinity at other investigated 5-HT receptors. The C10 
butyramide series 100a-b of compounds had slightly better affinity when compared to the C10 acetamide 
series 99a-b. The C10 sulfonamide series of compounds had binding affinity comparable to C10 acetamide 
substituted analogs. Of the C10 acylated or sulfonated compounds with an N6-methyl substituent, the N6-
methylated C10 formamide analog 104 had comparatively higher binding affinity than compounds 99a (C10 
acetamide), 100a (C10 butyramide), and 101a (C10 methanesulfonamide) but lower binding affinity than 
105a (C10 trifluoroacetamide) and 106a (C10 benzamide). The C10 trifluoroacetamide series provided the 
best binding affinity at 5-HT1AR across both N6-methylated and N6-propylated analogs; among N6-
methylated congeners compound 105a had a binding affinity of 17 nM and among N6-propylated 
compounds 105b provided the highest binding affinity of 9.1 nM. C10 benzamide analogs displayed lowest 
level of preference at 5-HT1AR between N6-methylated and N6-propylated analogs (e.g. compare 106a and 
106b), with high affinity for both analogs.  
 
Compounds 102a and 102b with C10 N, N-dimethyl substitution showed the lowest binding affinity for 5-
HT1AR among the compounds tested from this series (Ki = 458 ± 59 nM, Ki = 256 ± 33 nM), respectively. 
Analogs with a C10 urea moiety reversed the preference shown for 5-HT1AR by N6-propyl-containing 
analogs; compound 103a (Ki = 49 nM) provided higher binding affinity at 5-HT1AR than compound 103b (Ki 
= 236 nM).  
 
Overall, C10 monosubstituted aporphine alkaloids were well tolerated at 5-HT1AR. Across the series, the 
N6 substituent had a more pronounced effect on binding affinity at 5-HT1AR than the C10 nitrogen 
functionalities. However, it was observed that C10 nitrogen functionalities can be utilized to fine tune binding 




2.1.2.2. SAR at the 5-HT2A Receptor and 5-HT6 Receptor: 
 
Binding affinity for C10 monosubstituted compounds was weak or absent at 5-HT2AR and 5-HT6R for almost 
all monosubstituted aporphine derivatives. Compound 102a with C10 N, N-dimethyl substitution provided 
the highest binding affinity at 5-HT2AR (Ki = 566 nM) and 5-HT6R (Ki = 1588 nM). 
 
2.1.2.3. SAR at the 5-HT7A receptor: 
 
C10 monosubstituted nitrogen derivatives provided high binding affinity at 5-HT7AR ranging from 4.5 nM to 
984 nM. In an opposite manner to the SAR of these analogs at 5-HT1AR, N6-propyl substitution was 
disfavored over N6-methyl substitution at 5-HT7AR and lead to a decrease in binding affinity for C10 
sulfonamide, C10 N,N-dimethyl, and C10 urea analogs (compare 100-103a vs 100-103b).  
 
Compared to the precursor 98b, all C10 functionalities with N6-propyl substitution led to reduction of binding 
affinity; 100b (C10 sulfonamide), 102b (C10 N,N-dimethylated), and 103b (C10 urea).  Among the tested 
analogs, compound 103a had the highest 5-HT7AR binding affinity (Ki = 4.5 nM); 103a is 10-fold selective 
for 5-HT7AR versus 5-HT1AR and is among the most potent aporphinoid 5-HT7AR ligands identified to date. 
Compound 104 (C10 formamide with N6-methyl substitution) provides the second highest binding affinity 
at 5-HT7AR (Ki = 9.0 nM) with 7-fold selectivity over 5-HT1AR.  
 
It appears that irrespective of C10 nitrogen functionality, N6-propyl substitution is favored for binding at 5-
HT1AR in comparison to 5-HT7AR and the reverse holds true for N6-methyl substitution. This SAR finding 





 SAR of C10 Aminothiazole Aporphine Derivatives at Serotonin Receptors: 
 
Table 2-2: Affinity of benzofused aminothiazole aporphines at serotonin receptors 
 
Compound # R1 Ki (nM)a 5-HT1AR 
5-HT7AR 5-HT1ARb 5-HT2ARc 5-HT6Rd 5-HT7ARd 
107a Me 187 ± 24 1040 ± 130 naf 9.9 ± 1.3 18.9 
107b Pr 93 ± 12 na na 150 ± 19 0.60 
108a Me 23 ± 3.0 na na 6.5 ± 0.8 3.54 
108b Pr 7.5 ± 0.97 na na 132 ± 17 0.06 
8-OH DPAT  0.8 ± 0.01     
Clozapine   3.0 ± 0.4 4.0 ± 0.5 11.4 ± 1.5  
aExperiments carried out in triplicate; b[3H]WAY100635 used as radioligand; c[3H]Ketanserin used as 
radioligand; d[3H]LSD used as radioligand; fna – not active (compounds displayed < 50% inhibition in a 
primary assay) 
 
In a similar manner to C10 monosubstituted series, compounds with a benzo-fused aminothiazole motif 
displayed higher affinity at 5-HT1AR and 5-HT7R in comparison to 5-HT2AR and 5-HT6R. In fact, these 
compounds lacked binding affinity at 5-HT6R, altogether. Another similarity in SAR with C10-
monosubstituted series was the selectivity profile displayed by N6-alkyl substitutions; N6-methyl substituted 
compounds 107a and 108a were more selective towards 5-HT7AR, whereas N6-propyl substituted 
compounds 107b and 108b  preferred 5-HT1AR over 5-HT7AR. Compound 107a and 108a with N6-methyl 
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substitution had approximately 19-fold and 4-fold selectivity respectively for 5HT7AR over 5-HT1AR, whereas 
compound 107b and 108b (N6-propyl analogs) had roughly 2- and 17-fold selectivity respectively for 5-
HT1AR over 5HT7AR. 
 
 SAR of C10 Urea and Aminothiazole Aporphine Derivatives at Dopamine Receptors 
 
Aporphine alkaloids are known for their affinity at dopamine receptors. An investigation regarding the 
binding affinity profile of the most potent 5-HT7AR ligands (compounds 103a, 107a, 108a) was conducted 
at dopamine receptor subtypes. Compound 103a lacked affinity at all dopamine receptor except at D3R 
where the binding affinity was low (Ki = 2460 nM). Compound 107a was active at D1R, D2R, D3R and D4R 
with low binding affinity (Ki = 1150, 1740, 381 and 481 nM respectively) but had no affinity at D5R. In fact, 
none of the tested compounds showed affinity at D5R. Compound 108a lacked binding affinity at all 
dopamine receptors. A similar binding study of most potent 5-HT1AR ligand, compound 108b was 
conducted. Compound 108b showed low affinity for D3R (Ki = 2110 nM) and lacked affinity at all other 
dopamine receptors.  
 
Table 2-3: Affinity of 121a, 107a, 108a and 108b at dopamine receptors 
 Ki (nM)a 
Compound  D1Rb D2Rc D3Rc D4Rc D5R 
103a nad na 2460 ± 320 na na 
107a 1150 ± 150 1740 ± 220 381 ± 49 481 ± 62 na 
108a na na na na na 
108b na na 2110 ± 270 na na 
(+)-butaclamol 4.30 ± 0.55     
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Haloperidol  5.58 ± 0.72    
Nemonapride   1.18 ± 0.15 0.86 ± 0.11  
aExperiments carried out in triplicate; b [3H] SCH23390 used as radioligand; c[3H] N-Methylspiperone 
used as radioligand; dna – not active (compounds displayed < 50% inhibition in a primary assay) 
 
 Functional Assay 
 
The compounds with highest affinity at 5-HT7AR (103a and 108a) were evaluated for 5-HT7R functional 
activity using Hit Hunter® agonist and antagonist cAMP assays at Eurofins Pharma Discovery Services. A 
summary of functional activity of the two compounds is presented in Table 2-4. Both of these compounds 
were found to be active as antagonists at 5-HT7R with EC50 values of 1.25 µM and 0.26 µM respectively for 
103a and 108a; the compounds lacked agonist activity in this assay. Antagonist potency of compound 103a 
is comparable to the 5-HT7R antagonist spiperone which was used as a positive control. 
 
Table 2-4: Functional activity of compounds 103a and 108a in cAMP assays 
Compound Assay modea Agonist 
EC50(µM) 
Max response (%) Antagonist IC50 
(µM) 
103a agonist >10 0 - 
103a antagonist - 96 1.25 
108a agonist >10 3.3 - 
108a antagonist - 101.3 0.26 
Serotonin agonist 0.07 100.9 - 
Spiperone.HCl antagonist - 101.3 0.31 




 Modelling Studies 
 
Computational docking simulations were performed in order to rationalize the high measured 5-HT7R 
binding affinities for compounds 103a, 107a and 108a. In this context, we investigated the docked ligand 
poses and identified key receptor-ligand interactions that influence binding to the 5-HT7R and provide a 
deeper appreciation of the observed high affinity towards this receptor system. 
  
A homology model of the 5-HT7R was generated from the high-resolution crystal structure of the human 
serotonin 5-HT1B G protein-coupled receptor with pdb code 4IAQ.181 This approach involved utilization of 
the Schrödinger Prime Structure Prediction and Glide software modules and manual intervention to support 
the generation of known key receptor-ligand interactions. The model for the 5-HT7R structure, therefore, 
comprised suitable backbone and side-chain orientations within the binding site. The docking simulations 
of compounds 103a, 107a and 108a into the 5-HT7R binding site exploited the Schrödinger Induced Fit and 
Glide methodologies in Standard Precision (SP) mode. Using this docking protocol, the Glidescore scoring 
function was used to give an estimate of the ligand binding affinities for the highest ranked poses of 
compounds 103a, 107a and 108a in the 5-HT7R target. The ligand binding poses are depicted in Figure 
2.3.  
 
Compounds 103a and 108a give very similar binding poses in the serotonin 5-HT7R binding pocket as 
shown in Figures 2.3 (A and C). The docked poses of both compound in the 5-HT7AR shows the quaternary 
N6 atom within key salt-bridge interaction distance from Asp162. Along the C10 nitrogen functionality 
motifs, the compounds are stabilized by hydrogen bonding with Ser243; carbonyl oxygen for compound 
103a and nitrogen atom of heterocycle for compound 108a. Both compounds are further supported in the 
binding site by interactions of extended anime group with Ala247 backbone, and π-π-stacking interactions 
between the ligand aromatic rings and receptor Phe343 and Phe352 residues. The difference in predicted 
binding energy between compound 108a (-10.0 kcal/mol) and compound 103a (-8.9 kcal/mol) can be 
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attributed to a slightly stronger protonated N-Asp salt bridge, C10-N-Ser243 hydrogen bond, and better π-
π interactions involving the fused thiazole ring in 108a. This could potentially provide an explanation for the 
difference of antagonistic activity between these compounds, where compound 108a despite having slightly 
lower binding affinity provides more antagonistic property at 5-HT7AR.  
 
 
Figure 2.3: Docked poses of compound 103a, 107a and 108a at 5-HT7AR 
A. compound 103a (with binding energy of -8.9 kcal/mol), B. compound 107a (with binding energy of -8.7 kcal/mol) and 
C. compound 108a (with binding energy of -10.0 kcal/mol) shown by green carbon atoms in the serotonin 5-HT7 receptor 
target shown by secondary structure elements and grey carbon atoms for select residues. Key quaternary N – Asp salt 
bridges are depicted by the pink dashed lines, H-bonding interactions by the yellow dashed lines, π-π stacking by the 




For compound 107a, in order to accommodate the modified position of the fused thiazole ring, the best 
binding pose identified by induced fit docking involves a refined 5-HT7AR structure with a rotated Asp162 
side-chain orientation. As depicted in Figure 2.3B, key receptor-ligand interactions include the quaternary 
N – Asp162 salt bridge, H-bonds to Ser234 and Ser243 and a π-cation interaction between the same 
quaternary N and Phe352. As a consequence of the modified binding pose, the binding energy for 
compound 107a (-8.7 kcal/mol) is worse than that for 108a (-10.0kcal/mol) primarily due to the lack of 
complementary π-π interactions involving the ligand aromatic rings in 107a. 
 
 Synthesis of Second Generation of C10 monosubstituted Analogs: Enantiomerically Pure 
(C6a) and Benzofused Imidazole Heterocycle 
 
Molecular chirality can significantly impact the affinity of ligands for their targets. Aporphines have a chiral 
center at C6a. Most of the aporphine ligands described in the literature for 5-HT7AR have the (R)-
configuration. However, there is evidence that at some serotonin receptor subtypes aporphines with an (S)-
configuration are eutomeric.  The compounds that we have evaluated in the previous sections were 
racemic.  In this section, we discuss the synthesis of the enantiomers of the most active racemic analogs 
(103a, 104, 107a, and 108a) as a prelude to getting a clearer picture of the role of chirality in the 5-HT7R 
binding affinity of the compounds.   
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Scheme 2-4: Reagents and conditions: (a) POCl3, ACN, reflux, 12h;  (b) (S,S)-110(5 mol-%), HCO2H / 
Et3N, DMF, rt, 1h (c) (Boc)2O, K2CO3, ACN, rt, 60% over 3 steps; (d) Pd(OAc)2, tris(4-
fluorophenyl)phosphine, K2CO3, (CH3)3CCOOH, DMA, 100 °C, 70%; (e) TFA, CHCl3, rt, 2h, 78%; (f) HCHO, 
NaBH(OAc)3, DCM, 18h, overnight ,75%; (g) HSiCl3, ACN, 0°-rt, 18 h, 80%  
 
Asymmetric hydrogenation of imine (109) with (S,S)- RuCl(p-cymene)[(S,S)-Ts-DPEN], (S,S-110) 
generated (R)-111.182 Thereafter chemical manipulations as previously described in Scheme 2-1 were 
deployed to generate the chiral (R)-98a.  Similarly, reaction of imine 109 with (R,R)- RuCl(p-cymene)[(S,S)-
Ts-DPEN], (R,R-110), gave (S)-111 which was transformed to the chiral (S)-98a. The C10 aniline moieties 
of (R)-98a and (S)-98a were then transformed into the corresponding C10 urea [(R)- and (S)-103a] and 
C10 methanesufonamide analogs [(R)- and (S)-101a] as previously described for the racemic series 
(Scheme 2-5).  The chiral benzofused aminothiazole analogs [(R)- and (S)-107a and -108a] were also 
synthesized from the key chiral aniline precursors (R)-98a and (S)-98a using methodologies as previously 




Scheme 2-5: Reagents and conditions: (a) KCN, AcOH, water, 1h, rt, 55-60%; (b) KSCN, AcOH, Br2, 
12h,0oC rt,45% (c) HCOOH, reflux, 2h, 40% 
 
 Synthesis of Benzimidazole Heterocycle: 
 
As an extension to the interesting SAR results obtained from the benzofused aminothiazole series, we set 
out to synthesize other C10 nitrogenated benzofused heterocycles.  To that end compound 98a was nitrated 
using conc. HNO3 giving isomers 112 and 116 in a 3:1 ratio (isolated yield). This was followed by 
deprotection of the amino group giving C10 amine compounds (113 and 117) and subsequent reduction of 
this new nitro group to an amine functionality (dianilines 114 and 118). These dianiline moieties were 
converted into imidazole rings utilizing Philips method of benzimidazole synthesis (reflux with carboxylic 






Scheme 2-6: Reagents and conditions: (a) AcOH, HNO3, 2h, 0oC (60% (3:1 isomeric ratio)) (b) HCl, EtOH, 
reflux, 2h, 80% (c) HSiCl3, DIPEA, CH2Cl2, 0oC-rt, overnight, 86% (d) HCOOH, reflux 
 
 Expected Biological Evaluation Results: 
 
Results on the biological assay of the chiral analogs synthesized in section 2.1.7 and 2.1.8 are pending.  
Compounds, (S)-103a, (S)-104a, (S)-107a, and (S)-108a may display improved binding affinity as 
compared to the previously synthesized racemic compounds (103a, 104, 107a, and 108a) at the 5-HT7AR.  
At this time, we are not able to predict which enantiomer will be eutomeric in each case, but evaluation of 
the enantiomers of each compound will shed more light on this aspect of the SAR.  Compound 115 with a 
benzofused imidazole moiety is expected to display affinity for serotonin or dopamine receptors.  Their 
biological evaluation will shed more light on the tolerance for nitrogenated substituent groups in ring D on 






In this study we sought to evaluate the extent to which C10 nitrogen substituents on the aporphine core 
impact affinity and selectivity for serotonin and dopamine receptors. Aporphines with C10 substituted 
substitution patterns and ring D aminothiazole moieties were investigated.  
 
We found that among the C10 N-substituent groups investigated (amine, amide, methanesulfonamide and 
urea), the methanesulfonamide group seems to offer better tolerance for 5-HT7AR affinity than amides. 
Nevertheless, compound 103a with a C10 urea substitution was the best 5-HT7AR ligand identified from this 
series in terms of 5-HT7AR affinity and selectivity versus the other 5-HT receptors tested. 
 
The C10 monosubstituted group of compounds was found to selectively target 5-HT1AR and 5-HT7AR and 
largely lacked affinity for 5-HT2AR and 5-HT6R. In general, an N6-methyl substituent engenders 5-HT7AR 
selectivity over 5-HT1AR whereas this selectivity is reversed with an N6-propyl substituent. 
 
A summary of the SAR relationships for C10 N-monosubstituted aporphine alkaloids derived from binding 
data is represented in Figure 2.4. N6-substitutions was established as a major factor affecting the binding 
affinity and selectivity at 5-HT1AR and 5-HT7AR; N6-methyl substitution improved binding affinity and 
selectivity of 5-HT7AR over 5-HT1AR, and N6-propyl substitution favored 5-HT1AR binding versus 5-HT7AR 
binding. Among the N6-methyl congeners investigated in this thesis substitution of C10 nitrogen 
substitutions proved to be vital in achieving high binding affinity at 5-HT7AR, as shown by C10 urea and 
C10 N-benzofused aminothiazole moiety substitution. This combined with the binding affinity shown by N6-
methyl, C10 N,N-dimethyl substituted aporphine analog 102a (Ki = 17 nM) could potentially be due to the 
C10 nitrogen’s hydrogen bonding ability inside the 5-HT7AR binding site. Another important discovery was 
the improvement of binding affinity at 5-HT1AR where hydrophobic substitutions at C10 nitrogen improved 




Figure 2.4: Summary of SAR of C10 monosubstituted aporphine at 5-HT1AR and 5-HT7AR  
 
Docking studies revealed that compounds 103a, 107a and 108a engage some similar residues in 
interacting with the 5-HT7R.  In that regard all three compounds had an ionic interaction between the 
protonated N6 and Asp162, π-π interactions between the ring A phenyl moiety and Phe352 and H-bond 
interactions between the C10 substituent group and Ser243.  Compound 107a showed a slightly different 
preferred docking pose as compared to 103a and 108a but nevertheless showed similar interactions.  Thus, 
the C10 nitrogenated analogs may be accommodated in the binding pocket in different orientations but it 
appears that the three interactions mentioned above are especially critical for 5-HT7R affinity of the series. 
 
Compounds 103a and 108a were found to function as antagonists in assays that measured cAMP 
production.  These compounds do not display any appreciable affinity for dopamine receptors.  Given their 
promising selectivity profiles and favorable predicted physicochemical properties (e.g.: - clogP values 
predictive of good drug-like properties), compounds 103a and 108a represent interesting starting points 
from which to further optimize this series of aporphines as selective 5-HT7R antagonist tools and drugs.  





 Synthetic Experimental Procedures 
 
All glass apparatus was oven-dried prior to use. HRESIMS spectra were obtained using an Agilent 6520 
Q-TOF instrument. 1H NMR and 13C NMR spectra were recorded using a Bruker DPX-500 spectrometer 
(operating at 500 and 600 MHz for 1H; 125 and 150 MHz, respectively, for 13C) using CDCl3 as solvent. 
Tetramethylsilane (δ 0.00 ppm) served as an internal standard in 1H NMR and 13C NMR unless stated 
otherwise. Chemical shift (δ 0.00 ppm) values are reported in parts per million and coupling constants in 
Hertz (Hz). Splitting patterns are described as singlet (s), doublet (d), triplet (t), and multiplet (m). HPLC 
analysis were conducted on Agilent 1200 series HPLC with DAD detector and UV detector at 214 nm. 
Reactions were monitored by TLC with Whatman Flexible TLC silica gel G/UV 254 precoated plates (0.25 
mm). TLC plates were visualized in UV light (254 nm) and by staining with phosphomolybdate spray 
reagent, vanillin, or iodine. Flash column chromatography was performed with silica gel 60 (EMD 
Chemicals, 230-400 mesh, 0.04-0.063 mm particle size). Preparative thin layer chromatography was 
performed with silica gel GF plates (Analtech, catalog # 02003). All chemicals and reagents were obtained 
from Sigma-Aldrich and Fischer Scientific (USA) in reagent grade and were used without further purification. 
 
2.1.10.1. 2-(2-bromo-4-nitrophenyl)-N-phenethylacetamide (93): 
2-(2-bromo-4-nitrophenyl) acetic acid (91) (5.0 g, 19.2 mmol) and N,N,N′,N′-tetramethyl-O-(1H-
benzotriazol-1-yl)uronium hexafluorophosphate (HBTU) (8.0 g, 21.1 mmol) was dissolved in THF and 
stirred vigorously for 30 min under nitrogen atmosphere. A solution of amine 92 (25 mmol) in THF was 
added to the mixture and was allowed to react further for 30 min. N,N-diisopropylethylamine (14.3 g, 57.6 
mmol) was added to the flask and the solution was stirred at room temperature overnight. Water was added 
to the flask and stirred for 30 min. The precipitate thus formed was filtered under vacuum to provide amide 
68.   
90% yield. Brownish-white solid. Melting point: 124.5 oC - 126.3 oC. 1H NMR (600 MHz, CDCl3): δ 8.18 (d, 
1H, J =2.6 Hz), 8.01 (dd, 1H, J = 6.1 Hz, 2.7 Hz), 7.75 (d, 1H,  J = 8.76 Hz), 7.28 (t, 2H,  J = 7.4 Hz, Ar-
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2H), 7.23 (d, 1H,  J = 7.3 Hz), 7.15 (d, 1H,  J = 7.3 Hz), 5.67 (s, 1H), 5.13 (s, 2H),  3.74 (s, 2H), 3.57 (q, 2H, 
J = 6.6 Hz), 2.83 (t, 2H, J = 7.0 Hz). 13C NMR (150 MHz, CDCl3): δ 168.0, 147.2, 138.5, 137.3, 136.9, 133.9, 
132.3, 129.0, 128.7, 127.2, 126.6, 126.3, 123.5, 43.6, 40.9, 35.4 ppm. HRESIMS m/z 363.0340 [M+H]+ 
(calcd. for C16H15BrN2O3, 363.0339)  
 
2.1.10.2. tert-butyl-1-(2-bromo-4-nitrobenzyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (94): 
Compound 93 (6.5 g, 17.9 mmol) was transferred into a flask and ACN (100 ml) was added to the flask to 
make a suspension. This suspension was kept at 0 oC and POCl3 (4 mmol) was added dropwise to the 
flask. After complete addition of POCl3, the reaction mixture became clear and the reaction was heated to 
reflux for 2 h under nitrogen atmosphere. The reaction mixture was concentrated in-vacuo and treated with 
1M NaOH and extracted with DCM (3x100 mL). The combined organic layer was dried using anhydrous 
Na2SO4, filtered and concentrated in-vacuo to obtain an orange solid. 
 
This solid was dissolved in methanol (100 mL) and the solution stirred vigorously under ice for 30 min. 
NaBH4 (10 equiv) was added to portion-wise to the reaction flask. The reaction was allowed to come to 
room temperature and stirred overnight. The reaction mixture was concentrated in-vacuo, treated with 
saturated solution of NaHCO3 and extracted with ethyl acetate (3x50 mL). The combined organic layer was 
dried using anhydrous Na2SO4, filtered and concentrated to obtain an intermediate tetrahydroisoquinoline. 
 
This tetrahydroisoquionoline was dissolved in ACN (50 mL) and Boc anhydride (9.4 g, 43 mmol) was added 
to the solution. To this mixture DMAP (catalytic) and triethylamine (5.7 g, 57.6 mmol) were added, and the 
reaction was stirred under nitrogen atmosphere overnight. The reaction mixture was concentrated in-vacuo 
and treated with 5% aqueous HCl (125 mL).  The mixture was extracted with DCM (3x50 mL) and the 
combined organic extract was dried using anhydrous Na2SO4, filtered and concentrated in-vacuo.  The 
crude product was purified using silica-gel flash column chromatography eluting in 20% EtOAc/Hexanes to 
give the title compound, 94. 
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50% over three steps. Yellow-orange solid. Melting point: 146.3 oC -148.7 oC. 1H NMR (600 MHz, CDCL3): 
δ 7.94-7.85 (m, 2H, Ar-2H), 7.70-7.66 (m, 1H, Ar-H), 7.26-7.22 (m, 1H, Ar-H), 7.19-7.07 (m, 3H, Ar-3H), 
5.47-5.38 (m, 1H, CH),  4.30-4.01 (m, 1H, CH), 3.40-3.24 (m, 2H, CH2),  3.13-3.03(m, 1H, CH), 2.94-2.81 
(m, 1H, CH), 2.74-2.69 (m, 1H, CH), 1.17-1.04 (9H, 3-CH3). 13C NMR (150 MHz, CDCl3): δ 154.3, 154.0, 
147.1, 146.8, 140.3, 140.1, 136.4, 136.3, 134.8, 134.5, 133.5, 132.8, 132.6, 129.4, 128.9, 127.2, 127.1, 
127.0 ,126.9, 126.4 , 126.3, 126.1, 125.7, 122.9, 122.7, 79.8 , 79.7, 54.0, 53.2, 42.8, 42.5, 38.5, 36.7, 28.8, 
28.4, 28.1, 28.0 ppm. HRESIMS m/z 470.0684 [M+Na]+ (calcd for C21H24BrN2O4, 470.0765) 
 
2.1.10.3. tert-butyl-10-nitro-4,5,6a,7-tetrahydro-6H-dibenzo[de,g]quinoline-6-carboxylate (95):   
Palladium diacetate (225 mg, 1 mmol), K2CO3 (2.17 g, 15.7 mmol), tris (4-fluorophenyl)phosphine  (782 
mg, 2 mmol) and pivalic acid (200 mg, 2 mmol) were added to a 100 mL round bottom flask.   Degassed 
DMA (15 mL) was added, and the mixture stirred under nitrogen atmosphere for 45 min. Compound 94 (2.2 
g, 4.9 mmol) was dissolved in degassed DMA (10 mL) and added to the reaction flask.   The reaction was 
heated with stirring for 18 h at 100 OC. The reaction mixture was adsorbed onto silica gel silica and loaded 
into a silica gel column and purified by column chromatography, eluting in 20% EtOAc/Hexanes to obtain 
compound 95. 
 
78% yield. Yellow solid.  Melting point: 175.1 - 177.4 oC. 1H NMR (600 MHz, CDCl3): δ 8.50-8.15 (m, 1H, 
Ar-H), 8.08-8.04 (m, 2H, Ar-2H), 6.75-6.63 (1H, Ar-H), 4.66 (d, H, CH), 4.36 (s,1H, CH), 3.86-3.81 (3H, 
CH3), 3.05-3.03 (1H, CH), 2.86-2.81 (3H), 2.64-2.54 (1H, CH), 1.431-1.426 (9H, 3-CH3). 1.41 (7H, 3-CH3). 
13C NMR (125 MHz, CDCl3): δ 154.1, 150.8, 150.7, 146.7, 146.0, 145.8, 142.7, 139.1, 138.6, 138.1, 137.4, 
136.7, 132.8, 129.3, 128.7, 128.4, 128.3, 126.6, 126.4, 125.9, 125.5, 123.3, 122.1, 121.9, 118.1, 113.2, 
111.2, 84.0, 80.4, 80.2, 56.3, 56.2, 50.8, 38.3, 35.0, 30.5, 30.1, 28.5, 28.5, 27.6 ppm. HRESIMS m/z 




2.1.10.4. 10-nitro-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline (96):  
Compound 95 (1.2 g, 3 mmol) was dissolved in DCM (18 mL) and TFA (2 mL) added.  The mixture was 
stirred for 2 h, quenched via addition of a saturated solution of NaHCO3 and extracted with DCM (3*15 mL). 
The combined organic layer was concentrated and purified via preparative TLC, eluting in 2% MeOH/DCM 
to obtain compound 96.   
75% yield.  Brown solid. Melting point: 146.3  - 148.7 oC. 1H NMR (600 MHz, CDCl3): δ 8.20 (d, J = 8.6 Hz, 
1H), 8.15 (s, 1H), 7.87 (d, J = 8.5 Hz , 1H), 7.64 (d, J = 7.7 Hz , 1H), 7.34 (t, J = 7.6 Hz, 1H), 7.23 (d, J = 
7.6 Hz, 1H), 4.09 (dd, J = 14.3 Hz and 4.7 Hz, 1H), 3.45-3.43 (m, 1H), 3.13-3.04 (m, 3H), 2.91-2.81 (m, 
2H), 1.82 (s, 1H). 13C NMR (150 MHz, CDCl3): δ 146.7, 140.8, 136.6, 134.5, 134.1, 130.1, 127.3, 124.5, 
123.6, 122.9, 122.7, 61.4, 53.3, 44.0, 34.0, 29.0 ppm. HRESIMS m/z 267.1129 [M+H]+ (calcd. for 
C16H14N2O2, 266.3000) 
 
General method for N6-alkylation 
Compound 96 (0.5 g, 1.8 mmol) was dissolved in DCM (20 mL) and respective aldehyde (0.17 g, 5.6 mmol) 
and sodium triacetoxyborohydride (4.0 g, 18 mmol) were added and the reaction stirred overnight under 
nitrogen atmosphere. The reaction mixture was quenched with saturated NaHCO3 solution and extracted 
with DCM (3x10 mL). The combined organic layer was dried with anhydrous Na2SO4, filtered, and 
concentrated in-vacuo.  The concentrated extract was purified by preparative TLC eluting in 2% 
methanol/DCM to yield compound 97a and 97b 
 
2.1.10.5. 6-methyl-10-nitro-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline (97a):  
49% yield.  Yellow solid.  Melting point: 174.3 - 176.9 oC. 1H NMR (500 MHz, CDCl3): δ 8.09 (m, 2H), 7.75 
(d, J = 7.6 Hz, 1H), 7.52 (d, J = 6.6 Hz, 1H),  7.24 (t, J= 6.6 Hz,1H), 7.12 (d, J = 6.6 Hz, 1H), 3.23-3.02 (m, 
4H), 2.73-2.64 (m, 2H), 2.50 (merged, 4H). 13C NMR (125 MHz, CDCl3): δ 146.7, 140.8, 136.6, 134.5, 
134.1, 131.5, 130.1, 127.3, 124.5, 123.6, 122.9, 122.7, 61.4, 53.3, 44.0, 34.0, 29.0 ppm. HRESIMS m/z 
280.1285 [M+H]+ (calcd. for C17H16N2O2, 280.1206) 
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2.1.10.6. 10-nitro-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline (97b): 
Yield: 50%. Brown oil. 1H NMR (500 MHz, CDCl3) δ 8.09 (d, J = 6.7 Hz, 2H), 7.74 (d, J = 9.2 Hz, 1H), 7.51 
(d, J = 7.7 Hz, 1H), 7.22 (t, J = 7.6 Hz, 1H), 7.11 (d, J = 7.6 Hz, 1H), 3.42 (dd, J = 18.6, 5.6 Hz, 1H), 3.38 
(d, J = 1.0 Hz, 1H), 3.22 (dd, J = 14.5, 4.3 Hz, 1H), 3.16 (dd, J = 11.5, 5.8 Hz, 1H), 3.12 – 3.03 (m, 1H), 
2.86 (ddd, J = 12.7, 10.2, 6.3 Hz, 1H), 2.69 (dd, J = 30.8, 16.3 Hz, 2H), 2.50 – 2.39 (m, 2H), 1.65 – 1.46 
(m, 2H), 0.91 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 146.7, 141.0, 136.9, 135.2, 134.5, 131.7, 
130.0, 127.2, 124.4, 123.6, 122.9, 122.7, 58.8, 56.3, 49.2, 34.0, 29.2, 19.3, 12.1 ppm.  
 
General method for synthesis of Amine 
To a magnetically stirred solution of compound (97a-b, 1 eq) in ACN (10 mL) was added HSiCl3 (5eq) at 0 
˚C in a dropwise manner under nitrogen atmosphere.  This was followed by the addition of DIPEA (5 eq) at 
the same temperature. The reaction was brought to room temperature and stirred for 18 h. After completion 
of the reaction, the reaction mixture was quenched with 40% aqueous KOH (10 mL) and stirred until a clear 
solution appeared. The mixture was extracted with DCM (3x20 mL) and the combined organic layer was 
dried over anhydrous Na2SO4, filtered, and concentrated in-vacuo to give crude compound 98a-b, which 
was purified by preparative TLC using 5% MeOH/DCM  
 
2.1.10.7. 6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-amine (98a):  
80% yield. Brown foamy solid. Melting point: 94.3 – 96.7 oC. 1H NMR (600 MHz, CDCl3): δ 7.56-7.49 (m,2H), 
7.25 (t, J = 7.7 Hz , 1H), 7.03 (d, J = 6.1 Hz , 1H), 6.64 (d, J = 5.8 Hz , 1H), 6.56 (s, 1H), 3.74 (s, 2H), 3.25-
3.23 (m, 2H), 3.08-3.04 (m, 2H), 2.69 (d, J = 15.9 Hz , 1H), 2.69 (t, J = 13.8 Hz ,1H), 2.58 (m, 4H). 13C NMR 
(150 MHz, CDCl3): δ 146.2, 136.7, 133.9, 133.4, 132.6, 126.9, 126.6, 125.0, 120.7, 114.7, 114.2, 62.2, 




2.1.10.8. 6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-amine (98b)  
85 % yield. Dark brown oil. 1H NMR (500 MHz, CDCl3) δ 7.57 (d, J = 8.3 Hz, 1H), 7.49 (d, J = 7.7 Hz, 1H), 
7.25 (t, J = 7.6 Hz, 1H), 7.04 (d, J = 7.5 Hz, 1H), 6.66 (dd, J = 8.2, 2.1 Hz, 1H), 6.60 (s, 1H), 3.79 (s, 2H), 
3.52 (dd, J = 13.9, 3.4 Hz, 1H), 3.28 – 3.14 (m, 2H), 3.08 (dd, J = 14.2, 4.2 Hz, 1H), 3.03 – 2.94 (m, 1H), 
2.82 – 2.76 (m, 1H), 2.70 (t, J = 14.1 Hz, 1H), 2.61 – 2.49 (m, 2H), 1.68 (dddd, J = 16.5, 13.4, 8.5, 4.3 Hz, 
2H), 1.04 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 146.2, 137.0, 134.1, 133.8, 133.4, 126.7, 126.6, 
125.3, 125.0, 120.8, 114.7, 114.1, 59.5, 56.4, 49.5, 34.5, 29.3, 19.3, 12.3 ppm. HRESIMS m/z 279.1860 
[M+H]+ (calcd. for C19H23N2, 279.1856). 
 
General Method for synthesis of acetamide analogs: 
To a stirred solution of the corresponding aniline (0.2 mmol) in DCM (10 mL) was added acetic anhydride 
(12 µl,0.4 mmol) and the resulting reaction mixture was stirred at rt for 2 h under nitrogen atmosphere. After 
completion of the reaction (monitored by TLC) the reaction mixture was concentrated in-vacuo and a 
solution of NaOH (0.2 g) in methanol (10 mL) was added and stirred for another 30 min at the same 
temperature. The reaction mixture was concentrated in-vacuo and the obtained crude mass was dissolved 
in water and extracted with DCM (3x10 mL). The organic layer was dried over anhydrous Na2SO4, filtered, 
and concentrated in-vacuo to give crude product, which was purified by preparative TLC purification eluting 
in 5% MeOH/DCM. 
 
2.1.10.9. N-(6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)acetamide (99a): 
34% yield.  Yellow oil.  1H NMR (600 MHz, CDCL3): δ 7.59 (d, J = 8.3 Hz, 1H), 7.50 (s, 1H), 7.44-7.40 
(m,2H), 7.26 (d, J = 7.9 Hz , 1H), 7.14 (t, J = 7.6 Hz, 1H), 6.98 (d, J = 7.4 Hz , 1H), 3.12-3.05 (m, 3H), 3.00-
2.98 (m, 1H), 2.67 (d, J = 15.6 Hz , 1H),  2.59 (t, J = 14.0 Hz , 1H),  2.46-2.44 (m, 4H), 2.10 (s, 3H). 13C 
NMR (150 MHz, CDCl3): δ 171.4, 137.3, 136.2, 133.5, 133.2, 133.1, 130.4, 127.7, 126.9, 124.3, 121.4, 
119.6, 118.6, 61.9, 53.5, 53.3, 43.9, 39.7, 34.2, 28.9, 19.1, 13.8ppm. HREMIS m/z 293.1649 [M+H]+ (calcd. 




2.1.10.10. N-(6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)acetamide (99b) 
73% yield. Off-white solid. Melting point: 99.8 oC – 100.3 oC.  1H NMR (600 MHz, CDCl3): δ 7.56 (d, J = 8.4 
Hz, 1H), 7.51 (s, 1H), 7.41 (d, J = 7.7 Hz, 1H), 7.30 (m, 1H), 7.22 (t, J = 11.5 Hz, 1H), 7.15 (t, J = 7.6 Hz, 
1H), 6.98 (d, J = 7.5 Hz, 1H), 3.44 (m, 1H), 3.18 – 3.09 (m, 2H), 3.07 (m, 1H), 2.87 (m, 1H), 2.72 – 2.67 (m, 
1H), 2.63 (m, 1H), 2.52 – 2.40 (m, 2H), 2.11 (s, 3H), 1.63 – 1.48 (m, 2H), 0.90 (t, J = 7.4 Hz, 3H) ppm.13C 
NMR (125 MHz, CDCl3): δ 168.4, 137.3, 136.1, 133.6, 133.3, 130.4, 127.7, 127.0, 124.3, 121.6, 119.5, 
119.4, 118.7, 59.3, 56.2, 49.4, 33.9, 28.9, 24.7, 18.9, 12.0 ppm. HRESIMS m/z 329.1964 [M+H]+ (calcd. for 
C21H25N2O, 321.1961) 
 
General Method for synthesis of butyramide analogs: 
Compound 73 (0.2 mmol) was dissolved in DCM (10 mL). Butyric anhydride (19 µl, 0.4 mmol) was added 
to the flask and resulting mixture was stirred for 2 h under nitrogen atmosphere. The reaction mixture was 
then concentrated in-vacuo and solid NaOH (0.2 g) along and methanol (10 mL) were added to the flask 
and stirred for 30 min.  The reaction mixture was concentrated in-vacuo, dissolved in water, and extracted 
with DCM (3x10 mL). The organic layer was dried using anhydrous Na2SO4, filtered and concentrated in-
vacuo. The product 74b was obtained by preparative TLC purification with 5% MeOH/DCM as eluent.  
 
2.1.10.11. N-(6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)butamide (100a):  
34% yield. Light brown solid.  Melting point: 78.3 oC -79.5 oC. 1H NMR (600 MHz, CDCl3): δ 7.56-7.54 
(m,2H), 7.41 (d, J = 7.8 Hz, 1H), 7.37 (s, 1H), 7.25 (d, J = 8.3 Hz, 1.2 Hz , 1H), 7.15 (t, J = 7.6 Hz , 1H), 
6.97 (d, J = 7.6 Hz , 1H), 3.16-3.10 (m, 2H), 3.08-3.05 (m, 1H), 3.02-2.99 (m, 1H), 2.67 (dd, J = 16.4 Hz 
and 3.1 Hz, 1H),  2.61 (t, J = 14.1 Hz , 1H),  2.49-2.45 (m, 4H), 2.27 (t, J = 7.4  Hz), 1.69 (td, J = 7.4 Hz , 
2H), 0.94 (t, J = 7.4 Hz ,1H). 13C NMR (150 MHz, CDCl3): δ 171.4, 137.3, 136.2, 133.5, 133.2, 133.1, 130.4, 
127.7, 126.9, 124.3, 121.4, 119.6, 118.6, 61.9, 53.5, 53.3, 43.9, 39.7, 34.2, 28.9, 19.1, 13.8ppm. HREMIS 




2.1.10.12. N-(6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)butyramide (120)  
50% yield. Pale yellow solid. Melting point: 104.9 oC – 106.5 oC. 1H NMR (600 MHz, CDCl3): δ 7.66 (d, J = 
7.4 Hz, 2H), 7.51 (d, J = 7.6 Hz, 1H), 7.34 (d, J = 7.0 Hz, 1H), 7.25 (t, J = 7.6 Hz, 1H), 7.07 (d, J = 7.4 Hz, 
1H), 3.61 – 3.50 (m, 1H), 3.31 – 3.15 (m, 3H), 3.01 – 2.92 (m, 1H), 2.84 – 2.71 (m, 2H), 2.66 – 2.52 (m, 
2H), 2.37 (t, J = 7.4 Hz, 2H), 1.80 (m, 2H), 1.74 – 1.59 (m, 2H), 1.05 (t, J = 7.3 Hz, 3H), 1.00 (t, J = 7.3 Hz, 
3H) ppm.13C NMR (150 MHz, CDCl3): δ 171.5, 137.3, 136.2, 133.5, 133.2, 133.1, 130.4, 127.7, 126.9, 
124.4, 121.5, 119.6, 118.6, 61.9, 53.5, 53.4, 43.9, 39.7, 34.2, 29.7, 28.9, 19.1, 13.8 ppm. HRESIMS m/z 
349.2279 [M+H]+ (calcd. for C23H29N20, 349.2274) 
 
General procedure for preparation of methanesulfonamide analogs:  
To a stirred solution of corresponding aniline (0.1 mmol) in DCM (10 mL), methanesulfonic anhydride (0.25 
mmol) and triethylamine (0.3 mmol) were added. The resulting mixture was stirred at rt for 12h under 
nitrogen atmosphere. After completion of the reaction, the reaction mixture was concentrated in-vacuo and 
a solution of NaOH (0.2 g) in methanol (10 mL) was added to the flask and stirring was continued for another 
30 min. The reaction mixture was concentrated in-vacuo, dissolved in water, and extracted with DCM (3x10 
mL). The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated in-vacuo. The crude 
product thus obtained was purified using preparative TLC eluting in 5% MeOH/DCM to give respective 




48% yield. Light brown oil. 1H NMR (500 MHz, CDCl3): δ 7.61 (d, J = 8.1 Hz, 1H), 7.44 (d, J = 7.7 Hz, 1H), 
7.21 – 7.17 (m, 1H), 7.12 – 7.07 (m, J = 8.5 Hz, 2H), 7.02 (d, J = 7.6 Hz, 1H), 3.18 (m, 2H), 3.14 – 3.02 (m, 
2H), 2.99 (s, 3H), 2.74 – 2.67 (m, 1H), 2.63 (m, 1H), 2.56 – 2.47 (m, 4H) ppm. 13C NMR (125 MHz, CDCl3): 
δ 135.9, 135.0, 132.6, 132.1, 131.7, 130.6, 127.2, 126.2, 124.1, 120.7, 119.5, 118.6, 60.8, 52.4, 42.9, 38.5, 






38% yield. Dark brown oil. 1H NMR (500 MHz, CDCl3): δ 7.61 (d, J = 8.3 Hz, 1H), 7.42 (d, J = 7.7 Hz, 1H), 
7.17 (t, J = 7.6 Hz, 1H), 7.10 (s, 1H), 7.07 (dd, J = 8.3, 2.1 Hz, 1H), 7.01 (d, J = 7.6 Hz, 1H), 3.39 (dd, J = 
14.0, 3.8 Hz, 1H), 3.17 – 3.05 (m, 3H), 3.00 (s, 3H), 2.86 (m, 1H), 2.69 (m, 1H), 2.59 (m, 1H), 2.47 – 2.35 
(m, 2H), 1.63 – 1.48 (m, 2H), 0.91 (t, J = 7.4 Hz, 3H) ppm. 13C NMR (125 MHz, CDCl3): δ 136.2, 134.9, 
133.0, 131.9, 130.9, 127.7, 127.2, 126.0, 124.1, 120.7, 119.4, 118.6, 58.2, 55.4, 48.4, 38.5, 33.2, 28.1, 
18.3, 11.1 ppm.  HRESIMS m/z 357.1636 [M+H]+ (calcd. for C20H25N2O2S, 357.1631) 
 
General procedure for synthesis of urea analogs: 
To a magnetically stirred solution of amine (100 mg, 1 equiv.) in 10% acetic acid solution (10 mL) (v/v), a 
solution of KCN (2 equiv.) in water (5 mL) was added. The reaction was stirred at rt for 2h. After completion 
of the reaction (monitored by TLC), the reaction was quenched with saturated sodium bicarbonate and 
extracted with EtOAc (3x15 mL). The combined organic layer was dried over Na2SO4, filtered, concentrated 
under reduced pressure and the crude product thus obtained was purified using preparative TLC, eluting 
in 5% MeOH/DCM to give the respective urea analogs. 
 
2.1.10.15. 1-(6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)urea (103a) 
83% yield. White solid. Melting point: 125.6 oC – 126.9 oC.  1H NMR (500 MHz, CDCl3): δ 7.56 (d, J = 8.2 
Hz, 1H), 7.42 (d, J = 7.5 Hz, 1H), 7.34 (bs, 1H), 7.26 (s, 1H), 7.20 (m, 2H), 7.04 (d, J = 7.5 Hz, 1H), 5.12 
(bs, 2H), 3.25 – 3.16 (m, 2H), 3.08 (m, 2H), 2.74 (m, 1H), 2.65 (m, 1H), 2.54 (m, 4H) ppm. 13C NMR (125 
MHz, CDCl3): δ 156.7, 137.9, 136.0, 133.1, 133.0, 132.5, 130.0, 127.7, 127.2, 124.6, 121.5, 120.6, 119.9, 




2.1.10.16. 1-(6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)urea (103b) 
86% yield. Brown Solid. Melting point: 114.5 oC – 114.9 oC. 1H NMR (600 MHz, Acetone-d6) δ 8.26 (dd, J 
= 2.2, 1.0 Hz, 1H), 8.20 (ddd, J = 8.6, 2.5, 0.9 Hz, 1H), 8.05 (d, J = 8.6 Hz, 1H), 7.75 (d, J = 7.7 Hz, 1H), 
7.34 (t, J = 7.7 Hz, 1H), 7.23 (d, J = 7.6 Hz, 1H), 3.60 – 3.55 (m, 1H), 3.44 (m, 1H), 3.24 (m, 1H), 3.08 (m, 
1H), 3.02 (m, 1H), 2.90 (bs, 2H), 2.79 (m, 1H), 2.62 (m, 1H), 2.50 – 2.42 (m, 2H), 1.69 – 1.56 (m, 2H), 0.99 
(t, J = 7.4 Hz, 3H) ppm. 13C NMR (125 MHz, Acetone-d6): δ 147.7, 141.8, 138.4, 136.5, 135.6, 132.5, 130.8, 
128.0, 125.6, 124.3, 123.9, 123.3, 59.9, 56.8, 50.0, 34.6, 30.1, 20.5, 12.2 ppm. HRESIMS m/z 322.1922 
[M+H]+ (calcd. for C20H24N3O, 322.4315) 
 
General procedure for synthesis of N,N-dimethylated analogs:   
To a stirred solution of the corresponding aniline (0.1 mmol) in DCM (10 mL) was added formaldehyde 
(37% aqueous solution, 5 μL, 0.1 mmol) and the reaction mixture was stirred at rt for 1h.   NaBH(OAc)3 
(200 mg, 1 mmol) was added and the resulting reaction mixture was stirred at rt for 12h.  After completion 
of the reaction (monitored by TLC) the reaction mixture was quenched with saturated sodium bicarbonate 
solution and extracted with DCM (3x15 mL). The combined organic layer was dried over Na2SO4, filtered, 
and concentrated in-vacuo. The residue thus obtained was purified using preparative TLC eluting in 5% 
MeOH/DCM to give the N-methylated analogs. 
 
2.1.10.17. N,N,6-trimethyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-amine (102a) 
63% yield. Brown oil. 1H NMR (500 MHz, CDCl3): δ 7.52 (d, J = 8.6 Hz, 1H), 7.38 (d, J = 7.7 Hz, 1H), 7.12 
(t, J = 7.6 Hz, 1H), 6.89 (d, J = 7.5 Hz, 1H), 6.61 (dd, J = 8.6, 2.6 Hz, 1H), 6.54 (d, J = 2.2 Hz, 1H), 3.17 – 
3.08 (m, 2H), 3.07 – 3.02 (m, 1H), 3.02 – 2.96 (m, 1H), 2.91 (s, 6H), 2.69 – 2.65 (m, 1H), 2.63 (m, 1H), 2.50 
(s, 3H), 2.46 (m, 1H) ppm. 13C NMR (125 MHz, CDCl3): δ 150.1, 136.4, 134.1, 133.3, 132.6, 126.8, 126.3, 
124.8, 123.1, 120.6, 111.9, 111.5, 62.4, 53.6, 44.2, 40.6, 35.0, 29.2 ppm. HRESIMS m/z 279.1861 [M+H]+ 




2.1.10.18. N,N-dimethyl-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-amine (102b) 
62%. Light brown solid. Melting point: 164.5 oC – 165.8 oC.  1H NMR (500 MHz, CDCl3): δ 7.63 (d, J = 8.6 
Hz, 1H), 7.48 (d, J = 7.7 Hz, 1H), 7.22 (t, J = 7.6 Hz, 1H), 7.00 (d, J = 7.5 Hz, 1H), 6.73 (dd, J = 8.6, 2.6 
Hz, 1H), 6.66 (d, J = 2.4 Hz, 1H), 3.59 – 3.51 (m, 1H), 3.29 – 3.22 (m, 1H), 3.20 – 3.12 (m, 2H), 3.02 (s, 
6H), 3.01 – 2.95 (m, 1H), 2.80 (s, 1H), 2.76 (s, 1H), 2.58 (m, 2H), 1.77 – 1.58 (m, 2H), 1.01 (t, J = 7.4 Hz, 
3H) ppm. 13C NMR (125 MHz, CDCl3): δ 150.1, 136.6, 134.3, 133.6, 133.1, 126.7, 126.3, 124.8, 123.2, 
120.6, 111.9, 111.5, 59.6, 56.4, 49.4, 40.6, 34.9, 29.2, 19.2, 12.2 ppm. HRESIMS m/z 307.2168 [M+H]+ 
(calcd. for C21H27N2, 307.2169) 
 
2.1.10.19. N-(6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)formamide (104): 
A stirred solution of aniline 98a (50mg, 0.2 mmol) in formic acid (10 mL) was refluxed for 2 h under nitrogen 
atmosphere. After completion of the reaction (monitored by TLC) the reaction mixture was concentrated in-
vacuo and treated with saturated Na2CO3 solution and extracted with 3x10 mL of ethyl acetate. The organic 
layer was dried over anhydrous Na2SO4, filtered, and concentrated in-vacuo to give crude product, which 
was purified by preparative TLC purification eluting in 5% MeOH/DCM. Formamide analogs were obtained 
as rotamers. 
 
40% yield. Yellow oil.1H NMR (600 MHz, CDCl3) δ 1H NMR (600 MHz, CDCl3) δ 8.67 (d, J = 11.4 Hz, 1H), 
8.29 (s, 1H), 8.24 (d, J = 11.4 Hz, 1H), 7.60 (dd, J = 17.1, 8.3 Hz, 2H), 7.55 (s, 1H), 7.50 (s, 1H), 7.43 (d, J 
= 7.6 Hz, 2H), 7.29 (d, J = 8.2 Hz, 1H), 7.15 (s, 2H), 7.00 (dd, J = 12.5, 7.6 Hz, 2H), 6.96 (d, J = 8.3 Hz, 
1H), 6.90 (s, 1H), 3.13 (t, J = 13.4 Hz, 4H), 3.09 – 3.04 (m, 2H), 3.01 (dd, J = 11.5, 5.7 Hz, 2H), 2.73 – 2.65 
(m, 2H), 2.61 (td, J = 14.1, 7.1 Hz, 2H), 2.51 – 2.45 (m, 8H). 13C NMR (150 MHz, CDCl3) δ 13C NMR (151 
MHz, CDCl3) δ 162.4, 159.0, 137.1, 136.4, 136.2, 135.9, 133.7, 133.6, 133.4, 133.3, 132.9, 132.6, 131.6, 
131.0, 128.1, 127.9, 127.1, 127.0, 125.2, 124.5, 121.5, 119.8, 118.7, 118.6, 117.6, 61.9, 61.8, 53.4, 44.0, 





General procedure for synthesis of trifluoroacetamide analogs:   
To a stirred solution of the corresponding aniline (0.2 mmol) in DCM (10 mL) was added the respective 
anhydride (0.4 mmol) and the resulting reaction mixture was stirred at rt for 2 h under nitrogen atmosphere. 
After completion of the reaction (monitored by TLC) the reaction mixture was concentrated in-vacuo and a 
solution of NaOH (0.2 g) in methanol (10 mL) was added and stirred for another 30 min at the same 
temperature. The reaction mixture was concentrated in-vacuo and the obtained crude mass was dissolved 
in water and extracted with DCM (3x10 mL). The organic layer was dried over anhydrous Na2SO4, filtered, 
and concentrated in-vacuo to give crude product, which was purified by preparative TLC purification eluting 




55% yield. Brown solid. 1H NMR (500 MHz, CDCl3) δ 8.12 (s, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.50 (s, 1H), 
7.42 (d, J = 7.7 Hz, 1H), 7.34 (dd, J = 8.4, 1.6 Hz, 1H), 7.17 (dd, J = 9.4, 4.2 Hz, 1H), 7.01 (d, J = 7.5 Hz, 
1H), 3.17 – 3.10 (m, 2H), 3.07 (dd, J = 14.3, 4.4 Hz, 1H), 3.00 (dd, J = 11.7, 5.8 Hz, 1H), 2.68 (dd, J = 16.2, 
2.9 Hz, 1H), 2.60 (t, J = 14.1 Hz, 1H), 2.50 – 2.44 (m, 4H). 13C NMR (125 MHz, CDCl3) δ 155.2 - 154.39, 
136.6, 134.2, 133.7, 133.4, 132.58, 132.5, 128.4, 127.1, 124.6, 121.8, 120.4, 119.5, 61.8, 53.4, 44.0, 34.1, 




60% yield. Brown solid.1H NMR (600 MHz, CDCl3) δ 7.98 (s, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.53 (s, 1H), 
7.42 (d, J = 7.6 Hz, 1H), 7.35 (d, J = 7.2 Hz, 1H), 7.16 (d, J = 7.6 Hz, 1H), 7.01 (d, J = 7.5 Hz, 1H), 3.42 (d, 
J = 13.8 Hz, 1H), 3.14 (dd, J = 11.1, 5.4 Hz, 1H), 3.11 – 3.03 (m, 2H), 2.85 (m, J = 12.9, 10.0, 6.2 Hz, 1H), 
2.69 (d, J = 16.0 Hz, 1H), 2.63 (t, J = 14.2 Hz, 1H), 2.51 – 2.39 (m, 2H), 1.63 – 1.47 (m, 2H), 0.90 (t, J = 
7.3 Hz, 3H). 13C NMR (150 MHz, CDCl3) δ 154.6, 154.3, 136.9, 134.2, 134.0, 132.7, 132.7, 128.3, 127.0, 
126.9, 124.6, 121.8, 120.3, 119.4, 59.1, 56.3, 49.3, 34.2, 29.1, 19.2, 12.0 ppm. HRESIMS m/z 375.1682 
[M+H]+ (calcd. for C21H22F3N2O, 375.1679) 
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General procedure for synthesis of benzamide analogs:   
To a stirred solution of the corresponding aniline (0.2 mmol) in DCM (10 mL) was added the respective 
anhydride (0.4 mmol) and the resulting reaction mixture was stirred at rt for 12 h under nitrogen atmosphere. 
After completion of the reaction (monitored by TLC) the reaction mixture was treated with saturated Na2CO3 
solution and extracted with DCM (3x10 mL). The organic layer was dried over anhydrous Na2SO4, filtered, 
and concentrated in-vacuo to give crude product, which was purified by preparative TLC purification eluting 
in 5% MeOH/DCM. 
 
2.1.10.22. N-(6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)benzamide (106a): 
35% yield. Yellow solid.1H NMR (600 MHz, CDCl3) δ 7.87 (s, 1H), 7.81 (d, J = 7.4 Hz, 2H), 7.67 (s, 1H), 
7.63 (d, J = 8.4 Hz, 1H), 7.50 – 7.44 (m, 2H), 7.41 (dd, J = 16.2, 8.3 Hz, 3H), 7.17 (d, J = 7.6 Hz, 1H), 6.99 
(d, J = 7.5 Hz, 1H), 3.19 – 3.15 (m, 1H), 3.12 (dd, J = 14.3, 4.2 Hz, 2H), 3.01 (dd, J = 11.3, 5.8 Hz, 1H), 
2.66 (dd, J = 29.6, 15.4 Hz, 2H), 2.52 – 2.45 (m, 4H). 13C NMR (150 MHz, CDCl3) δ 165.7, 137.2, 136.4, 
135.0, 133.6, 133.4, 133.1, 131.9, 130.8, 128.9, 127.8, 127.0, 127.0, 124.5, 121.5, 120.0, 119.0, 62.0, 53.4, 
44.0, 34.3, 29.1 ppm. HRESIMS m/z 347.1806 [M+H]+ (calcd. for C24H23N2O, 355.4605) 
 
2.1.10.23. N-(6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)benzamide (106b): 
29% yield. Yellowish-brown solid.1H NMR (600 MHz, CDCl3) δ 7.98 (s, 1H), 7.79 (d, J = 7.5 Hz, 2H), 7.67 
(s, 1H), 7.57 (d, J = 8.3 Hz, 1H), 7.46 – 7.32 (m, 5H), 7.13 (t, J = 7.5 Hz, 1H), 6.95 (d, J = 7.4 Hz, 1H), 3.39 
(d, J = 11.6 Hz, 1H), 3.13 – 2.99 (m, 3H), 2.85 – 2.77 (m, 1H), 2.66 (d, J = 16.1 Hz, 1H), 2.60 (t, J = 14.1 
Hz, 1H), 2.47 – 2.35 (m, 2H), 1.60 – 1.44 (m, 2H), 0.88 (t, J = 7.3 Hz, 3H). 13C NMR (150 MHz, CDCl3) δ 
165.8, 137.3, 136.7, 135.0, 134.2, 134.0, 133.3, 131.8, 131.0, 128.8, 127.8, 127.1, 126.7, 124.4, 121.5, 







General Procedure for synthesis of compounds 107-108 (a-b)  
To a magnetically stirred solution of respective compound 98a-b (1 eq) in acetic acid, potassium 
thiocyanate (2 eq) was added, and the reaction mixture was kept under ice. This was followed by addition 
of solution of bromine (1.2 eq) in 1 ml acetic acid in a dropwise manner. The resulting mixture was allowed 
to come to room temperature and stirred overnight. Completion of reaction was verified by LC-MS. The 
reaction mixture was then concentrated in-vacuo, treated with saturated sodium bicarbonate solution, and 
extracted using ethyl acetate (3x20 mL). The combined organic layer was dried using anhydrous Na2SO4 
and concentrated in-vacuo. The compounds were loaded onto preparative silica-gel and eluted using 5% 




30% yield. Orange solid. Melting point: 215-216 oC. 1H NMR (500 MHz, CDCl3) δ 7.65 (d, J = 8.5 Hz, 1H), 
7.49 (d, J = 7.8 Hz, 1H), 7.43 (d, J = 8.4 Hz, 1H), 7.22 – 7.16 (m, 1H), 6.99 (d, J = 7.3 Hz, 1H), 5.30 (bs, 
2H), 3.29 (d, J = 10.4 Hz, 1H), 3.20 – 3.12 (m, 1H), 3.08 – 2.97 (m, 2H), 2.78 (t, J = 13.9 Hz, 1H), 2.70 (d, 
J = 15.9 Hz, 1H), 2.61 – 2.47 (m, 4H) ppm. 13C NMR (126 MHz, CDCl3) δ 165.6, 151.8, 133.6, 133.5, 132.4, 
131.8, 128.5, 128.1, 127.6, 127.1, 122.3, 121.8, 118.2, 61.6, 53.4, 44.1, 34.2, 29.0 ppm. HRESIMS m/z 
308.1219 [M+H]+ (calcd. for C26H27N2O, 308.1216) 
 
2.1.10.25. 6-methyl-5,6,6a,7-tetrahydro-4H-benzo[de]thiazolo[5',4':4,5]benzo[1,2-g]quinolin-10-
amine (108a):  
32% yield. Light yellow oil. 1H NMR (600 MHz, CDCl3) δ 7.80 (s, 1H), 7.41 (d, J = 7.7 Hz, 1H), 7.32 (s, 1H), 
7.14 (t, J = 7.6 Hz, 1H), 6.96 (d, J = 7.5 Hz, 1H), 5.86 (s, 2H), 3.41 (d, J = 11.8 Hz, 1H), 3.13 (dd, J = 13.8, 
4.1 Hz, 2H), 3.11 – 3.03 (m, 1H), 2.88 (ddd, J = 12.8, 10.5, 6.1 Hz, 1H), 2.67 (d, J = 14.8 Hz, 2H), 2.49 – 
2.38 (m, 2H), 1.55 (dddd, J = 23.0, 13.7, 10.1, 6.1 Hz, 2H), 0.90 (t, J = 7.4 Hz, 3H). 13C NMR (151 MHz, 
CDCl3) δ 166.8, 151.5, 134.1, 134.0, 133.9, 133.7, 130.6, 129.5, 127.6, 126.8, 121.6, 118.4, 116.2, 59.5, 






35% yield. Brownish-white solid. Melting point: 198.1- 199.5 oC. 1H NMR (500 MHz, CDCl3) δ 7.84 (s, 1H), 
7.45 (d, J = 7.7 Hz, 1H), 7.34  (s, 1H), 7.17 (t, J = 7.6 Hz, 1H), 6.99 (d, J = 7.5 Hz, 1H), 5.50 (bs, 2H), 3.17 
(dd, J = 14.7, 4.1 Hz, 3H), 3.03 (dd, J = 11.6, 5.4 Hz, 1H), 2.69 (dd, J = 19.7, 8.9 Hz, 2H), 2.52 (s, 3H), 2.49 
(t, J = 6.0 Hz, 1H) ppm. 13C NMR (126 MHz, CDCl3) δ 166.4, 151.6, 133.9, 133.6, 133.5, 133.5, 130.9, 
129.4, 127.6, 127.0, 121.6, 118.6, 116.3, 62.2, 53.4, 44.0, 34.6, 29.1 ppm. HRESIMS m/z 308.1219 [M+H]+ 
(calcd. for C18H18N3S, 308.1216) 
 
2.1.10.27. 6-propyl-5,6,6a,7-tetrahydro-4H-benzo[de]thiazolo[5',4':4,5]benzo[1,2-g]quinolin-10-
amine (108b):  
35% yield. Off-yellow solid. Melting point: 156.6-157.5 oC.  1H NMR (600 MHz, CDCl3) δ 7.80 (s, 1H), 7.41 
(d, J = 7.7 Hz, 1H), 7.32 (s, 1H), 7.14 (t, J = 7.6 Hz, 1H), 6.96 (d, J = 7.5 Hz, 1H), 5.86 (s, 2H), 3.41 (d, J = 
11.8 Hz, 1H), 3.17 – 3.11 (m, J = 13.8, 4.1 Hz, 2H), 3.07 (dd, J = 19.7, 8.1 Hz, 1H), 2.88 (ddd, J = 12.8, 
10.5, 6.1 Hz, 1H), 2.66 (t, J = 14.4 Hz, 2H), 2.49 – 2.38 (m, 2H), 1.55 (dddd, J = 23.0, 13.7, 10.1, 6.1 Hz, 
2H), 0.90 (t, J = 7.4 Hz, 3H) ppm. 13C NMR (151 MHz, CDCl3) δ 166.8, 151.5, 134.1, 134.0, 133.9, 133.7, 
130.6, 129.5, 127.6, 126.8, 121.6, 118.4, 116.2, 59.5, 56.3, 49.3, 34.5, 29.1, 19.2, 12.2 ppm. HRESIMS 
m/z 336.1534 [M+H]+ (calcd. for C20H22N3S, 336.1529). 
 
2.1.10.28. Synthesis of enantiomeric tetrahydroisoquinoline moiety (111a/b) 
To a stirring solution of dihydroisoquinoline (5.1 g), ruthenium catalyst in degassed DMF (25 ml) at 0 oC, a 
mixture of HCCOH and Et3N (5:2; 15 mL) was added.   The reaction mixture was stirred at room temperature 
for 2h. The reaction was worked up by addition of saturated NaCO3 solution until basic, followed by addition 
of cold water (50 mL) and extracted with ethyl acetate (3x 50 mL). The combined organic fraction was 
treated with Na2SO4 and concentrated in-vacuo to obtain crude amine. This product was used without 
further purification.  
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The chiral amine was boc protected and purified via column chromatography to obtain pure (R)-94, 91% or 
(S)-94, 98%. Enantiomeric excess of (R)-122 and (S)-122 established by HPLC 
HPLC system: Agilent 1200 
Column: Chiralcel OD, 10mm, 4.6x250mm, 3,5 dimethylphenyl carbamate 
Mobile Phase A: 5% isopropanol in hexanes 
Mobile Phase B: Hexanes 
Runtime: 30 mins 
Method: Gradient, 0 to 10% A in 20 mins     
Remaining steps were followed as described in Scheme1. 
 
2.1.10.29. (R)-1-(6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)urea (R-103a): 
1H NMR (500 MHz, CDCl3) δ 7.91 (s, 1H), 7.30 (d, J = 8.3 Hz, 1H), 7.15 (d, J = 7.6 Hz, 1H), 7.05 – 6.93 (m, 
3H), 6.85 (d, J = 7.6 Hz, 1H), 5.47 (s, 2H), 3.32 – 3.07 (m, 1H), 3.05 – 2.92 (m, 1H), 2.88 – 2.70 (m, 3H), 
2.51 (d, J = 14.7 Hz, 1H), 2.40 (t, J = 12.7 Hz, 1H), 2.29 – 2.11 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 
157.6, 138.1, 135.8, 133.2, 133.0, 132.7, 129.3, 127.5, 127.0, 124.4, 121.4, 120.0, 119.3, 61.4, 53.1, 43.4, 
33.8, 28.7 ppm. HRESIMS m/z 294.1604 [M+H]+ (calcd. for C18H19N3O, 294.1601) 
 
2.1.10.30. (S)-1-(6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)urea (S-103a): 
 
1H NMR (500 MHz, CDCl3) δ 7.91 (s, 1H), 7.30 (d, J = 8.3 Hz, 1H), 7.15 (d, J = 7.6 Hz, 1H), 7.05 – 6.93 (m, 
3H), 6.85 (d, J = 7.6 Hz, 1H), 5.47 (s, 2H), 3.32 – 3.07 (m, 1H), 3.05 – 2.92 (m, 1H), 2.88 – 2.70 (m, 3H), 
2.51 (d, J = 14.7 Hz, 1H), 2.40 (t, J = 12.7 Hz, 1H), 2.29 – 2.11 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 
157.6, 138.1, 135.8, 133.22 133.0, 132.7, 129.4, 127.5, 127.0, 124.4, 121.4, 120.0, 119.3, 61.5, 53.1, 43.4, 
33.8, 28.7 ppm. HRESIMS m/z 294.1604 [M+H]+ (calcd. for C18H19N3O, 294.1601) 
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2.1.10.31. (R)- N-(6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)formamide (R-104): 
1H NMR (600 MHz, CDCl3) δ 8.67 (d, J = 11.4 Hz, 1H), 8.29 (s, 1H), 8.24 (d, J = 11.4 Hz, 1H), 7.60 (dd, J 
= 17.1, 8.3 Hz, 2H), 7.55 (s, 1H), 7.50 (s, 1H), 7.43 (d, J = 7.6 Hz, 2H), 7.29 (d, J = 8.2 Hz, 1H), 7.15 (s, 
2H), 7.00 (dd, J = 12.5, 7.6 Hz, 2H), 6.96 (d, J = 8.3 Hz, 1H), 6.90 (s, 1H), 3.13 (t, J = 13.4 Hz, 4H), 3.09 – 
3.04 (m, 2H), 3.01 (dd, J = 11.5, 5.7 Hz, 2H), 2.73 – 2.65 (m, 2H), 2.61 (td, J = 14.1, 7.1 Hz, 2H), 2.51 – 
2.45 (m, 8H). 13C NMR (150 MHz, CDCl3) δ 13C NMR (151 MHz, CDCl3) δ 162.4, 159.0, 137.1, 136.4, 
136.2, 135.9, 133.7, 133.6, 133.4, 133.3, 132.9, 132.6, 131.6, 131.0, 128.1, 127.9, 127.1, 127.0, 125.2, 
124.5, 121.5, 119.8, 118.7, 118.6, 117.6, 61.9, 61.8, 53.4, 44.0, 44.0, 34.2, 29.0 ppm. HRESIMS m/z 
279.1492 [M+H]+ (calcd. for C18H19N2O, 279.1492) 
 
2.1.10.32. N-(6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)formamide (S-104): 
1H NMR (600 MHz, CDCl3) δ 8.67 (d, J = 11.4 Hz, 1H), 8.29 (s, 1H), 8.24 (d, J = 11.4 Hz, 1H), 7.60 (dd, J 
= 17.1, 8.3 Hz, 2H), 7.55 (s, 1H), 7.50 (s, 1H), 7.43 (d, J = 7.6 Hz, 2H), 7.29 (d, J = 8.2 Hz, 1H), 7.15 (s, 
2H), 7.00 (dd, J = 12.5, 7.6 Hz, 2H), 6.96 (d, J = 8.3 Hz, 1H), 6.90 (s, 1H), 3.13 (t, J = 13.4 Hz, 4H), 3.09 – 
3.04 (m, 2H), 3.01 (dd, J = 11.5, 5.7 Hz, 2H), 2.73 – 2.65 (m, 2H), 2.61 (td, J = 14.1, 7.1 Hz, 2H), 2.51 – 
2.45 (m, 8H). 13C NMR (150 MHz, CDCl3) δ 13C NMR (151 MHz, CDCl3) δ 162.4, 159.0, 137.1, 136.4, 
136.2, 135.9, 133.7, 133.6, 133.4, 133.3, 132.9, 132.6, 131.6, 131.0, 128.1, 127.9, 127.1, 127.0, 125.2, 
124.5, 121.5, 119.8, 118.7, 118.6, 117.6, 61.9, 61.8, 53.4, 44.0, 44.0, 34.2, 29.0 ppm. HRESIMS m/z 




1H NMR (500 MHz, CDCl3) δ 7.93 (s, 1H), 7.54 (d, J = 7.7 Hz, 1H), 7.43 (s, 1H), 7.26 (d, J = 7.6 Hz, 1H), 
7.09 (d, J = 7.5 Hz, 1H), 5.74 (s, 2H), 3.32 – 3.19 (m, 3H), 3.11 (dd, J = 11.2, 5.5 Hz, 1H), 2.77 (t, J = 14.8 
Hz, 2H), 2.61 (s, 3H), 2.57 (dd, J = 12.0, 3.1 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 166.5, 151.6, 133.9, 
133.6, 133.6, 133.4, 130.8, 129.4, 127.6, 127.0, 121.6, 118.6, 116.3, 62.2, 53.4, 44.1, 34.6, 29.1 ppm. 







1H NMR (500 MHz, CDCl3) δ 7.82 (s, 1H), 7.43 (d, J = 7.7 Hz, 1H), 7.33 (s, 1H), 7.16 (t, J = 7.6 Hz, 1H), 
6.98 (d, J = 7.5 Hz, 1H), 5.75 (s, 2H), 3.14 (dd, J = 15.3, 12.7 Hz, 3H), 3.01 (dd, J = 11.2, 5.6 Hz, 1H), 2.67 
(t, J = 14.6 Hz, 2H), 2.50 (s, 3H), 2.49 – 2.44 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 166.7, 151.6, 133.9, 
133.6, 133.5, 133.4, 130.8, 129.3, 127.6, 127.0, 121.6, 118.5, 116.3, 62.2, 53.4, 44.1, 34.6, 29.1 ppm. 
HRESIMS m/z 336.1582 [M+H]+ (calcd. for C20H22N3S, 336.1529) 
 
2.1.10.35. (R)- 7-methyl-6a,7,8,9-tetrahydro-6H-benzo[de]thiazolo[4',5':5,6]benzo[1,2-g]quinolin-2-
amine (R-107a) : 
1H NMR (500 MHz, CDCl3) δ 7.65 (d, J = 8.5 Hz, 1H), 7.49 (d, J = 7.8 Hz, 1H), 7.43 (d, J = 8.4 Hz, 1H), 
7.22 – 7.16 (m, 1H), 6.99 (d, J = 7.3 Hz, 1H), 5.30 (bs, 2H), 3.29 (d, J = 10.4 Hz, 1H), 3.20 – 3.12 (m, 1H), 
3.08 – 2.97 (m, 2H), 2.78 (t, J = 13.9 Hz, 1H), 2.70 (d, J = 15.9 Hz, 1H), 2.61 – 2.47 (m, 4H) ppm. 13C NMR 
(126 MHz, CDCl3) δ 165.6, 151.8, 133.6, 133.5, 132.4, 131.8, 128.5, 128.1, 127.6, 127.1, 122.3, 121.8, 
118.2, 61.6, 53.4, 44.1, 34.2, 29.0 ppm. HRESIMS m/z 308.1219 [M+H]+ (calcd. for C26H27N2O, 308.1216) 
 
2.1.10.36. (S)- 7-methyl-6a,7,8,9-tetrahydro-6H-benzo[de]thiazolo[4',5':5,6]benzo[1,2-g]quinolin-2-
amine (S-107a) : 
1H NMR (500 MHz, CDCl3) δ 7.65 (d, J = 8.5 Hz, 1H), 7.49 (d, J = 7.8 Hz, 1H), 7.43 (d, J = 8.4 Hz, 1H), 
7.22 – 7.16 (m, 1H), 6.99 (d, J = 7.3 Hz, 1H), 5.30 (bs, 2H), 3.29 (d, J = 10.4 Hz, 1H), 3.20 – 3.12 (m, 1H), 
3.08 – 2.97 (m, 2H), 2.78 (t, J = 13.9 Hz, 1H), 2.70 (d, J = 15.9 Hz, 1H), 2.61 – 2.47 (m, 4H) ppm. 13C NMR 
(126 MHz, CDCl3) δ 165.6, 151.8, 133.6, 133.5, 132.4, 131.8, 128.5, 128.1, 127.6, 127.1, 122.3, 121.8, 




Synthesis of compound 116 and 120 
A soution of conc HNO3 (1.4 mmol) in 1 ml of acetic acid was added to a stirring solution of 
compound 98a (200 mg,0.7mmol) (refer to chapter 1 for synthesis) in acetic acid. The reactiion mixture was 
stirred overnight at room temperature. After comppletion of the reaction the reaction mixture was 
concentrated in-vacuo and treated with saturated biocarbonate solution anf extracted with EtOAc (3x 15 
mL). Thr organic fractions were combined and concentrated to obtain crude product. The crude product 
was loaded into a silica gel column and eluted with 5% MeOH in DCM to obtain compound 112 and 116 as 
regioisomers in a 3:1 ratio.   
 
2.1.10.37. N-(6-methyl-9-nitro-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]83uinoline-10-yl)acetamide (112): 
45% yield. Yellow solid. 1H NMR (500 MHz, CDCl3) δ 10.38 (s, 1H), 8.67 (s, 1H), 8.48 (s, 1H), 7.51 (d, J = 
7.7 Hz, 1H), 7.24 (t, J = 7.7 Hz, 1H), 7.08 (d, J = 7.6 Hz, 1H), 3.24 (ddd, J = 28.7, 16.4, 4.8 Hz, 3H), 3.10 
(dd, J = 12.1, 4.8 Hz, 1H), 2.75 (t, J = 15.2 Hz, 2H), 2.58 (s, 1H), 2.55 (s, 3H), 2.25 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 169.2, 144.3, 135.6, 133.9, 133.6, 131.0, 130.0, 129.1, 127.6, 121.9, 121.4, 121.4, 120.7, 
61.1, 53.3, 43.7, 34.2, 28.6, 25.8 ppm. HRESIMS m/z 325.1062 [M+H]+ (calcd. for C17H15N3O4, 325.1063) 
 
2.1.10.38. N-(6-methyl-11-nitro-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)acetamide (116): 
15% yield. Light yellow solid. 1H NMR (500 MHz, CDCl3) δ 8.33 (s, 1H), 8.14 (d, J = 8.2 Hz, 1H), 7.79 (d, J 
= 8.7 Hz, 1H), 7.42 (d, J = 7.7 Hz, 1H), 7.22 (t, J = 7.7 Hz, 1H), 7.07 (d, J = 7.6 Hz, 1H), 3.18 – 3.08 (m, 
3H), 3.08 – 3.02 (m, 1H), 2.70 (dd, J = 16.1, 2.6 Hz, 1H), 2.60 (t, J = 15.6 Hz, 1H), 2.55 – 2.49 (m, 1H), 
2.47 (s, 3H), 2.16 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 168.7, 141.5, 133.6, 132.6, 132.1, 131.4, 129.7, 
129.6, 128.9, 127.8, 127.4, 122.5, 122.2, 60.9, 53.2, 43.7, 29.5, 28.6, 24.9 ppm. HRESIMS m/z 325.1062 
[M+H]+ (calcd. for C17H15N3O4, 325.1063)  
Syntheis of Diamine compounds 114: 
Compound 112 was refluxed with excess HCl in ethanol for 2hs. The reaction mixture was basified with 
NH4OH in ice  and extracted with (3x 15 mL) of EtOAc to obtain compound 113. To a stirred solution of 
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compound 113 (1eq) in DCM at 0 oC and trichlorosilane (5 eq) , DIPEA (5 eq) was added in a dropwise 
manner and the reaction mixture was allowed to continue for 12 hours. After the completion of reaction, the 
mixture was treated with 40% KOH solution and extracted with EtOAc (3x 15 mL). The combined organic 
fraction was concntrated in-vacuo to obtian crude compound 114. The crude mixture was then loaded into 
a TLC plate and extracted with 5% MeOH in DCM to obtain pure compound. 
 
2.1.10.39. 6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-9,10-diamine (118): 
80% yield. Brown oil. 1H NMR (500 MHz, CDCl3) δ 7.34 (d, J = 7.7 Hz, 1H), 7.13 (t, J = 7.6 Hz, 1H), 7.02 
(s, 1H), 6.92 (d, J = 7.5 Hz, 1H), 6.53 (s, 1H), 3.14 (dd, J = 25.1, 10.0 Hz, 4H), 3.03 (dd, J = 11.2, 5.6 Hz, 
2H), 2.93 (dd, J = 14.0, 4.0 Hz, 2H), 2.67 (d, J = 15.4 Hz, 1H), 2.58 – 2.51 (m, 2H), 2.49 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 135.1, 133.9, 133.5, 133.2, 132.6, 127.7, 126.8, 126.7, 126.2, 120.8, 116.2, 112.6, 
62.4, 53.3, 43.7, 33.3, 28.8 ppm. HRESIMS m/z 265.1578 [M+H]+ (calcd. for C17H19N3, 265.1579) 
 
 Biological Evaluation Procedures 
  
2.1.11.1. Receptor binding assays  
All receptor binding assays were performed by the Psychoactive Drug Screening Program (PDSP).  
Complete details of the assays performed may be found online in the PDSP assay protocol book. 
(http://pdsp.med.unc.edu/PDSP%20Protocols%20II%202013-03-28.pdf). 
 
For primary binding assays, compounds were usually tested at a single concentration (10 µM) and in 
quadruplicate in 96-well plates. Compounds showing a minimum of 50% inhibition at 10 µM were tagged 
for secondary radioligand binding assays to determine equilibrium binding affinity at specific targets. In 
secondary binding assays, selected compounds are usually tested at 11 concentrations (0.1, 0.3, 1, 3, 10, 
30, 100, 300 nM, 1, 3, 10 µM) and in triplicate (3 sets of 96-well plates).  Both primary and secondary 
radioligand binding assays were carried out in a final of volume of 125 μl per well in appropriate binding 
85 
 
buffer. The hot ligand concentration was usually at a concentration close to the Kd (unless otherwise 
indicated). Total binding and nonspecific binding were determined in the absence and presence of 10 μM 
appropriate reference compound, respectively. In brief, plates were usually incubated at room temperature 
and in the dark for 90 min (unless otherwise indicated). Reactions were stopped by vacuum filtration onto 
0.3% polyethyleneimine (PEI) soaked 96-well filter mats using a 96-well Filtermate harvester, followed by 
three washes with cold wash buffer. Scintillation cocktail was then melted onto the microwave-dried filters 
on a hot plate and radioactivity was counted in a Microbeta counter.  
 
2.1.11.2. 5-HT7R Hit Hunter® cAMP assays 
Cell Handling 
cAMP Hunter cell lines were expanded from freezer stocks according to standard procedures.  Cells were 
seeded in a total volume of 20 L in white-walled 384-well microplates and incubated at 37 ˚C for the 
appropriate time prior to testing.  cAMP modulation was determined using the DiscoverX Hit Hunter cAMP 
XS+ assay 
Gs agonist format 
For agonist determination, cells were incubated with sample to induce response.  Media was aspirated from 
cells and replaced with 15 µL 2:1 HBSS/10 mM Hepes: cAMP XS + Ab reagent.  Intermediate dilution of 
sample stocks was performed to generate 4X sample in assay buffer.  5 L of 4X sample was added to 
cells and incubated at 37 ˚C or room temperature for 30 or 60 minutes. Vehicle concentration was 1%. 
Gs antagonist format 
For antagonist determination, cells were pre-incubated with sample followed by agonist challenge at the 
EC80 concentration.  Media was aspirated from cells and replaced with 10 L 1:1 HBSS/HEPES:cAMP XS 
+ Ab reagent.  5 µL of 4X compound was added to the cells and incubated at 37 ˚C or room temperature 
for 30 minutes.  5 µL of 4X EC80 agonist was added to the cells and incubated at 37 ˚C or room temperature 




After appropriate compound incubation, assay signal was generated through incubation with 20 µL cAMP 
XS + ED/CL lysis cocktail for one hour followed by incubation with 20 µL cAMP XS + EA reagent for three 
hours at room temperature.  Microplates were read following signal generation with a Perkin-elmer Envision 
TM instrument for chemiluminescent signal detection. 
Data analysis 
Compound activity was analyzed using CBIS data analysis suite (ChemInnovation, CA).  For Gs agonist 
mode assays, percentage activity is calculated using the following formula: %Activity = 100% x (mean RLU 
of test sample – mean RLU of vehicle control)/(mean RLU of MAX control – mean RLU of vehicle control). 
For Gs antagonist mode, percentage inhibition is calculated using the following formula: %Inhibition 
=100%x (1-(mean RLU of test sample – mean RLU of vehicle control)/(mean RLU of EC80 control – mean 










3. SYNTHESIS AND EVALUATION OF C1,2,10-TRISUBSTITUTED 
APORPHINE ANALOGS AT SEROTONIN AND DOPAMINE 
RECEPTORS  







D1-like receptors are implicated in various physiological responses such as locomotion, cognition, reward, 
and memory.  The D1-like family consists of two subtypes D1R and D5R. There is a high level of homology 
between D1R and D5R in the transmembrane regions (>80% sequence homology).  There is a lack of 
dopamine ligands that differentiate between the subtypes of D1-like family.  Currently available D1-like 
ligands fail to display binding selectivity for D1R over D5R. Selective D1R ligands, if available, can be used 
as pharmacological tools to distinguish the physiological functions of D1R and D5R.  Thus, there is a 
continued interest in the identification of D1R ligands that are selective versus the D5R. 
 
Synthesis of selective D1 ligand versus D5 not only requires ligands to differentiate between these but also 
D2-like receptors. Structural modifications on 10,11-disubstituted aporphines (i.e. apomorphine analogs) 
and 1,2,9,10-tetrasusbstituted (i.e. boldine analogs) improved selectivity of aporphine alkaloids towards 
D1R (section 1.4.5).   C1-(4-hydroxybenzyl) substitution (86, Ki = 40 nM) on apomorphine improved D1R 
binding, however the ligands were not able to differentiate between D1R and D2R.  C3-iodination of boldine 
provided highest affinity at D1R (90, Ki = 2 nM) with 34-fold selectivity over D2R.    
 
Hypothesis: Given the importance of hydrogen bonding of the C10-OH  group in binding and agonistic 
activity of apomorphine derivatives at the D1R, 174 the reduced D2 binding in the absence of C11 OH group, 
and improvement in D1 affinity via C1 substitutions on the aporphine scaffold (Fig. 3-1), we hypothesize 
that “structurally modified aporphine derivatives with selective D1 receptor affinity may be identified by fine 





Figure 3.1: Target analogs - C1,2,10-trisusbtituted library of compounds 
 
Rationale for ligand designs: C1,2,9,10 tetraoxygenated aporphine alkaloids have shown preferential 
binding at dopamine D1R compared to D2R. 178,179 To date there have been no structure-activity studies on 
aporphines that contain a C10 nitrogen substituent at dopamine and serotonin receptors. To begin to fill 
this current deficit in knowledge, we embarked on a project to prepare and evaluate via an SAR study, 
series of aporphines that contain 1,2,10-trisubstituted patterns (Figure 3.1), in which the C10 functional 
group is nitrogenous (acetamides, butyric amides, methanesulfonamides, N,N-dialkylated, and urea). The 
C10 nitrogen functionalities of these new ligands are expected to serve as bio-isosteric replacements of the 
C10 oxygen and preserve/improve the functioning in D1R binding site. Some functional group attachments 
will also contain a double bonded oxygen motif which may act as a hydrogen bond acceptor motifs. The 
compounds were prepared as racemates and were evaluated across a subset of serotonin and dopamine 







Results and Discussion 
 Synthesis 
 
The 1,2,10-trisubstituted analogs were prepared as outlined in Scheme 3-1 using similar chemistry as 
previously described for the C10 monosubstituted analogs.  Amine 120 was coupled with acid 91 to obtain 
amide 121, which was then subjected to sequential Bischler-Napieralski cyclization, imine reduction, O-
debenzylation and di-N,O-Boc protection thus affording 122. The tetracyclic aporphine scaffold was 
obtained through biaryl cyclization of 122 and was followed by selective O-Boc deprotection under basic 
conditions to reveal phenol 123. Alkylation of phenol 124 with various alkyl halides gave the O-alkylated, 
N-Boc protected derivatives 125b-e.  Compounds 125b-e were transformed into 126b-e in two steps via 
sequential N-Boc cleavage and N-methylation.  A similar two-step sequence was used to prepare 126a 
from compounds 124.  Reduction of the nitro group in 126(a-e) provided the corresponding aniline analogs 
127a-e.   
 
The target analogs were synthesized as outlined in Scheme 3-2. The synthesized aniline moiety was 
utilized to synthesize acetanilide 128a-d, butyramide 129a-d, sulfonamide 130a-b; trifluoroacetamide 134a-
c, and benzamide 135a-c functional group via reaction with respective anhydrides. Compounds with a C10 
urea functionality 132a-c were synthesized by reaction of aniline with KCN. Synthesis of the C10 formamide 
moiety in compounds 133a-b was achieved by refluxing aniline in formic acid in a solvent free reaction. 








Scheme 3-1: Reagents and conditions: (a) HBTU, DIPEA, THF, rt, 96%; (b) POCl3, DCM, 0 °C - rt, 16h; (c) 
NaBH4, MeOH, 0 °C; (d) HCl (conc.), EtOH, reflux, 2h; (e) K2CO3, (Boc)2O, ACN, rt, 30% over 4 steps; (f) 
Pd(OAc)2, tris(4-fluorophenyl)phosphine, K2CO3, (CH3)3CCOOH, DMA, 60 °C, 12h, 66%; (g) 1M NaOH, 
dioxane, 100 °C, 3h, 80%; (h) alkyl bromide, K2CO3, ACN, reflux, 12h, 90%; (i) TFA, DCM, rt, 2h (j) HCHO, 





Scheme 3-2: Reagents and conditions: (a) Ac₂O, DCM, 2h, rt, (40-65%) (b) (CH₃CH₂CH₂CO)₂O, DCM, 2h, 
rt, (40-60%) (c) (CH3SO2)2O, Et3N, DCM, rt, 14h, (30-40%) (d) HCHO, NaBH(OAc)3, DCM, rt, 18h, (75-
80%) (e) KCN, AcOH, water, 1h, rt, (30-40%) (f) HCOOH, reflux, 2h, (30-40%) (g) TFAA, DCM, rt, 2h, (60-






 Binding Affinity of C1,2,10-trisubstuted Aporphine Alkaloids at Serotonin and Dopamine 
Receptors 
 SAR of C1,2,10-trisubstituted Aporphine Alkaloids: C10 nitro and C10 aniline Analogs 
 
Table 3-1: Binding affinity of C1,2,10 trisubstituted aporphine analogs at serotonin and dopamine receptors: 




## R1 5-HT1AR 5-HT2AR D1R D2R D5R 
42 Nantenine ns 832 895 858 2397 
126a H 548 ± 71 908 ± 120 316 ± 41 320 ± 41 na 
126b Me 458 ± 59 1347 ± 170 726 ± 94 478 ± 62 na 
126c 
 
439 ± 57 na na na na 
126d 
 
1676 ± 220 na na na na 
126e 
 
206 ± 27 na 536 ± 69 2048 ± 260 na 
127a H na 850 + 110 301 ± 39 231 ± 30 418 ± 54 
127b Me 156 ± 20 585 ± 75 691 ± 89 260 ± 34 na 
127c 
 





na 234 ± 30 830 ± 110 759 ± 98 na 
127e 
 
428 ± 55 378 ± 49 709 ± 91 431 ± 56 na 
 8-OH-DPAT 0.8 ± 0.01     
 Clozapine  3.03 ± 0.39    
 (+)-Butaclamol   2.0 ± 0.26   
 Haloperidol    1.97 ± 0.25  
 SKF 83566     2 
 Apomorphine (35) 117 120 372 82 45 
a Experiments carried out in triplicate. b na – not active (primary binding assay value < 50%).  
 
C10 nitro and C10 aniline analogs (126a-e and 127a-e, respectively) of C1,2,10-trisusbtituted aporphine 
alkaloids were evaluated for binding affinity at serotonin and dopamine receptors (Table 3-1). A brief 
discussion of SAR is presented below.  
 
3.1.3.1. SAR at 5-HT1AR: 
Nantenine,42 lacks binding affinity at 5-HT1AR receptor. Compounds with a C10 nitro functionality (126a-e) 
displayed weak binding affinity for the 5-HT1AR, ranging in Ki values from approximately 200 nM to 1700 
nM. C1-OH substituted 126a provided a low binding affinity of 548 nM at 5-HT1AR. This lack of binding 
continued with C1-O-methyl (126b) and C1-O-cyclopropylmethyl (126c) substitution where the 
steric/hydrophobic effect was insignificant to produce a difference in binding affinity at 5-HT1AR. C1-O-alkyl 
substitution was provided the lowest binding at 5-HT1AR (Ki = 1676 nM).  Compound 126e with C1-O-
propargyl substitution was most potent compound at 5-HT1AR with binding affinity of 206 nM  
 
Conversion of the bulkier C10 nitro group into C10 aniline 127a-e produced significant difference in binding 
affinity at 5-HT1AR. Compound 127b (Ki = 156 nM) and 127d (Ki = 428 nM) displayed an approximately 3-
fold improvement in binding affinity compared to their respective C10 nitro precursor 126b (Ki = 458 nM) 
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and 126d. This improvement of binding affinity was not observed in compounds 127a, 127c, and 127d; 
C10 aniline substitution was detrimental to 5-HT1AR affinity.   
 
3.1.3.2. SAR at 5-HT2AR: 
C10 nitro substituted analogs of 1,2,10-trisubstituted aporphine analogs were not tolerated at 5-HT2AR. 
Among the investigated compounds 126a-e, only compounds with C1-OH and C1-O-methyl substitution 
(126a and 126b respectively) displayed low binding affinity. All other compounds 126c-e did not bind to 5-
HT2AR.  
 
Reduction of C10 nitro to C10 aniline moiety provided a substantial improvement of binding affinity for all 
investigated compounds at 5-HT2AR. Compounds with C10 aniline functionality 127b-e had higher affinity 
than nantenine at 5-HT2AR. Compound 127b (Ki = 585 nM) was more than twice as potent as its 
predecessor 126b. Compound 127c  (C1-O-cyclopropylmethyl) had a moderate affinity of 110 nM, which 
was the highest among the investigated C1-O-alkyl, C2-O-methyl, and C10 aniline substituted aporphines. 
In fact, compound 127c (C1-O-cyclopropylmethoxy) provided highest binding affinity at 5-HT2AR across all 
the 1,2,10-trisubstituted series investigated in this chapter. These finding are in line with previous finding 
from studies conducted by our lab.144,156 Compounds 127d and 127e both had low binding affinity at 5-
HT2AR with C1-O-alkyl substitution (127d) providing slightly better binding affinity.  
 
3.1.3.3. SAR at Dopamine Receptor: 
At D1R and D2R, C10 nitro substituted compound 126a and 127b provided improved binding than 
nantenine. Compound 126a had similar binding affinity at D1R and D2R and compound 126b had slightly 
better binding at D2R. Compound 126c and 126d did not bind to dopamine receptors. Compound 126e 




All C10 aniline functionalized 1,2,10-trisusbtituted aporphine alkaloid displayed low to moderate binding 
affinity at D1R and D2R. Similar to C10 nitro substitution, C1-OH substituted 127a did not provide preference 
for D1R or D2R, however there was a slight improvement of D2R binding. Compound 127b also displayed 
small improvement in binding over its precursor at D2R, improving its preference for D2R. Compounds 127c-
e had low binding affinity and selectivity at both D1R and D2R.   
 
• All compounds except compound 127a (Ki = 418 nM) lacked binding at D5R. 
 
 SAR of C1,2,10-trisubstituted Aporphine Alkaloids: C10 acetamide, C10 butyramide and C10 
methanesulfonamide Analogs 
 
Table 3-2: Binding affinity of C1,2,10 trisubstituted aporphine analogs at serotonin and dopamine receptors: 
C10 acetamide, C10 butyramide, and  C10 methanesulfonamide analogs 
 
   Ki (nM)a,b,c 
## R1 R2 5-HT1AR 5-HT2AR D1R D2R D5R 
128a Me 
 
na na 756 ± 98 978 ± 130 na 
128b   









na 1272 ± 160 58 ± 7.5 854 ±110 na 
129a Me 
 
521 ± 69 509 ± 56 1010 ± 130 1425 ± 173 na 
129b 
  
1442 ± 183 665 ± 86 1283 ± 155 na na 
129c 
  
492 ± 63 442 ± 54 260 ± 34 866 ± 109 na 
129d 
  
819 ± 107 1067 ± 138 1271 ± 168 na na 
130a Me 
 
1067 ± 86 na 2702 ± 341 na na 
130b   
409 ± 54 1272 ± 168 619 ± 78 1767 ± 220 na 
130c  
 




na 1207 ± 156 344 ± 44 na na 
a Experiments carried out in triplicate. b na – not active (compounds displayed < 50% inhibition in a 
primary binding assay)  
 
3.1.4.1. SAR at 5-HT1AR: 
Binding analysis of C10 amide (acetamide, butyramide) and C10 methanesulfonamide substitution of 
1,2,10-trisubstituted compound was evaluated at serotonin and dopamine receptors (Table 3-2).  
 
Of the investigated C10 acetamide substitution of 1,2,10-trisusbtituted aporphine analogs 128a-d only 128b 
with C1-O-cyclopropylmethyl substitution offered low binding at 5-HT1AR (Ki = 1742 nM). The binding affinity 
was significantly better for C10 butyramide substituted compounds where all C1-O-alkyl substituted analogs 
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129a-d had low binding (492 nM to 1442 nM). Among the C10 butyramide series, C1-O-methyl substituted 
(129a) and C1-O-alkyl substituted (129c) compound had better affinity at 521 nM and 492 nM respectively.  
 
Among investigated C10 sulfonamide series 130a-d, only compound 130b (Ki = 409 nM) and 130a (Ki = 
1067 nM) exhibited binding activity. Compared to aniline precursor 127b (Table 3-1) compound 130a had 
reduced binding affinity, whereas C10 sulfonamide substitution improved 5-HT1AR binding for C1-O-
cyclopropylmethyl substituted aniline precursor 127c. 
 
3.1.4.2. SAR at 5-HT2AR: 
C10 acetamide substitution 128a-d, led to reduction in binding affinity compared to its C10 aniline 
congeners 127b-e, respectively.  The highest binding affinity among the C10 acetamide series was 
displayed by compound 128b (Ki = 350 nM) containing C1-O-cyclopropylmethoxy substitution.  
 
C10 butyramide substitution 129a-d was able to improve the binding affinity at 5-HT2AR compared to 128a-
d series. however, was not able to recover the binding affinity displayed by C10 aniline precursor 127a-e.   
 C10 sulfonamide substitution 130a-d decreased binding of 1,2,10-trisubstituted series compared to C10 
aniline, and C10 butyramide series (127a-e and 129a-d, respectively).  
 
3.1.4.3. SAR at Dopamine Receptor 
C10 acetamide and C1-O-propargyl substitution containing compound 128d had moderate binding affinity 
(Ki = 58 nM) at D1R and at least 15-fold selectivity over D2-like receptors. Compared to its precursor 127e 
(Ki = 378 nM) acylation of C10-aniline lead to a 12-fold increase in binding. In fact, compound 128d provided 




Also, compound 127c (Ki = 155 nM) had improved binding affinity compared to its aniline precursor 127d 
(Ki = 830 nM). Compound 127c did not have affinity for D2R making it D1R selective.  
 
C10 butyramide substitution 129d negated the binding affinity displayed by its congener compound 128b. 
Compound 129c with C1-O-allyl provided highest binding at D1R among C10 sulfonamide series (Ki = 260 
nM) with low D2R binding (Ki = 866 nM). Other C10 sulfonamide compounds lacked binding affinity at D2R. 
 
• All investigated compound lacked binding affinity at D5R. 
 
 SAR of C1,2,10-trisubstituted Aporphine Alkaloids: C10 urea, C10 N, N-dimethyl, C10 
formamide, C10 trifluoroacetamide, and C10 benzamide Analogs 
 
Table 3-3: Binding affinity of C1,2,10-trisubstituted analogs at serotonin and dopamine receptor: C10 urea, 
C10 N,N-dimethyl, C10 formamide, C10 trifluoroacetamide, and C10 benzamide analogs 
 
    Ki (nM)a,b,c 
## R1 R2 R3 5-HT1AR 5-HT2AR D1R D2R D5R 
131a Me Me Me 1570 ± 197 296 ± 37 2448 ± 309 na na 
131b  Me Me 1285 ± 164 878 ± 110 2827 ± 348 5699 ± 709 na 
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131c  Me Me na 318 ± 37 5841 ± 735 na na 
132a Me H 
 
911 ± 113 509 ± 64 2458 ± 661 na na 
132b  H  
na 665 ± 83 5275 ± 41 na na 
132c  H  
429 ± 57 449 ± 56 344 ± 133 na na 
133a Me H 
 
368 ± 46 nd 903 ± 25 nd nd 
133b  H  
674 ± 81 nd 309 ± 35 nd nd 
134a Me H 
 
301 ± 38 nd 1063 ± 133 nd nd 
134b Allyl H 
 
446 ± 56 nd 245 ± 31 nd nd 
134c  H  
1073 ± 135 nd 191 ± 20 nd nd 
135a Me H 
 
506 ± 63 nd 1268 ± 159 nd nd 
135b  H 
 
430 ± 52 nd 849 ± 104 nd nd 
135c  H 
 
278 ± 35 nd 590 ± 74 nd nd 
a Experiments carried out in triplicate. b na – not active (compounds displayed < 50% inhibition in a 
primary binding assay) c nd → not determined 
 
A brief description of SAR evaluation from Table 3-3 is presented below. 
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3.1.5.1. SAR at 5-HT1AR: 
C10 N, N-dimethyl substituted compounds 131a-c were not tolerated at 5-HT1AR with low binding affinity 
(1285 nM to 1570 nM), various C1-O-alkyl substitution did not afford any improvement of binding.  
 
C10 urea analogs 132a-c also provided low binding affinity at 5-HT1AR, which were slightly higher than C10 
N, N-dimethyl analogs. C1-O-allyl substituted 132c (Ki = 429 nM) afforded moderate improvement binding 
over C1-O-methyl substituted compound 132a (Ki = 911 nM).  
 
Substitution of C10 aniline with smaller C10 formamide did not improve binding at 5-HT1AR with affinity 
ranging from 368 nM to 674 nM for compound 133a and 133b, respectively. Similar trend for binding 
continued for bulkier C10 trifluoroacetamide 134a-c and C10 benzamide substitution 135a-c (278 nM to 
1073 nM). Compounds 134a-c and 135a-c were however more tolerant to the C1-O-alkyl substitutions 
where all C1-O substitution provided binding at 5-HT1AR.    
 
3.1.5.2. SAR at 5-HT2AR: 
Among the investigated compounds C10 N, N-dimethyl substituted compounds 131a-c provided moderate 
binding affinity at 5-HT2AR (296 nM to 878 nM). Compounds 131a and 131c were more than 2-fold more 
potent than parent Nantenine, 42. Compound 131a (Ki = 296 nM) had improved binding than its precursor 
C10 aniline compound 127b.     
 
C10 urea substituted analogs 132a-c (449 nM to 665 nM) overall had lower binding than compound 131a-
c. However, the binding affinities for various C1-O-alkyl substitutions were grouped together displaying the 




All C10 N-butyramide analogs 129(a-d) displayed low binding affinity across 5-HT1AR suggesting the 
dependency of 5-HT1AR binding on C10 substitution. Therefore, it appears that among the various C10 
nitrogen functionalities examined, electron rich groups such as nitro, trifluoroacetamide, and benzamide at 
C10 is generally best tolerated for 5-HT1AR affinity.  
 
3.1.5.3. SAR at Dopamine Receptors 
The evaluated C10 N, N-dimethyl substituted compounds 131a-c have insignificant to low binding at D1R 
and D2R. Among C10 urea analogs, C1-O-allyl substituted compound 132c drastically improved binding at 
D1R compared to other investigated C1-O-alkyl substitution. D2R binding was absent for all C10 urea 
analogs.  
 
Among C10 formamide 133a-b, C10 trifluoroacetamide 134a-c, and C10 benzamide 135a-c series of 
compounds; C1-O-propargyl substituted analogs (133b, 134c, 135c) displayed highest binding affinity (Ki 
= 309 nM, 191 nM, and 590 nM, respectively). These binding affinities are lower than binding affinity of 
compound 128d (Ki = 58 nM).     
 
• All investigated compounds lacked binding affinity at D5R. 
 
These finding at serotonin and dopamine receptors highlight the fact that these receptors interact differently 
with the various substitution in aporphine scaffold. The C10 nitrogen functionalities are not tolerated at D5R 
however it was tolerated at the closely related D1R. At D1R, tandem substitution at C1-O-alkyl and C10 
nitrogenous functional group lead to the discovery of compound 128d which has a moderate affinity and 






 Predicted physiochemical properties property and drug-likeness 
 
Compounds 128d had highest D1R binding affinity among all the compounds tested. The calculated 
properties of compound 128d were indicative of having good blood-brain barrier (BBB) penetrability and 
“drug-likeness”. Table 3-4 displays the calculated properties of 128d and apomorphine,32 calculated using 
®Molsoft molecular properties and drug-likeness algorithm.184 Compound 128d has molecular weight of 
376 amu (<500), four HBA (< 10) and one HBD (< 5), a partition coefficient (logP) of 2.88 (< 5). Compound 
128d calculated property also shows a polar surface area (PSA) of 41.27 A2, BBB score of 4.94 (6 being 
highest) and a drug-likeness value of 0.31 (positive value indicative of better drug-likeness). 184   
 
Table 3-4: Calculated drug likeness properties of apomorphine and compound 128d   
Compound Mol wt HBA HBD MolLogP MolPSA BBB Score 
Drug-likeness 
model score 
APO (32) 267.13 3 2 2.17 34.82 A2 5.25 0.38 
128d 376.18 4 1 2.88 41.27 A2 4.94 0.31 
 
 Drug Metabolism Studies 
 
Apomorphine contains a catechol moiety which is susceptible to biotransformation.  The catechol function 
undergoes glucuronidation and sulfonation and these polar metabolites are eliminated from the body 
decreasing the drug-plasma concentration of apomorphine.  We were interested to see if compound 128d 
with a C10 amide functionality could improve on the shortcoming shown by apomorphine. Metabolic stability 
study of apomorphine and 128d was evaluated in human liver microsomes (HLMs). As seen in Table 3-5, 
compound 128d has considerably improved metabolic stability than apomorphine. After 60 mins, there is a 
rapid degradation of apomorphine,32 whereas compound 128d was stable for more than 2 hours. This 
improved metabolic stability indicates a promising physiochemical characteristic of C10 amides such as 
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128d that can be utilized in the design of metabolically stable pharmacological tools and experimental 
therapeutics. 
 
Table 3-5: Metabolic stability of compound 128d in human liver microsomes (HLMs).b 
Compound 0 min 15 min 30 min 60 min 120 min 
Propathelinea 100 65.33 36.32 6.4 0.16 
Apomorphine (32) 100 89.33 99.73 80.43 36.68 
128d 100 99.76 97.8 95.6 102.69 
a control b experiments conducted in duplicate 
 
 
 Modelling Studies 
 
Computational studies were conducted to elucidate receptor-ligand interactions that have a significant 
impact on binding affinity and provide a deeper recognition of the high selectivity displayed by compound 
128d for D1R over D5R. The generation D1R homology model was conducted via utilization of the high-
resolution crystal structure of the human β2-adrenergic G protein-coupled receptor with pdb code 
2RH1185 followed by induced fit docking involving several benzazepine analogs. Similarly, the D5 receptor 
homology model was developed from the high-resolution crystal structure of the β1-adrenergic G protein-
coupled receptor with pdb code 6H7J186 followed by induced fit docking with the benzazepine analogs. 
Models for the D1R and D5R structures were, thus, prepared with suitable backbone and side-chain 
orientations within the binding site. This optimization process was conducted by application of the 
Schrödinger Prime Structure Prediction and Glide software modules and manual intervention to support the 
generation of known key receptor-ligand interactions. The docking investigations of compound 128d into 
the D1R and D5R binding sites exploited the Schrödinger Glide methodology in Standard Precision (SP) 
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mode. In this context, the Glidescore scoring function was used to give an estimate of the ligand binding 
affinities and the values of the highest ranked pose for 128d in the D1R and D5R target receptors. 
Docked poses of compound 128d at D1R and D5R are shown in Figure 3.2. In the D1R binding pocket the 
basic nitrogen (N6) of compound 128d forms a key salt bridge interaction with sidechain of Asp103, and 
the positively ionizable nature of N6 participates in formation of π-cation interaction with Trp99 The C1-
propagyloxy substitution of 128d is surrounded by the fused rings of the ligand and Phe288, Phe289 and 
Phe313 and forms important hydrophobic interactions within the binding pocket (Figure 3.2 A). Compound 
128d at D5R binding pocket interacts with amino-acid sidechains in a similar manner to D1R; the key salt 
bridge interaction with Asp120 and forms π-cation interaction with Phe312 (Figure 3.2 B). The predicted 
binding energy is more favorable towards D1R (−7.5 kcal/mol) in comparison to D5R (−6.7 kcal/mol). This 
difference in binding energy is mainly due to stabilization of receptor-ligand formation by higher number of 





Figure 3.2: Binding Pose and interactions made by compound 128d at A) D1R B) D5R 
 
Synthesis of Enantiomerically Pure (C6a)(R/S)-C1,2,10-trisusbtituted Aporphine Analogs for 
Improvement of Binding Affinity at D1 Receptor 
 
Apomorphine the (R)-isomer shows agonistic activity at dopamine receptors whereas the (S)-isomer shows 
antagonistic activity at dopamine receptors. Similarly, in case of C1,2,9,10-tetraoxygenated aporphine 
alkaloids such as boldine, (S)-boldine displays antagonistic property at dopamine receptors. In this section, 
we discuss the synthesis of the enantiomers of the most active racemic analogs (127e, 128c-d, 129c, and 
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130d) as a prelude to getting a clearer picture of the role of chirality in the D1R binding affinity and functional 
activity of the compounds.        
Enantiomerically pure C1,2,10-trisubstituted aporphine alkaloids were synthesized. This was achieved 
utilizing similar steps as mentioned in Scheme 3-1. The new Scheme 3-3 consists of three major steps 
including Bischler-Napierlaski cyclization with subsequent Noyori reduction, palladium assisted 
intramolecular biaryl coupling, selective deprotection and reduction of C10 nitro moiety to synthesize C10 
amino handle.  
 
 
Scheme 3-3: Reagents and conditions: (a) POCl3, DCM, 0 °C - rt, 16h; (b) (S,S)-12(5 mol-%), HCO2H / 
NEt3, DMF, rt, 1h; (d) HCl (conc.), EtOH, reflux, 2h; (e) (Boc)2O, K2CO3, ACN, rt , 50% over 4 steps;  (f) 
Pd(OAc)2, tris(4-fluorophenyl)phosphine, K2CO3, (CH3)3CCOOH, DMA, 60 °C, overnight, 65%; (g) 1M 
NaOH, dioxane, 100 °C, 3h, 80%; (h) alkyl bromide, K2CO3, ACN, reflux, overnight, 90%; (i) TFA, DCM, rt 




These enantiomeric (R/S)-132 series of compounds were reacted with their respective anhydrides to 
synthesize C10 acetamide, C10 butyramide and C10 sulfonamides to obtain compounds [(R)- and (S)-
128(c-d)],[(R)- and (S)-129c] and [(R)- and (S)-130d] (shown in Scheme 3-4 and 3-5). 
 
Scheme 3-4: Reagents and condition: (a) Ac2O, DCM, 0oC- rt, 2h, 50% (b) (CH₃CH₂CH₂CO)₂O, DCM, 0oC- 
rt, 2h, 65% 
 
 
Scheme 3-5: Reagents and condition: (a) Ac2O, DCM, 0oC- rt, 2h, 40% (b) (CH3SO2)2O, DCM, Et3N, 0oC- 
rt, 12 h, 50% 
 
Expected Results 
The chiral compounds [(R)- and (S)-128(c-d)], [(R)- and (S)-129c] and [(R)- and (S)-130d] compounds are 
expected to improve binding affinity at dopamine receptors thus improving activity of previously synthesized 
racemic compound 128d at D1R. Previous SAR studies have established that (R)-enantiomers show 
agonistic activity at dopamine receptors and (S)-enantiomers to have antagonistic property. 174 Biological 
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evaluations on these (R) and (S) enantiomers will also provide additional information to establish eudysmic 




In conclusion, this SAR study has provided important insights about the tolerance of structural modifications 
of the aporphine scaffold pertaining to binding activity at serotonin and dopamine receptors. The structural 
modification primarily discussed in this study addresses C10 nitrogen containing motifs, which has not been 
studied before.  
 
Figure 3.3: SAR summary of C1,2,10-trisubstituted aporphine alkaloids 
 
The binding data showed varying levels of tolerance for C10- nitro, aniline, acetamide, butyric amide 
methanesulfonamide, N,N-dimethyl, and urea groups at different receptors and highlighted the role played 
by other substituents appended to the aporphine core (summarized in Figure 3.3). C1,2,10-trisubstituted 
compounds lacked high binding at 5-HT1AR. C1-O-propargyl substitution led to better binding affinity at D1R 
across various C10 functionalities. C10 acetamide substitution is an ideal substitution where increase or 
decrease in amidic side chain length, bulkier substitutions, and electron rich substitution all lead to decrease 
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in binding affinity. At the C10 position, bulkier nitrogenous moieties were not tolerated at 5-HT2AR leading 
to low or absence of binding affinity, with C10 aniline moiety providing better affinity than other investigated 
C10 substitutions. One major SAR finding established from this study is that C10 nitrogen functionality 
substitution is not tolerated at D5R. 
 
A docking study conducted to understand the binding nature of C10-aniline substituted 127c led to 
identification of unique binding orientation of this analog at the 5-HT2AR binding site. At the D1R binding 
site, C10 N-acetamide in combination with C1 O-propargyl substitution provided highest binding among the 
investigated series. Replacement of either C1 O-propargyl or C10 N-acetamide lead to a reduction in 
binding affinity of aporphine alkaloids at D1R. 
 
As discussed in section 1.1.9., previously identified D1R ligands fail to show discernable selectivity over 
D5R, with D5R binding affinity being comparable. It is interesting that almost all ligands synthesized during 
this study lack D5R affinity alluding to the fact that C10 nitrogen containing aporphine scaffolds are not 
supported at the D5R binding pocket. A difference in activity between D1R and D5R have been previously 
reported in a handful of arylbenzazepine class and in few allosteric D1R ligands. As shown by binding 
affinities in Table 3-1, aporphine alkaloids examined had significant D1R affinity but lacked D5R affinity 
providing a unique pharmacological profile for these compounds. This study affirms our notion that 
aporphines can be utilized as templates for identification of D1R agents that are selective particularly versus 
D5R.  
 
The modification purposed in this study clearly needs additional refinement in order to improve overall 
binding affinity at D1R, the selectivity preference shown by these ligands at D1R against D5R is noteworthy 
and valuable. As such, compound 128d can act as a starting point for further development to achieve novel 





 Synthetic Experimental Procedures 
 
All glass apparatus was oven-dried prior to use. HRESIMS spectra were obtained using an Agilent 6520 
Q-TOF instrument. 1H NMR and 13C NMR spectra were recorded using a Bruker DPX-500 spectrometer 
(operating at 500 and 600 MHz for 1H; 125 and 150 MHz, respectively, for 13C) using CDCl3 as solvent. 
Tetramethyl silane (δ 0.00 ppm) served as an internal standard in 1H NMR and 13C NMR unless stated 
otherwise. Chemical shift (δ 0.00 ppm) values are reported in parts per million and coupling constants in 
Hertz (Hz). Splitting patterns are described as singlet (s), doublet (d), triplet (t), and multiplet (m). HPLC 
analysis were conducted on Agilent 1200 series HPLC with DAD detector and UV detector at 214 nm. 
Reactions were monitored by TLC with Whatman Flexible TLC silica gel G/UV 254 precoated plates (0.25 
mm). TLC plates were visualized in UV light (254 nm) and by staining with phosphomolybdate spray 
reagent, vanillin, or iodine. Flash column chromatography was performed with silica gel 60 (EMD 
Chemicals, 230-400 mesh, 0.04-0.063 mm particle size). Preparative thin layer chromatography was 
performed with silica gel GF plates (Analtech, catalog # 02003). All chemicals and reagents were obtained 
from Sigma-Aldrich and Fischer Scientific (USA) in reagent grade and were used without further purification. 
 
3.1.9.1. N-(4-(benzyloxy)-3-methoxyphenethyl)-2-(2-bromo-4-nitrophenyl) acetamide (126):  
Synthesized as described for compound 93.  
96% yield. Off-white solid. Melting point: 146.5 oC -148.8 oC. 1H NMR (500 MHz, CDCl3): δ 8.18 (d, 1H, J 
=2.4 Hz), 7.97 (dd, 1H, J = 8.75 Hz, 2.5 Hz), 7.68 (d, 1H,  J = 8.75 Hz), 7.45(d, 2H, J= 9Hz), 7.38 (t, 2H, J= 
7.3 Hz), 7.31 (t, 1H, J= 7.4 Hz)  ( 6.75 (d, 1H, J= 8.1 Hz), 6.68 (s,1H),6.56 (d, 1H, J = 8.1 Hz), 5.47 (s, 1H), 
5.13 (s, 2H),  3.85 (s, 3H), 3.71 (s, 2H), 3.51 (q, J = 6.25Hz), 2.74 (t, J = 13.6 Hz). 13C NMR (125 MHz, 
CDCl3): δ 167.8, 149.8, 147.2, 146.9, 137.2, 136.8, 133.9, 132.1, 131.4, 128.6, 127.9, 127.2, 126.24, 123.4, 
120.6, 114.2, 112.4, 114.2, 112.4, 71.1, 56.0, 43.6, 40.8, 34.9ppm. HREMIS m/z 499.0857 [M+H]+ (calcd. 




dihydroisoquinoline-2(1H)-carboxylate (127) :  
5.3 g (10.6 mmol) of previously prepared amide 126 was transferred into a flask and ACN was added to 
the flask to make a suspension. This suspension as kept at 0oC and POCl3 (8.2 g, 53 mmol) was added 
dropwise to the flask. After complete addition of POCl3 the reaction mixture became clear and the reaction 
flask was heated to reflux. The reaction was refluxed under nitrogen atmosphere for 16 hours and the 
completion of reaction was monitored by Alumina plate TLC with 20% EtOAc in Hexane. After complete 
consumption of starting material, the reaction mixture was concentrated in-vacuo and treated with 1M 
NaOH and extracted with DCM (3*100 mL). The collected organic layer was dried using anhydrous Na2SO4 
concentrated in-vacuo to obtain an orange solid (4.8 gm), which was used further without any purification. 
 
Methanol (100 mL) was added to the round bottom flask and stirred vigorously under ice for 30 mins. 3.3 g 
(10 eq) of sodium borohydride (NaBH4) was added to the reaction flask gradually. Then the reaction was 
allowed to come to room temperature and stirred overnight. The reaction mixture was concentrated in-
vacuo, treated with saturated sodium bicarbonate (NaHCO3) solution, and extracted with ethyl acetate (3*50 
mL). The combined organic layer was dried using anhydrous Na2SO4 and concentrated to obtain amine 
as a yellow colored solid and used as is for further reaction. 
 
The yellow solid from previous step was dissolved in 200 mL of ethyl alcohol and 50 mL of concentrated 
HCl was added to the mixture in a dropwise manner. Then the reaction was heated till reflux for 4 hours. 
After completion of the reaction the reaction mixture was concentrated in-vacuo and then reaction was 
quenched with conc ammonium hydroxide. Then the compound was extracted with EtOAc (3*50 mL) and 
combined organic fraction was dried using anhydrous Na2SO4 and concentrated in-vacuo to obtain yellow 
solid (5.0 g).  This was used in the next step without purification. 
(5.0 g, 14.4 mmol) of tetrahydroisoquinilone deravitive was dissolved in ACN and (9.4 g, 43 mmol) of Boc 
anhydride was added to the solution. To this mixture catalytic amount of DMAP and (5.7 g, 57.6 mmol) of 
triethylamine was added and the reaction as stirred under nitrogen atmosphere for overnight. The reaction 
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mixture was then concentrated in-vacuo and treated with 5% HCl in water. This solution was extracted with 
DCM (3*50 mL) and the combined organic solvent was dried using anhydrous Na2SO4 and concentrated 
in-vacuo and purified using silica-gel column using 20% EtOAc in Hexane to obtain compound 127.   
47% yield over 3 steps. Yellow-orange solid. Melting point: 160.1 oC -161.5 oC. 1H NMR (600 MHz, CDCl3): 
δ 7.93-7.84 (m, 2H, Ar-2H), 7.69-7.64 (m, 1H, Ar-H), 6.97-6.92 (m, 1H, Ar-H), 6.67-6.63(m, 1H, Ar-H), 5.39-
5.30 (m, 1H, CH),  4.30-4.00 (m, 1H, CH), 3.77-3.76 (m, 3H, CH3), 3.35-3.18 (m,2H, CH2), 3.08-3.00(m, 
1H, CH), 2.89-2.77 (m,1H, CH), 2.97-2.64 (m, 1H), 1.50-1.48 (9H, 3-CH3). 1.18-1.02 (9H, 3-CH3). 13C NMR 
(150 MHz, CDCl3): δ 154.2, 153.9, 151.7, 151.4, 150.1, 150.1, 147.1, 146.9, 140.2, 140.0, 138.7, 138.6, 
133.5, 133.5, 133.3, 132.9, 132.7, 132.5, 128.5, 128.4, 126.1 , 125.6, 122.8, 122.6, 120.9, 120.6, 112.8, 
112.5, 83.7, 83.5, 79.9, 79.8, 60.4, 56.1, 53.3, 52.5, 42.7, 42.3, 38.2, 36.4, 28.4, 28.0, 27.9, 27.6ppm. 
HREMIS m/z 615.1301 [M+Na]+ (calcd. for C27H33N2O8, 615.1313)  
 
3.1.9.3. tert-butyl-1-((tert-butoxycarbonyl)oxy)-2-methoxy-10-nitro-4,5,6a,7-tetrahydro-6H-
dibenzo[de,g]quinoline-6-carboxylate (128):   
Synthesized from 127 via procedure as described for preparation of 95.   
60% yield. Yellow solid. Melting point: 174.6 oC -175.8 oC. 1H NMR (600 MHz, CDCl3): δ 8.50-8.15 (1H, Ar-
H), 8.08-8.04 (2H, Ar-2H), 6.75-6.63 (1H, Ar-H), 4.66 (d, H, CH), 4.36 (s,1H, CH), 3.86-3.81 (3H, CH3), 
3.05-3.03 (1H, CH), 2.86-2.81 (3H), 2.64-2.54 (1H, CH), 1.431-1.426 (9H, 3-CH3). 1.41 (7H, 3-CH3). 13C 
NMR (150 MHz, CDCl3): δ 154.1, 150.8, 150.7, 146.7, 146.0, 145.8, 142.7, 139.1, 138.6, 138.1, 137.4, 
136.7, 132.8, 129.3, 128.7, 128.4, 128.3, 126.6, 126.4, 125.9, 125.5, 123.3, 122.1, 121.9, 118.1, 113.2, 
111.2, 84.0, 80.4, 80.2, 56.3, 56.2, 50.8, 38.3, 35.0, 30.5, 30.1, 28.5, 28.5, 27.6ppm. HREMIS m/z 513.2218 




Compound 128 (2 g, 3.9 mmol) was dissolved in dioxane (20 mL) and NaOH (50 mL, 1N) was added to the 
mixture. The reaction mixture was heated to reflux under nitrogen atmosphere for 12 h. The reaction mixture 
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was concentrated and treated with saturated NH4Cl solution and extracted with DCM (3x20 mL). The 
combined organic layer was dried using anhydrous Na2SO4, filtered and concentrated in-vacuo to obtain 
compound 129.  
80% yield. Melting point: 230 oC - 231 oC. 1H NMR (600 MHz, CDCl3): δ 8.51 (d, J =8.5 Hz, 1H), 8.04-8.09 
(m, 2), 6.63 (s,1H), 6.27 (s,1H), 4.66 (d, J =8.5 Hz, 1H), 4.35 (s, 1H), 3.89 (s, 3H), 3.04 (d, J = 11.8 Hz, 
1H), 2.89 – 2.73 (m, 3H), 2.56 (d, J = 14.4 Hz), 1.43 (s, 9H). 13C NMR (150 MHz, CDCl3) δ 154.5, 146.0, 
145.8, 142.7, 138.6, 138.1, 129.3, 128.7, 126.7, 125.6, 122.0, 118.1, 111.2, 80.3, 67.1, 56.4, 50.9, 30.1, 
29.7, 28.6ppm. HREMIS m/z 413.1699 [M+H]+ (calcd. for C22H24N2O6, 413.1707) 
General method for synthesis of compounds 130a – e. 
Step 1- O-alkylation: Compound 129 (1 equiv) was dissolved in ACN (25 mL) and potassium carbonate 
(3.2 equiv.) was added to the mixture, followed by the addition of respective alkyl halide (2 equiv) and the 
mixture was heated to reflux under nitrogen atmosphere overnight. The reaction mixture was concentrated 
in-vacuo. Water (50 mL) was added to the flask and extracted with DCM (3x25 mL) and the combined 
organic layer was dried using anhydrous Na2SO4, filtered and concentrated in-vacuo to afford intermediates 
130a – d which were used without further purification in the next step.   
Step 2 – N-Boc deprotection: The above unpurified compound (130a – d) was dissolved in DCM (18 mL) 
and TFA (1 mL, 13 mmol) added.  The reaction was stirred at room temperature for 2 h, diluted with 
saturated aqueous NaHCO3 and extracted with DCM. The combined organic layer was concentrated to 
obtain a secondary amine intermediate which used without purification in the next step.  
Step 3 – N-methylation: Thus, the unpurified secondary amine was dissolved in DCM (10 mL) and 
formaldehyde (37% aqueous solution, 5 µL, 0.5 mmol) and NaBH(OAc)3 (200 mg, 1 mmol) were added to 
the reaction flask.  The reaction was stirred overnight at room temperature, diluted with aqueous sodium 
bicarbonate solution, and extracted with DCM (3x15 mL). The combined organic layer was dried (Na2SO4), 
filtered and concentrated in-vacuo. The residue thus obtained was purified using preparative TLC eluting 
in 5% MeOH/DCM to give compounds 131b – e.  Compound 131a was prepared similarly from 129 but 
without the first O-alkylation step. 
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3.1.9.5. 2-methoxy-6-methyl-10-nitro-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-1-ol (131a):  
53% yield. Reddish brown gum.  1H NMR (600 MHz, CDCl3): δ 8.50 (d, 1H, J =8.6 Hz), 8.13-8.12 (m,2H), 
6.67 (s, 1H), 6.41 (s, 1H), 3.93 (s, 3H), 3.23 (dd, 1H, J = 14.0 Hz, 3.7 Hz), 3.17-3.12 (m,1H), 3.07-3.05 (m, 
2H), 2.69-2.65 (m, 2H), 2.67 (s, 3H), 2.51 (m, 1H). 13C NMR (150 MHz, CDCl3): δ 146.0, 145.8, 142.3, 
139.1, 129.0, 127.7, 124.3, 122.7, 122.0, 117.5, 111.1, 61.6, 56.3, 53.2, 43.7, 34.7, 28.6ppm. HREMIS m/z 
327.1340 [M+H]+ (calcd. for C18H18N2O4, 327.1339). 
 
3.1.9.6. 1,2-dimethoxy-6-methyl-10-nitro-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline (131b):  
61% yield. Reddish-brown gum. 1H NMR (600 MHz, CDCl3): δ 8.51 (d, 1H, J =8.6 Hz), 8.16-8.13 (m, 2H), 
6.73 (s,1H), 3.89 (s, 3H), 3.68 (s, 3H), 3.23 (dd, 1H, J = 14.0Hz, 3.7 Hz), 3.18-3.12 (m,1H), 3.07-3.00 (m, 
2H), 2.72-2.66 (m, 2H), 2.57 (s, 3H), 2.51 (m, 1H). 13C NMR (150 MHz, CDCl3): δ 152.1, 146.2, 145.8, 
138.9, 138.0, 129.3, 129.1, 128.1, 125.1, 122.8, 122.1, 113.2, 61.7, 60.5, 56.0, 53.1, 44.0, 35.0, 29.1ppm. 
HREMIS m/z 341.1495 [M+H]+ (calcd. for C19H20N2O4, 340.1418) 
 
3.1.9.7. 1-(cyclopropylmethoxy)-2-methoxy-6-methyl-10-nitro-5,6,6a,7-tetrahydro-4H-
dibenzo[de,g]quinoline (131c) :  
45% yield. Yellowish brown gum. 1H NMR (600 MHz, CDCl3): δ 8.66 (d, J =8.7 Hz, 1H, Ar-H), 8.16-8.13 (m, 
2H), 6.72 (s,1H), 3.89 (s, 3H), 3.80 (dd, J = 10.3 Hz, 6.9 Hz), 3.42 (dd, J = 10.0 Hz, 7.4 Hz), 3.22 (dd, J = 
14.0 Hz, 3.8 Hz), 3.18-3.12 (m,1H), 3.07-3.00 (m, 2H), 2.70 (dd, J = 16.0 Hz,3.0 Hz, 1H),  2.66-2.61 (m, 
1H), 2.56 (s, 3H), 2.52 (td, J = 12 Hz, 3.8 Hz, 1H), 0.43 (m, 2H) , 0.14 (m, 1H), 0.03(m, 1H). 13C NMR (150 
MHz, CDCl3): δ 152.1, 146.1, 144.5, 139.3, 137.8, 129.7, 129.1, 125.7, 122.7, 121.8, 112.9, 78.4, 61.7, 







65 % yield. Light brown gum. 1H NMR (600 MHz, CDCl3): δ 8.53 (d, 1H, J =8.5 Hz), 8.17-8.08 (m, 2H), 6.73 
(s,1H), 5.91 (ddt, J= 16.4 Hz, 10.4 Hz, 6.0 Hz, 1H), 5.25-5.20 (m, 1H), 5.14 (dd, 1H, J = 10.4 Hz, 1.4 Hz, 
1H), 4.48-4.43 (m, 1H), 4.19-4.16 (m, 1H), 3.89 (s, 3H), 3.22 (dd, 1H, J = 14.0 Hz, 4.0 Hz), 3.15 (m,1H), 
3.06 (q, J = 5.8 Hz, 1H), 3.01 (dd, J = 11.9 Hz, 3.5 Hz, 1H), 2.71 (dd, J = 16.3 Hz, 3.4 Hz, 1H), 2.64 (t, J = 
13.7 Hz, 1H), 2.56 (s, 3H), 2.52 (m, td, J = 11.9 Hz, 3.8 Hz, 1H). 13C NMR (150 MHz, CDCl3): δ 152.2, 
146.2, 144.4, 138.9, 137.7, 133.8, 129.5, 129.1, 127.6, 125.6, 122.8, 121.9, 118.0, 113.1, 74.2, 61.6, 56.0, 
52.9, 43.6, 34.7, 28.7ppm. HREMIS m/z 367.1649 [M+H]+ (calcd. for C21H22N2O4, 367.1652) 
 
3.1.9.9. 2-methoxy-6-methyl-10-nitro-1-(prop-2-yn-1-yloxy)-5,6,6a,7-tetrahydro-4H-
dibenzo[de,g]quinoline (131e):   
34% yield. Dark brown gum. 1H NMR (600 MHz, CDCl3): δ 8.54 (d, 1H, J =8.5 Hz, Ar-H), 8.16-8.13 (m, 
2H,), 6.74 (s,1H), 4.66 (dd, 1H, J= 15.2 Hz, 2.3 Hz, CH), 4.49 (dd, 1H, J = 15.2 Hz, 2.6 Hz), 3.90 (s, 3H), 
3.22 (dd, 1H, J = 13.9 Hz, 3.8 Hz), 3.15 (m,1H), 3.07-3.00 (m, 2H), 2.72 (dd, 1H, J = 16.3 Hz, 3.4 Hz), 2.65 
(m, 1H), 2.56 (s, 3H), 2.51 ( td, J = 11.8 Hz, 3.8 Hz, 1H), 2.28 (t, J = 2.3 Hz, 1H). 13C NMR (150 MHz, 
CDCl3): δ 152.0, 146.2, 143.0, 139.0, 137.9, 130.0, 129.8, 128.1, 126.1, 122.7, 122.0, 113.1, 78.7, 75.4, 
61.7, 60.1, 56.0, 53.1, 43.9, 34.9, 29.1.  HRESIMS m/z 365.1490 [M+H]+ (calcd. for C21H20N2O4, 365.1496) 
 
General procedure for nitro group reduction – synthesis of compounds 132a -e. 
The respective compound (131a – e, 0.9 mmol) was dissolved in ACN (10 mL) and stirred at 0 oC under a 
nitrogen balloon. HSiCl3 (0.5 mL, 4.5 mmol) was added dropwise to the mixture, followed by addition of 
DIPEA (1.6 mL, 8.9 mmol). The reaction was brought to room temperature and stirred overnight.  The 
reaction was quenched with 40% aqueous KOH (10 mL) and stirred until the solid in the aqueous layer 
dissolved. The mixture was extracted with DCM (3x20 mL) and the combined organic layer was dried using 
anhydrous Na2SO4, filtered and concentrated in-vacuo. Compound 132 a-e were obtained after purification 




3.1.9.10. 10-amino-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-1-o (132a):  
62% yield. Light brown gummy solid. Melting point: 96.2 oC -98.4 oC. 1H NMR (500 MHz, CDCl3): δ 8.11 (d, 
J = 8.4 Hz, 1H), 6.57 (d, J = 8.5 Hz, 1H), 6.51 (s, 1H) , 6.44 (s, 1H), 6.03 (s, 1H), 3.83 ( s, 3H), 3.54 (s, 2H,), 
3.09-3.05 (m, 1H), 3.03-2.97 (m, 2H), 2.91 (dd, J = 13.8 Hz, 3.8 Hz, 1H), 2.57-2.52 (m, 2H), 2.49-2.45 (m, 
4H,). 13C NMR (125 MHz, CDCl3): δ 145.8, 145.3, 140.5, 137.5, 129.6, 126.9, 123.6, 123.0, 119.8, 114.4, 
113.3, 108.2, 62.4, 56.1, 53.5, 43.9, 35.2, 28.9ppm. HREMIS m/z 297.1598 [M+H]+ (calcd. for C18H20N2O2, 
297.1598) 
 
3.1.9.11. 1,2-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-amine (132b) :  
95% yield. Brown foamy solid.  Melting point: 125.0oC-126.8oC. 1H NMR (500 MHz, CDCL3): δ 8.19 (d, J = 
8.5 Hz, 1H), 6.64 (dd, J= 8.5 Hz, 1.8 Hz, 1H), 6.58 (s, 1H) , 6.54 (s, 1H), 3.87 (s, 3H), 3.74 (s, 2H), 3.64(s, 
3H), 3.14-3.11 (m, 1H), 3.04-2.95 (m, 3H), 2.66 (d, J = 5 Hz) , 2.59-2.48 (m, 5H). 13C NMR (125 MHz, 
CDCl3): δ 145.8, 145.3, 140.5, 137.5, 129.6, 126.9, 123.6, 123.0, 119.8, 114.4, 113.3, 108.2, 62.4, 56.1, 
53.5, 43.9, 35.2, 28.9ppm. HREMIS m/z 311.1752 [M+H]+ (calcd. for C19H22N2O2, 311.1715) 
 
3.1.9.12. 1-(cyclopropylmethoxy)-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-
dibenzo[de,g]quinolin-10-amine (132c) :  
77% yield. Light Brown solid. Melting point: 111.2 oC - 112.6 oC.  1H NMR (500 MHz, CDCl3): δ 8.18 (d, J = 
8.4 Hz, 1H), 6.64 (d, J= 8.5 Hz, 1H), 6.43 (s, 1H) , 6.39 (s, 1H), 3.70 ( s, 3H), 3.61 (s, 2H), 3.51 (dd, J = 9.8 
Hz, 7.5 Hz, 1H), 3.27(dd, 1H, J= 18.5 Hz, 10.6 Hz, 1H), 3.02-2.96 (m, 1H), 2.89-2.80 (m, 3H), 2.52 (d, J = 
16.5 Hz, 1H) , 2.42-2.37 (m, 5H), 1.04-0.99 (m, 1H), 0.32-0.31 (m, 2H), 0.01-0.1 (m, 2H) .13C NMR (125 
MHz, CDCl3): 152.1, 145.5, 143.1, 137.9, 130.2, 128.4, 127.7, 127.0, 123.1, 114.1, 113.4, 109.8, 62.4, 55.8, 






95% yield. Light brown solid. Melting point: 151.8 oC - 153.9 oC.  1H NMR (500 MHz, CDCl3): δ 8.14 (d, J = 
8.5 Hz, 1H), 6.52 (d, J= 8.5 Hz, 1H), 6.58 (s, 1H) , 6.54 (s, 1H), 5.93 (m, 1H), 5.18 (d, J= 17.2 Hz, 1H), 5.04 
(d, J= 10.7 Hz, 1H), 4.27 (dd, J= 11.8 Hz, 5.9 Hz, 1H), 4.13 (dd, J = 12.0 Hz, 5.9 Hz, 1H), 3.79 (s, 3H), 3.67 
(s, 2H),  3.08 (m, J= 5.9 Hz, 1H), 2.96-2.91 (m, 2H), 2.87 (dd, J= 13.6 Hz, 3.5 Hz, 1H), 2.58 (d, J = 16.6 Hz, 
1H), 2.49-2.40 (m, 5H). 13C NMR (125 MHz, CDCl3): 152.1, 145.6, 142.9, 137.8, 134.5, 130.0, 128.5, 127.7, 
126.9, 127.7, 126.9, 117.2, 114.2, 113.5, 109.9, 73.4, 62.4, 55.8, 43.9, 35.2, 29.1 ppm. HREMIS m/z 
351.2065 [M+H]+ (calcd. for C22H26N2O2, 351.2067) 
 
3.1.9.14. 2-methoxy-6-methyl-1-(prop-2-yn-1-yloxy)-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-
10-amine (132e):  
87% yield. Brown foamy solid. Melting point: 86.2 oC-89.5 oC. 1H NMR (500 MHz, CDCl3): δ 8.22 (d, J = 8.4 
Hz, 1H), 6.64 (d, J= 8.5 Hz, 1H), 6.57 (s, 1H) , 6.54 (s, 1H), 4.50 (dd, J = 15 Hz, 0.4 Hz, 1H), 4.39 (dd, J = 
15 Hz, 0.4 Hz, 1H), 3.86(s, 3H), 3.75 (s, 2H), 3.17-3.10 (m, 1H), 3.09-2.94 (m, 4H), 2.66 (d, J = 16 Hz, 1H) 
, 2.56-2.47 (m, 5H), 2.38 (d, J=1.6 Hz, 1H). 13C NMR (125 MHz, CDCl3): δ 151.9, 145.7, 141.8, 138.0, 
129.8, 129.3, 127.8, 127.0, 122.5, 114.1, 113.6, 109.7, 79.4, 74.6, 62.3, 59.5, 55.8, 53.2, 44.0, 35.2, 29.2 
ppm. HREMIS m/z 335.1751 [M+H]+ (calcd. for C21H22N2O2, 335.1715) 
 
General Method for synthesis of compounds 128a – d:  
Compound 132(b-e) (1 equiv.) was dissolved in DCM (10 mL). Respective anhydride (2 equiv.) was added 
to the flask and resulting mixture was stirred for 2 h under nitrogen atmosphere. The reaction mixture was 
concentrated in-vacuo and solid NaOH (0.2 g) and methanol (10 mL) were added to the flask and stirred 
for 30 min. The reaction mixture was concentrated in-vacuo, dissolved in water, and extracted with DCM 
(3x10 mL). The combined organic layer was dried using anhydrous Na2SO4, filtered and concentrated in-
vacuo. The residue thus obtained was loaded onto a preparative TLC plate and eluted with 5% MeOH/DCM 
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45% yield. Yellow gum.  1H NMR (600 MHz, CDCl3): δ 8.23 (d, J= 8.6 Hz, 1H), 7.53 (m, 2H), 7.23 (dd, J= 
8.57 Hz, 1.8 Hz, 1H), 6.54 (s, 1H), 3.81 (s, 3H), 3.56 (s, 3H), 3.20-3.15 (m, 1H), 3.08-3.06 (m, 2H), 3.01 
(dd, J = 13.8 Hz, 3.9 Hz, 1H), 2.65-2.62 (m, 2H), 2.57-2.52 (m, 4H), 2.12 (s, 3H). 13C NMR (150 MHz, 
CDCl3): 167.5, 151.2, 143.9, 136.1, 135.8, 127.9, 127.1, 126.9, 125.5, 118.0, 117.2, 109.8, 61.0, 59.1, 54.8, 
52.0, 42.2, 33.6, 28.7, 27.4, 23.6 ppm. HREMIS m/z 353.1857 [M+H]+ (calcd for C21H24N2O3, 353.1820) 
 
3.1.9.16. N-(1-(cyclopropylmethoxy)-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-
dibenzo[de,g]quinolin-10-yl)acetamide (132b).    
48% yield. Dark yellow oil. 1H NMR (600 MHz, CDCl3): δ 8.29 (d, J = 8.6 Hz, 1H), 7.62 – 7.51 (m, 1H), 7.45 
(s, 1H), 7.20 (d, J = 8.4 Hz, 1H), 6.45 (s, 1H), 3.72 (s, 3H), 3.55 (m, 1H), 3.25 (m, 1H), 3.18 – 3.07 (m, 2H), 
3.07 – 2.99 (m, 1H), 2.98 – 2.91 (m, 1H), 2.64 – 2.52 (m, 3H), 2.48 (s, 3H), 2.05 (s, 3H), 0.98 (m, 1H), 0.34 
– 0.27 (m, 2H), 0.03 – -0.07 (m, 2H) ppm.13C NMR (125 MHz, CDCl3): δ 168.3, 152.4, 143.9, 136.9, 136.9, 
129.6, 128.4, 128.4, 128.0, 127.1, 118.9, 117.8, 110.8, 77.8, 62.2, 55.8, 53.2, 43.4, 34.8, 29.7, 24.8, 11.0, 
3.4, 3.1 ppm ppm. HREMIS m/z 393.2179 [M+H]+ (calcd. for C24H28N2O3, 393.2170) 
 
3.1.9.17. N-(1-(allyloxy)-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-
yl)acetamide (128c):  
53% yield.  Yellow gum.  1H NMR (600 MHz, CDCl3): δ 8.27 (d, J = 8.6 Hz, 1H, Ar-H), 7.58 (s, 1H, Ar-H), 
7.30 (s, 1H, NH), 7.16 (d, J= 8.5 Hz, 1H, Ar-H), 6.53 (s, 1H, Ar-H), 5.91-5.85 (m, 1H, CH), 5.16 (dd, J= 17.2 
Hz, 1.38 Hz, 1H, CH), 5.05 (d, J= 10.4 Hz, 1H, CH), 4.28 (q, J = 5.85 Hz, 1H, CH), 4.09 (q, J= 5.90 Hz, 1H, 
CH), 3.79 ( s, 3H, CH3), 3.16 (m, 1H, CH), 3.07-3.01 (m, 3H, (CH2, CH)), 2.65-2.60 (m, 2H, 2-CH), 2.53 
(merged, 4H, (CH, CH3)), 2.13 (s, 3H, CH3). 13C NMR (150 MHz, CDCl3): 168.4, 152.3, 143.5, 137.0, 134.2, 
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129.4, 128.1, 127.0, 119.0, 117.8, 117.6, 110.8, 73.7, 62.1, 55.9, 53.1, 43.4, 34.7, 28.5, 24.7 ppm. HREMIS 
m/z 379.2012 [M+H]+ (calcd. for C23H26N2O3, 379.1977)  
 
3.1.9.18. N-(2-methoxy-6-methyl-1-(prop-2-yn-1-yloxy)-5,6,6a,7-tetrahydro-4H-
dibenzo[de,g]quinolin-10-yl)acetamide (128d):  
59% yield. Yellow gum. 1H NMR (600 MHz, CDCl3): δ 8.27 (d, J= 8.6Hz, 1H, Ar-H), 7.63 (s, 1H, Ar-H), 7.26 
(s, 1H, NH), 7.14 (m, J=8.5 Hz,1H, Ar-H), 6.54 (s, 1H, Ar-H), 4.45 (dd,  J = 15.1 Hz, 2.3 Hz, 1H, CH), 4.33 
(dd, J = 15.1hz, 2.3 Hz, 1H, CH), 3.80 (s, 3H, CH3), 3.12-3.07 (m, 1H, CH), 3.03-3.00 (m, 3H, CH2, CH), 
2.61 (dd, J = 16.3 Hz, 2.9Hz, 1H,CH), 2.53 (t, J= 13.53 Hz, 1H, CH), 2.47-2.43 (m, 4H, (CH, CH3)), 2.27 (t, 
1H, J = 2.4 Hz), 2.13 (s, 3H, CH3). 13C NMR: (150 MHz, CDCl3): 168.3, 152.0, 142.3, 137.6, 137.0, 129.4, 
129.4, 128.2, 127.3, 127.3, 118.9, 117.8, 110.9, 79.2, 74.9, 62.1, 59.8, 55.9, 53.2, 43.9, 35.1, 29.1, 24.8.  
HRESIMS m/z 377.1856 [M+H]+ (calcd. for C23H24N2O3, 377.1820)    
 
3.1.9.19. N-(1,2-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-
yl)butyramide (129a)  
37% yield. Yellow oil. 1H NMR (600 MHz, CDCl3): δ 8.25 (d, J = 8.6 Hz, 1H), 7.66 (s, 1H), 7.28 (s, 1H), 7.18 
– 7.13 (m, 1H), 6.54 (s, 1H), 3.81 (s, 3H), 3.56 (s, 3H), 3.12 – 3.05 (m, 1H), 3.02 (m, 1H), 2.99 – 2.92 (m, 
2H), 2.61 (m, 1H), 2.54 (m, 1H), 2.48 – 2.41 (m, 4H), 2.29 (t, J = 7.4 Hz, 2H), 1.74 – 1.67 (m, 2H), 0.95 (t, 
J = 7.4 Hz, 3H) ppm. 13C NMR (150 MHz, CDCl3): δ 171.4, 152.0, 144.8, 137.6, 136.9, 128.9, 128.8, 128.1, 
127.5, 126.6, 119.0, 117.9, 110.8, 62.2, 60.2, 55.8, 53.3, 44.0, 39.8, 35.2, 29.2, 19.2, 13.8 ppm. HRESIMS 
m/z 381.2173 [M+H]+ (calcd. for C23H28N2O3, 381.2177) 
 
3.1.9.20. N-(1-(cyclopropylmethoxy)-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-
dibenzo[de,g]quinolin-10-yl)butyramide (129b)   
40% yield. White solid. Melting point: 89.1 oC – 90.1 oC. 1H NMR (500 MHz, CDCl3): δ 8.31 (d, J = 8.6 Hz, 
1H), 7.57 (s, 1H), 7.20 (s, 1H), 7.11 (dd, J = 8.5, 1.8 Hz, 1H), 6.46 (s, 1H), 3.72 (s, 3H), 3.56 (m, 1H), 3.25 
(m, 1H), 3.08 – 2.98 (m, 1H), 2.98 – 2.87 (m, 3H), 2.55 (m, 1H), 2.48 (m, 1H), 2.43 – 2.36 (m, 4H), 2.23 (t, 
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J = 7.4 Hz, 2H), 1.65 (m, 2H), 1.03 – 0.94 (m, 1H), 0.89 (t, J = 7.4 Hz, 3H), 0.30 (m, 2H), -0.02 (m, 2H) 
ppm. 13C NMR (125 MHz, CDCl3): δ 171.4, 152.1, 143.7, 137.4, 136.8, 129.6, 128.5, 128.4, 127.2, 127.1, 
118.9, 117.6, 110.8, 77.8, 62.2, 55.8, 53.3, 43.9, 39.8, 35.2, 29.1, 19.1, 13.8, 11.0, 3.4, 3.0 ppm. HRESIMS 
m/z 421.2490. [M+H]+ (calcd. for C26H33N2O3, 421.2486) 
 
3.1.9.21. N-(1-(allyloxy)-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-
yl)butyramide (129c)   
55% yield. Brown solid. Melting point: 99.1 oC – 99.6 oC. 1H NMR (500 MHz, CDCl3): δ 8.27 (d, J = 8.5 Hz, 
1H), 7.65 (s, 1H), 7.18-7.10 (m, 2H), 6.53 (s, 1H), 5.88 (m, 1H), 5.16 (m, 1H), 5.05 (m, 1H), 4.28 (m, 1H), 
4.09 (m, 1H), 3.79 (s, 3H), 3.10 (s, 1H), 3.05 – 2.93 (m, 3H), 2.61 (m, 1H), 2.54 (m, 1H), 2.45 (m, 4H), 2.29 
(t, J = 7.4 Hz, 2H), 1.71 (m, 2H), 0.95 (t, J = 7.4 Hz, 3H) ppm. 13C NMR (150 MHz, CDCl3) δ 171.3, 152.1, 
143.3, 137.5, 136.9, 134.2, 129.3, 128.7, 128.7, 128.2, 127.0, 118.9, 117.6, 117.5, 110.8, 73.7, 62.2, 55.9, 




dibenzo[de,g]quinolin-10-yl)butyramide (129d)  
52% yield. Yellow oil. 1H NMR (500 MHz, CDCl3): δ 8.27 (d, J = 8.6 Hz, 1H), 7.67 (s, 1H), 7.19 (s, 1H), 7.14 
(d, J = 8.5 Hz, 1H), 6.54 (s, 1H), 4.46 (dd, J = 15.0, 2.3 Hz, 1H), 4.33 (dd, J = 15.0, 2.4 Hz, 1H), 3.80 (s, 
3H), 3.16 – 3.06 (m, 1H), 3.05 – 2.95 (m, 3H), 2.62 (m, 1H), 2.55 (m, 1H), 2.51 – 2.43 (m, 4H), 2.31 – 2.25 
(m, 3H), 1.72 (m, 2H), 0.95 (t, J = 7.4 Hz, 3H) ppm. 13C NMR (125 MHz, CDCl3): δ 171.3, 152.0, 142.3, 
137.5, 137.1, 129.4, 128.0, 127.3, 127.2, 118.9, 117.8, 110.9, 79.2, 74.9, 62.1, 59.6, 55.9, 53.2, 43.8, 39.8, 
35.1, 29.0, 19.1, 13.8 ppm. HRESIMS m/z 405.2173   [M+H]+ (calcd. for C25H28N2O3, 405.2177) 
 
General procedure for preparation of methanesulfonamide analogs:  
To a stirred solution of corresponding aniline (0.1 mmol) in DCM (10 mL), methanesulfonic anhydride (0.25 
mmol) and triethylamine (0.3 mmol) were added. The resulting mixture was stirred at rt for 12h under 
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nitrogen atmosphere. After completion of the reaction, the reaction mixture was concentrated in-vacuo and 
a solution of NaOH (0.2 g) in methanol (10 mL) was added to the flask and stirring was continued for another 
30 min. The reaction mixture was concentrated in-vacuo, dissolved in water, and extracted with DCM (3x10 
mL). The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated in-vacuo. The crude 
product thus obtained was purified using preparative TLC eluting in 5% MeOH/DCM to give respective 




45% yield. Off-white solid. Melting point: 153.0 oC – 154.6 oC. 1H NMR (600 MHz, CDCl3): δ 8.26 (d, J = 
8.5 Hz, 1H), 7.09 (s, 1H), 7.05 – 7.02 (m, 1H), 6.55 (s, 1H), 3.80 (s, 3H), 3.59 (s, 3H), 3.13 – 3.04 (m, 1H), 
3.03 – 2.93 (m, 6H), 2.64 – 2.59 (m, 1H), 2.52 (m, 1H), 2.48 – 2.41 (m, 4H) ppm. 13C NMR (150 MHz, 
CDCl3): δ 152.0, 144.9, 138.3, 135.6, 129.7, 129.3, 128.8, 127.3, 126.1, 119.6, 118.7, 111.3, 62.0, 60.2, 
55.8, 53.2, 43.9, 39.6, 35.1, 29.1 ppm. HRESIMS m/z 389.1529 [M+H]+ (calcd. for C20H25N2O4S, 389.4895) 
 
3.1.9.24. N-(1-(cyclopropylmethoxy)-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-
dibenzo[de,g]quinolin-10-yl)methanesulfonamide (130b)  
46% yield. Brown solid. Melting point: 140.3 oC – 141.5 oC.   1H NMR (500 MHz, CDCl3): δ 8.41 (d, J = 8.5 
Hz, 1H), 7.18 (s, 1H), 7.08 (s, 1H), 7.03 (d, J = 7.0 Hz, 1H), 6.53 (s, 1H), 3.78 (s, 3H), 3.63 (m, 1H), 3.34 
(m, 1H), 3.16 – 3.06 (m, 2H), 3.06 – 2.97 (m, 5H), 2.63 (m, 2H), 2.58 – 2.44 (m, 4H), 1.08 – 0.99 (m, 1H), 
0.37 (d, J = 8.1 Hz, 2H), 0.10 – -0.03 (m, 2H) ppm. 13C NMR (125 MHz, CDCl3) δ 152.2, 143.8, 137.9, 
135.4, 130.4, 129.7, 128.7, 128.1, 126.6, 119.4, 118.4, 111.1, 77.9, 62.0, 55.8, 53.5, 53.2, 39.6, 35.0, 11.0, 





yl)methanesulfonamide (130c)  
33% yield. Light-yellow oil. 1H NMR (500 MHz, CDCl3): δ 8.30 (d, J = 8.5 Hz, 1H), 7.10 (d, J = 2.0 Hz, 1H), 
7.01 (dd, J = 8.5, 2.3 Hz, 1H), 6.55 (s, 1H), 5.88 (ddt, J = 16.4, 10.4, 5.9 Hz, 1H), 5.17 (dd, J = 17.2, 1.5 
Hz, 1H), 5.06 (dd, J = 10.4, 1.2 Hz, 1H), 4.31 (dd, J = 12.0, 5.9 Hz, 1H), 4.12 (dd, J = 12.0, 5.9 Hz, 1H), 
3.80 (s, 3H), 3.14 – 3.07 (m, 1H), 3.07 – 2.95 (m, 6H), 2.63 (dd, J = 16.3, 3.1 Hz, 1H), 2.55 – 2.44 (m, 4H) 
ppm. 13C NMR (125 MHz, CDCl3): δ 152.2, 143.5, 138.2, 135.5, 134.2, 130.1, 129.4, 128.8, 127.1, 126.5, 
119.4, 118.4, 117.6, 111.3, 73.8, 62.0, 55.9, 53.2, 43.8, 39.6, 35.0, 29.0 ppm. HRESIMS m/z 415.1690 
[M+H]+ (calcd. for C22H26N2O4S, 415.1686) 
 
3.1.9.26. N-(2-methoxy-6-methyl-1-(prop-2-yn-1-yloxy)-5,6,6a,7-tetrahydro-4H-
dibenzo[de,g]quinolin-10-yl)methanesulfonamide (130d)  
33% yield. Yellow oil.  1H NMR (500 MHz, CDCl3): δ 8.29 (d, J = 8.5 Hz, 1H), 7.10 (d, J = 1.9 Hz, 1H), 7.05 
(dd, J = 8.5, 2.2 Hz, 1H), 6.55 (s, 1H), 4.50 (m, 1H), 4.37 (m, 1H), 3.80 (s, 3H), 3.12 – 3.04 (m, 1H), 3.02 – 
2.92 (m, 6H), 2.62 (m, 1H), 2.49 (m, 5H), 2.26 (t, J = 2.4 Hz, 1H) ppm. 13C NMR (125 MHz, CDCl3): δ 152.0, 
142.3, 138.3, 135.7, 130.1, 129.6, 129.3, 127.4, 126.9, 119.5, 118.7, 111.2, 79.1, 75.01, 62.0, 59.8, 55.9, 
53.2, 44.0, 39.5, 35.1, 29.1 ppm. HRESIMS m/z 413.1532 [M+H]+ (calcd. for C22H24N2O4S, 413.1530) 
 
General procedure for synthesis of N,N-dimethylated analogs:   
To a stirred solution of the corresponding aniline (0.1 mmol) in DCM (10 mL) was added formaldehyde 
(37% aqueous solution, 5 μL, 0.1 mmol) and the reaction mixture was stirred at room temperature for 1h.   
NaBH(OAc)3 (200 mg, 1 mmol) was added and the resulting reaction mixture was stirred at rt for 12h.  After 
completion of the reaction (monitored by TLC) the reaction mixture was quenched with saturated sodium 
bicarbonate solution and extracted with DCM (3x15 mL). The combined organic layer was dried over 
Na2SO4, filtered, and concentrated in-vacuo. The residue thus obtained was purified using preparative TLC 






30% yield. Light purple solid. Melting point: 150.1 oC – 150.9 oC.  1H NMR (600 MHz, CDCl3): δ 8.20 (d, J 
= 8.8 Hz, 1H), 6.62 (dd, J = 8.8, 2.7 Hz, 1H), 6.54 (d, J = 2.5 Hz, 1H), 6.46 (s, 1H), 3.80 (s, 3H), 3.58 (s, 
3H), 3.15 – 3.07 (m, 1H), 3.05 – 2.95 (m, d H), 2.94 (s, 6H), 2.65 – 2.57 (m, 2H), 2.50-2.52 (m, 4H) ppm. 
13C NMR (125 MHz, CDCl3): δ 152.0, 149.6, 144.2, 137.7, 129.4, 128.5, 127.5, 127.0, 120.6, 111.3, 110.9, 




dibenzo[de,g]quinolin-10-amine (131b)  
40% yield. Orange oil.   1H NMR (500 MHz, CDCl3): δ 8.24 (d, J = 8.8 Hz, 1H), 6.53 (dd, J = 8.8, 2.7 Hz, 
1H), 6.44 (d, J = 2.6 Hz, 1H), 6.35 (s, 1H), 3.69 (s, 3H), 3.48 (m, 1H), 3.27 (m, 1H), 3.03 – 2.96 (m, 1H), 
2.90 – 2.86 (m, 3H), 2.84 (s, 6H), 2.53 – 2.45 (m, 2H), 2.39 (s, 3H), 2.39 – 2.33 (m, 1H), 1.07 – 0.98 (m, 
1H), 0.34 – 0.27 (m, 2H), 0.03 – -0.04 (m, 2H) ppm. 13C NMR (150 MHz, CDCl3): δ 152.1, 149.5, 143.1, 
137.5, 129.9, 128.3, 127.9, 126.9, 121.0, 111.2, 110.7, 109.5, 77.4, 62.6, 55.8, 53.4, 44.0, 40.4, 35.9, 29.2, 
11.1, 3.3, 3.1 ppm. HRESIMS m/z 379.2378 [M+H]+ (calcd. for C24H31N2O2, 379.2380) 
 
3.1.9.29. 1-(allyloxy)-2-methoxy-N,N,6-trimethyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-
amine (131c)  
48% yield. Brown oil. 1H NMR (600 MHz, CDCl3): δ 8.22 (d, J = 8.8 Hz, 1H), 6.59 (dd, J = 8.8, 2.6 Hz, 1H), 
6.53 (d, J = 2.2 Hz, 1H), 6.45 (s, 1H), 5.94 (ddt, J = 10.7, 5.8 Hz, 1H), 5.19 (dd, J = 17.2, 1.4 Hz, 1H), 5.06 
(d, J = 10.4 Hz, 1H), 4.25 (dd, J = 12.0, 5.9 Hz, 1H), 4.14 (dd, J = 12.0, 5.7 Hz, 1H), 3.78 (s, 3H), 3.14 – 
3.06 (m, 1H), 3.03 – 2.95 (m, 3H), 2.92 (s, 6H), 2.58 – 2.62 (m, 2H), 2.48 (m, 4H) ppm. 13C NMR (150 MHz, 
CDCl3): δ 152.2, 149.6, 142.9, 137.4, 134.6, 129.7, 128.3, 127.9, 126.6, 120.7, 117.2, 111.3, 110.8, 109.6, 
73.4, 62.5, 55.8, 53.3, 43.8, 40.4, 35.7, 29.0 ppm. HRESIMS m/z 365.2222 [M+H]+ (calcd. for C23H29N2O2, 
365.2224) 
General procedure for synthesis of urea analogs: 
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To a magnetically stirred solution of amine (100 mg, 1 equiv.) in 10% acetic acid solution (10 mL) (v/v), a 
solution of KCN (2 equiv.) in water (5 mL) was added. The reaction was stirred at rt for 2h. After completion 
of the reaction (monitored by TLC), the reaction was quenched with saturated sodium bicarbonate and 
extracted with EtOAc (3x15 mL). The combined organic layer was dried over Na2SO4, filtered, concentrated 
under reduced pressure and the crude product thus obtained was purified using preparative TLC, eluting 




40 % yield. Brown solid. Melting point: 208 oC – 209 oC. 1H NMR (600 MHz, CDCl3): δ 8.15 (d, J = 8.5 Hz, 
1H), 7.53 (s, 1H), 7.22 (s, 1H), 7.13 (d, J = 8.3 Hz, 1H), 6.50 (s, 1H), 5.12 (bs, 2H), 3.77 (s, 3H), 3.53 (s, 
3H), 3.15 – 3.06 (m, 1H), 3.00 (m, 2H), 2.93 (m, 1H), 2.59 (m, 1H), 2.53 (m, 1H), 2.45 (m, 4H). 13C NMR 
(150 MHz, CDCl3): δ 156.8, 152.2, 144.8, 137.9, 137.1, 129.1, 128.3, 127.2, 126.6, 126.3, 119.5, 118.8, 





30 % yield. Brown oil.  1H NMR (600 MHz, CDCl3): δ 8.26 (d, J = 8.5 Hz, 1H), 8.22 (s, 1H), 7.28 – 7.22 (m, 
1H), 6.46 (s, 1H), 5.48 (bs, 2H), 3.75 (s, 3H), 3.57 – 3.52 (m, 1H), 3.34 – 3.28 (m, 1H), 3.22 – 3.08 (m, 3H), 
2.94 (m, 1H), 2.62 (m, 3H), 2.54 (s, 3H), 1.01 (m, 1H), 0.34 (d, J = 6.5 Hz, 2H), 0.07 – -0.04 (m, 2H) ppm. 
13C NMR (150 MHz, CDCl3): δ 157.1, 152.6, 143.7, 138.49, 136.1, 129.5, 128.6, 127.2, 126.6, 124.6, 118.7, 
118.0, 110.4, 77.8, 61.9, 55.8, 52.8, 42.4, 34.1, 27.7, 11.0, 3.4, 3.2 ppm. HRESIMS m/z 394.2123 [M+H]+ 





dibenzo[de,g]quinolin-10-yl)urea (132c):  
30 % yield. Light brown solid. Melting point: 172.4 – 172.8 oC.  1H NMR (600 MHz, Acetone-d6): δ 8.25 (d, 
J = 8.6 Hz, 1H), 8.09 (s, 1H), 7.55 (s, 1H), 7.32 (d, J = 8.3 Hz, 1H), 6.70 (s, 1H), 5.44 (bs, 2H), 4.60 (m, 
1H), 4.44 (m, 1H), 3.86 (s, 3H), 3.08 – 3.04 (m, 2H), 2.98 (m, 1H), 2.87 – 2.83 (m, 2H), 2.64 (m, 1H), 2.47 
(s, 3H), 2.41 (m, 2H) ppm. 13C NMR (150 MHz, Acetone-d6): δ 155.7, 152.1, 142.1, 139.9, 137.5, 129.6, 
128.9, 127.7, 127.4, 125.6, 117.3, 116.1, 110.8, 79.5, 75.3, 62.6, 59.6, 59.1, 55.3, 53.1, 43.4, 35.3 ppm. 
HRESIMS m/z 378.1819 [M+H]+ (calcd. for C22H24N3O3, 378.4515). 
 
General procedure for synthesis of formamide analogs:   
To a stirred solution of the corresponding aniline (0.2 mmol) in formic acid (10 mL) was refluxed for 2 h 
under nitrogen atmosphere. After completion of the reaction (monitored by TLC) the reaction mixture was 
concentrated in-vacuo and treated with saturated Na2CO3 solution and extracted with 3x10 mL of ethyl 
acetate. The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated in-vacuo to give 
crude product, which was purified by preparative TLC purification eluting in 5% MeOH/DCM. Formamide 




40 % Yield. Light yellow oil. 1H NMR (600 MHz, CDCl3) δ 8.71 (d, J = 11.4 Hz, 1H), 8.33 – 8.25 (m, 3H), 
7.99 (d, J = 11.2 Hz, 1H), 7.61 (s, 1H), 7.42 (s, 1H), 7.21 (d, J = 8.6 Hz, 1H), 6.96 (dd, J = 8.5, 1.7 Hz, 1H), 
6.92 (s, 1H), 6.56 (d, J = 9.7 Hz, 2H), 3.81 (d, J = 4.1 Hz, 6H), 3.58 (d, J = 11.0 Hz, 6H), 3.12 – 3.05 (m, 
2H), 3.02 (dd, J = 13.8, 3.8 Hz, 2H), 2.97 (dd, J = 16.6, 10.5 Hz, 4H), 2.61 (d, J = 16.2 Hz, 2H), 2.54 (t, J = 
13.3 Hz, 2H), 2.47 (d, J = 5.4 Hz, 6H), 2.43 (dt, J = 11.9, 3.9 Hz, 2H). 13C NMR (151 MHz, CDCl3) δ 162.2, 
159.0, 152.02, 152.0, 144.9, 138.4, 137.7, 135.8, 135.4, 129.8, 129.4, 129.1, 128.9, 128.8, 128.8, 127.5, 
127.3, 126.4, 126.1, 119.3, 118.1, 117.9, 116.9, 111.3, 111.1, 62.1, 62.1, 60.2, 60.2, 55.9, 55.9, 53.3, 44.0, 






35 % Yield. Brown oil.1H NMR (600 MHz, CDCl3) δ 8.71 (d, J = 11.4 Hz, 1H), 8.33 (d, J = 6.7 Hz, 2H), 8.30 
(d, J = 8.5 Hz, 1H), 7.81 (s, 1H), 7.65 (s, 1H), 7.35 (s, 1H), 7.19 (s, 1H), 6.97 (dd, J = 8.5, 1.7 Hz, 1H), 6.91 
(s, 1H), 6.56 (d, J = 9.7 Hz, 2H), 4.50 (m, 2H), 4.36 (m, 2H), 3.81 (d, J = 3.9 Hz, 6H), 3.09 (dd, J = 19.7, 
8.5 Hz, 2H), 3.05 – 3.00 (m, 2H), 3.00 – 2.93 (m, 4H), 2.63 (d, J = 16.3 Hz, 2H), 2.54 (t, J = 13.5 Hz, 2H), 
2.48 (d, J = 4.2 Hz, 6H), 2.45 (d, J = 11.9 Hz, 2H), 2.27 (dd, J = 4.3, 2.2 Hz, 2H). 13C NMR (150 MHz, 
CDCl3) δ 162.1, 158.9, 152.0, 142.3, 142.3, 138.4, 137.7, 135.9, 135.5, 130.3, 129.6, 129.5, 129.3, 128.8, 
127.4, 127.3, 127.2, 126.9, 119.2, 117.9, 117.8, 116.9, 111.2, 111.1, 79.1, 79.1, 75.0, 74.9, 62.1, 62.0, 
59.8, 59.8, 55.9, 53.2, 43.9, 35.1, 31.0, 29.1 ppm. HREMIS m/z 363.1702 [M+H]+ (calcd. for C22H23N2O3, 
363.1703) 
 
General procedure for synthesis of trifloroamide analogs:   
To a stirred solution of the corresponding aniline (0.2 mmol) in DCM (10 mL) was added the respective 
anhydride (0.4 mmol) and the resulting reaction mixture was stirred at rt for 2 h under nitrogen atmosphere. 
After completion of the reaction (monitored by TLC) the reaction mixture was concentrated in-vacuo and a 
solution of NaOH (0.2 g) in methanol (10 mL) was added and stirred for another 30 min at the same 
temperature. The reaction mixture was concentrated in-vacuo and the obtained crude mass was dissolved 
in water and extracted with DCM (3x10 mL). The organic layer was dried over anhydrous Na2SO4, filtered, 
and concentrated in-vacuo to give crude product, which was purified by preparative TLC purification eluting 




52 % Yield. Light yellow oil. 1H NMR (600 MHz, CDCl3) δ 8.31 (d, J = 8.6 Hz, 1H), 7.96 (s, 1H), 7.58 (s, 
1H), 7.30 (d, J = 8.5 Hz, 1H), 6.57 (s, 1H), 3.81 (s, 3H), 3.58 (s, 3H), 3.09 (dd, J = 19.9, 8.4 Hz, 1H), 3.03 
(dd, J = 14.0, 3.6 Hz, 1H), 2.99 – 2.92 (m, 2H), 2.61 (d, J = 15.7 Hz, 1H), 2.55 (t, J = 13.7 Hz, 1H), 2.46 (s, 
3H), 2.43 (dd, J = 11.9, 3.1 Hz, 1H). 13C NMR (150 MHz, CDCl3) δ (155.04-154.30), 152.0, 145.0, 138.0, 
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133.8, 130.4, 129.3, 128.9, 127.6, 126.0, 119.7, 118.7, 111.5, 62.0, 60.2, 55.9, 53.2, 44.0, 35.2, 29.2 ppm. 




46 % Yield. Orange oil. 1H NMR (500 MHz, CDCl3) δ 8.33 (d, J = 8.7 Hz, 2H), 7.55 (s, 1H), 7.34 (d, J = 8.5 
Hz, 1H), 6.57 (s, 1H), 5.88 (m, 1H), 5.18 (d, J = 17.2 Hz, 1H), 5.07 (d, J = 10.3 Hz, 1H), 4.33 (dd, J = 11.9, 
5.7 Hz, 1H), 4.07 (dd, J = 11.9, 5.7 Hz, 1H), 3.80 (s, 3H), 3.26 (dd, J = 30.5, 10.3 Hz, 3H), 3.04 (d, J = 13.6 
Hz, 1H), 2.69 (dd, J = 18.3, 13.0 Hz, 3H), 2.59 (s, 3H).  13C NMR (126 MHz, CDCl3) δ (155.2 - 154.34), 
152.6, 143.9, 136.8, 134.3, 134.0, 13.0, 129.7, 127.8, 126.6, 119.8, 119.2, 119.0, 117.7, 111.3, 73.8, 61.4, 




39 % Yield. Brown oil. 1H NMR (600 MHz, CDCl3) δ 8.35 (d, J = 8.5 Hz, 1H), 7.94 (s, 1H), 7.61 
(s, 1H), 7.29 (d, J = 8.2 Hz, 1H), 6.57 (s, 1H), 4.51 (d, J = 15.1 Hz, 1H), 4.35 (d, J = 15.1 Hz, 1H), 
3.81 (s, 3H), 3.13 – 3.05 (m, 1H), 3.03 (dd, J = 13.9, 2.7 Hz, 1H), 3.00 – 2.91 (m, 2H), 2.62 (d, J 
= 15.9 Hz, 1H), 2.54 (t, J = 13.7 Hz, 1H), 2.47 (s, 3H), 2.44 (d, J = 11.8 Hz, 1H), 2.25 (s, 1H). 13C 
NMR (150 MHz, CDCl3) δ (155.2-154.3), 152.0, 142.4, 138.0, 133.9, 130.4, 129.8, 129.7, 127.6, 
126.9, 119.6, 118.6, 111.4, 79.0, 75.0, 62.0, 59.8, 55.9, 53.2, 43.9, 35.1, 29.1 ppm. HREMIS m/z 
431.1578 [M+H]+ (calcd. for C23H22F3N2O3, 431.1577). 
 
General procedure for synthesis of amide analogs:   
To a stirred solution of the corresponding aniline (0.2 mmol) in DCM (10 mL) was added benzoic anhydride 
(0.4 mmol) and the resulting reaction mixture was stirred at rt for 12 h under nitrogen atmosphere. After 
completion of the reaction (monitored by TLC) the reaction mixture was treated with saturated Na2CO3 
129 
 
solution and extracted with DCM (3x10 mL). The organic layer was dried over anhydrous Na2SO4, filtered, 
and concentrated in-vacuo to give crude product, which was purified by preparative TLC purification eluting 
in 5% MeOH/DCM. 
3.1.9.38. N-(1,2-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-
yl)benzamide(135a): 
65 % Yield. Light yellow oil. 1H NMR (600 MHz, CDCl3) δ 8.27 (d, J = 8.6 Hz, 1H), 7.88 (s, 1H), 7.80 (d, J 
= 7.5 Hz, 2H), 7.73 (s, 1H), 7.46 (t, J = 7.4 Hz, 1H), 7.40 (t, J = 7.5 Hz, 2H), 7.30 (d, J = 8.5 Hz, 1H), 6.53 
(s, 1H), 3.79 (s, 3H), 3.56 (s, 3H), 3.10 – 3.05 (m, 1H), 3.03 (dd, J = 13.8, 3.9 Hz, 1H), 2.98 – 2.91 (m, 2H), 
2.62 – 2.57 (m, 1H), 2.54 (t, J = 13.7 Hz, 1H), 2.44 (s, 3H), 2.41 (dd, J = 11.9, 3.5 Hz, 1H). 13C NMR (150 
MHz, CDCl3) δ 165.8, 152.0, 144.9, 137.8, 136.9, 135.0, 131.9, 129.1, 128.9, 128.8, 128.6, 127.6, 127.1, 
127.1, 127.0, 126.5, 119.4, 118.4, 111.0, 62.2, 60.2, 55.9, 53.3, 44.0, 35.3, 29.2 ppm. HREMIS m/z 




37 % Yield. Yellow oil. 1H NMR (500 MHz, CDCl3) δ 8.35 (d, J = 8.6 Hz, 1H), 7.97 (s, 1H), 7.77 (d, J = 7.7 
Hz, 2H), 7.64 (s, 1H), 7.41 (d, J = 6.9 Hz, 1H), 7.37 – 7.30 (m, 3H), 6.44 (s, 1H), 3.71 (s, 3H), 3.56 (dd, J = 
9.9, 7.0 Hz, 1H), 3.25 (dd, J = 9.8, 7.6 Hz, 1H), 3.17 – 3.05 (m, 2H), 3.04 – 3.01 (m, 1H), 2.98 (dd, J = 13.9, 
3.6 Hz, 1H), 2.57 (dd, J = 28.1, 12.2 Hz, 3H), 2.47 (s, 3H), 0.99 (tt, J = 12.1, 7.5 Hz, 2H), 0.35 – 0.26 (m, 
2H), 0.03 – -0.05 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 164.7, 151.4, 142.9, 136.0, 135.7, 133.8, 130.9, 
128.6, 127.8, 127.8, 127.7, 127.5, 126.8, 126.1, 126.1, 118.3, 117.3, 109.8, 76.8, 61.0, 54.8, 52.0, 33.6, 




dibenzo[de,g]quinolin-10-yl)benzamide (135c):  
47 % Yield. Yellow oil.1H NMR (600 MHz, CDCl3) δ 8.34 (d, J = 8.5 Hz, 1H), 7.81 (t, J = 6.8 Hz, 4H), 7.50 
(t, J = 7.3 Hz, 1H), 7.44 (t, J = 7.5 Hz, 2H), 7.29 (d, J = 8.4 Hz, 1H), 6.55 (s, 1H), 4.49 (dd, J = 15.1, 2.1 Hz, 
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1H), 4.36 (dd, J = 15.0, 1.8 Hz, 1H), 3.81 (s, 3H), 3.14 – 3.09 (m, 1H), 3.07 (dd, J = 13.8, 3.8 Hz, 1H), 2.99 
(dd, J = 11.2, 5.4 Hz, 2H), 2.62 (d, J = 16.2 Hz, 1H), 2.57 (t, J = 13.6 Hz, 1H), 2.48 (s, 3H), 2.46 (d, J = 11.9 
Hz, 1H), 2.27 (d, J = 2.2 Hz, 1H). 13C NMR (150 MHz, CDCl3) δ 165.7, 152.0, 142.4, 137.7, 137.0, 135.0, 
131.9, 129.5, 129.48, 128.9, 128.9, 128.5, 127.4, 127.3, 127.0, 119.3, 118.2, 111.0, 79.2, 74.9, 62.2, 59.8, 
55.9, 53.2, 43.9, 35.21, 29.2 ppm. HREMIS m/z 455.2017 [M+H]+ (calcd. for C28H27N2O3, 439.2016). 
 
Synthesis of enatiomeric tetrahydroisoquinoline moiety 
To a stirring solution of dihydroisoquinoline (5.1 g), ruthenium catalyst in degassed DMF (25 ml) at 0oC, a 
mixture of HCOOH and Et3N (5:2; 15 mL) was added.   The reaction mixture was stirred at room temperature 
for 2h. The reaction was worked up by addition of saturated NaCO3 solution (until basic), diluted with cold 
water (50 mL) and extracted with ethyl acetate. The combined organic fraction was treated with Na2SO4 
and concentrated in-vacuo to obtain crude amine. This product was used without further purification. The 
chiral amine was -boc protected and purified via column chromatography to obtain pure (R)-122, 96% or 
(S)-122, 98%. Enantiomeric ratio was of (R)-122 and (S)-122 established by HPLC 
HPLC system: Agilent 1200 
Column: Chiralcel OD, 10mm, 4.6x250mm, 3,5 dimethylphenyl carbamate  
Mobile Phase A: Isopropanol 
Mobile Phase B: Hexane 
Runtime: 30 mins 
Method: Gradient, 0 to 10% A in 20 mins     
Further synthesis was followed as per method described for synthesis of aniline handle series 132, resulting 





1H NMR (500 MHz, CDCl3) δ 8.24 (d, J = 8.4 Hz, 1H), 6.66 (d, J = 8.5 Hz, 1H), 6.59 (s, 1H), 6.56 (s, 1H), 
4.52 (d, J = 14.9 Hz, 1H), 4.42 (d, J = 15.0 Hz, 1H), 3.88 (s, 3H), 3.76 (d, J = 20.6 Hz, 2H), 3.17 (dd, J = 
19.7, 8.6 Hz, 1H), 3.07 (dd, J = 11.2, 5.4 Hz, 2H), 2.99 (dd, J = 13.7, 3.4 Hz, 1H), 2.69 (d, J = 16.0 Hz, 1H), 
2.60 (d, J = 13.6 Hz, 1H), 2.56 (s, 3H), 2.52 (d, J = 3.7 Hz, 1H), 2.39 (d, J = 2.1 Hz, 1H). 13C NMR (126 
MHz, CDCl3) δ 152.0, 145.8, 141.9, 137.9, 129.9, 129.2, 127.9, 126.8, 122.5, 114.2, 113.7, 109.8, 79.4, 




1H NMR (500 MHz, CDCl3) δ 8.24 (d, J = 8.6 Hz, 1H), 7.73 (s, 1H), 7.57 (s, 1H), 7.16 (d, J = 8.5 Hz, 1H), 
6.51 (s, 1H), 5.86 (dq, J = 11.1, 5.8 Hz, 1H), 5.14 (d, J = 17.2 Hz, 1H), 5.03 (d, J = 10.4 Hz, 1H), 4.27 (dd, 
J = 12.0, 5.9 Hz, 1H), 4.08 (dd, J = 11.9, 5.8 Hz, 1H), 3.77 (s, 3H), 3.12 – 3.01 (m, 1H), 3.00 – 2.89 (m, 
3H), 2.59 (d, J = 14.5 Hz, 1H), 2.51 (t, J = 13.4 Hz, 1H), 2.44 (d, J = 14.0 Hz, 3H), 2.42 – 2.38 (m, 1H), 2.10 
(s, 3H). 13C NMR (126 MHz, CDCl3) δ 168.7, 152.1, 143.3, 137.4, 137.0, 134.2, 129.3, 128.8, 128.3, 127.4, 




1H NMR (500 MHz, CDCl3) δ 8.35 (d, J = 8.5 Hz, 1H), 7.73 (s, 1H), 7.50 (s, 1H), 7.24 (d, J = 8.5 Hz, 1H), 
6.61 (s, 1H), 5.97 (ddd, J = 22.6, 10.9, 5.7 Hz, 1H), 5.25 (d, J = 17.2 Hz, 1H), 5.13 (d, J = 10.4 Hz, 1H), 
4.36 (dd, J = 11.9, 5.8 Hz, 1H), 4.18 (dd, J = 11.9, 5.8 Hz, 1H), 3.87 (s, 3H), 3.22 – 3.13 (m, 1H), 3.12 – 
3.00 (m, 3H), 2.73 – 2.66 (m, 1H), 2.62 (t, J = 13.4 Hz, 1H), 2.54 (s, 3H), 2.53 – 2.48 (m, 1H), 2.37 (t, J = 
7.4 Hz, 2H), 1.84 – 1.74 (m, 2H), 1.03 (t, J = 7.4 Hz, 3H).13C NMR (126 MHz, CDCl3) δ 171.5, 152.1, 143.3, 
137.4, 137.0, 134.2, 129.3, 128.7, 128.2, 127.3, 127.0, 119.0, 117.7, 117.4, 110.8, 73.7, 62.2, 55.9, 53.3, 






1H NMR (500 MHz, CDCl3) δ 8.25 (d, J = 8.5 Hz, 1H), 7.60 (s, 1H), 7.52 (s, 1H), 7.16 (d, J = 8.5 Hz, 1H), 
6.53 (s, 1H), 4.45 (d, J = 15.1 Hz, 1H), 4.33 (d, J = 15.1 Hz, 1H), 3.79 (s, 3H), 3.13 – 3.03 (m, 1H), 2.98 (dt, 
J = 19.7, 8.3 Hz, 3H), 2.60 (d, J = 16.2 Hz, 1H), 2.52 (t, J = 13.4 Hz, 1H), 2.45 (s, 3H), 2.42 (s, 1H), 2.26 
(s, 1H), 2.12 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 168.6, 152.0, 142.3, 137.4, 137.1, 129.4, 129.3, 128.1, 




1H NMR (500 MHz, MeOD) δ 8.51 (s, 1H), 7.30 (s, 1H), 6.74 (s, 1H), 4.59 – 4.53 (m, 1H), 4.40 (dd, J = 
15.2, 2.4 Hz, 1H), 3.87 (s, 3H), 3.25 – 3.19 (m, 3H), 3.16 (dd, J = 17.1, 5.2 Hz, 1H), 2.79 (d, J = 12.7 Hz, 
1H), 2.77 (t, J = 2.3 Hz, 1H), 2.76 – 2.71 (m, 1H), 2.69 (s, 3H), 2.63 (t, J = 14.5 Hz, 1H). 13C NMR (126 
MHz, MeOD) δ 170.8, 154.0, 152.5, 143.7, 135.1, 130.8, 129.8, 128.8, 126.8, 126.7, 122.3, 117.8, 111.9, 
80.1, 76.5, 63.7, 60.7, 56.3, 54.0, 43.3, 35.4, 29.0 ppm. 
 
 Biological Evaluation Process: 
 
All receptor binding assays were performed by the Psychoactive Drug Screening Program (PDSP).  
Complete details of the assays performed may be found online in the PDSP assay protocol book. 
(http://pdsp.med.unc.edu/PDSP%20Protocols%20II%202013-03-28.pdf). 
 
For primary binding assays, compounds were usually tested at a single concentration (10 µM) and in 
quadruplicate in 96-well plates. Compounds showing a minimum of 50% inhibition at 10 µM were tagged 
for secondary radioligand binding assays to determine equilibrium binding affinity at specific targets. In 
secondary binding assays, selected compounds are usually tested at 11 concentrations (0.1, 0.3, 1, 3, 10, 
30, 100, 300 nM, 1, 3, 10 µM) and in triplicate (3 sets of 96-well plates).  Both primary and secondary 
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radioligand binding assays were carried out in a final of volume of 125 μl per well in appropriate binding 
buffer. The hot ligand concentration was usually at a concentration close to the Kd (unless otherwise 
indicated). Total binding and nonspecific binding were determined in the absence and presence of 10 μM 
appropriate reference compound, respectively. In brief, plates were usually incubated at room temperature 
and in the dark for 90 min (unless otherwise indicated). Reactions were stopped by vacuum filtration onto 
0.3% polyethyleneimine (PEI) soaked 96-well filter mats using a 96-well Filtermate harvester, followed by 
three washes with cold wash buffer. Scintillation cocktail was then melted onto the microwave-dried filters 
on a hot plate and radioactivity was counted in a Microbeta counter.  
 
3.1.10.1. Microsomal Stability Determination: 
 
4 μL of working solutions was spiked to 796 μL of pre-incubated plasma to reach a final concentration of 5 
μM. The final concentration of solvent was 0.5%. 50 μL aliquots of the spiked plasma were added into new 
tubes for different time points including 15, 30, 60 and 120 minute and incubated at 37°C water bath with 
shaking at 60 rpm. The assay was performed in duplicate. The reaction was stopped by adding 300 μL of 
room temperature quench solution (acetonitrile containing internal standards (IS, 100 nM Alprazolam, 500 
nM Labetalol and 2 μM Ketoprofen)) to the spiked plasma samples at the appointed time points. Time 0 
samples were prepared by adding 50 μL of the spiked plasma to new tubes containing 300 μL of room 
temperature quench solution. Vortex for 5 minutes. Samples in plate were centrifuged at 3,220 g for 30 
minutes at 4°C to precipitate protein. 100 μL of the supernatant was transferred to a new plate. The 




A) APPENDIX: NMR SPECTRA 
 
 
Figure A.1: 1H NMR (600 MHz, CDCl3) of 2-(2-bromo-4-nitrophenyl)-N-phenethylacetamide (93)
 





Figure A.3: 1H NMR (600 MHz, CDCl3) of tert-butyl-1-(2-bromo-4-nitrobenzyl)-3,4-dihydroisoquinoline-
2(1H)-carboxylate (94) 
 





Figure A.5: 1H NMR (600 MHz, CDCl3) of tert-butyl-10-nitro-4,5,6a,7-tetrahydro-6H-
dibenzo[de,g]quinoline-6-carboxylate (95) 
   
 





Figure A.7: 1H NMR (600 MHz, CDCl3) of 10-nitro-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline (96) 
 
 














Figure A.11: 1H NMR (500 MHz, CDCl3) of 10-nitro-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline 
(97b) 
 










Figure A.14: 13C NMR (150 MHz, CDCl3) of 6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-




Figure A.15: 1H NMR (600 MHz, CDCl3) of 6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-
amine (98b)
 









Figure A.18: : 1H NMR (150 MHz, CDCl3) of  N-(6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-




Figure A.19: 1H NMR (600 MHz, CDCl3) of N-(6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-
yl)acetamide (99b) 
 





Figure A.21: 1H NMR (600 MHz, CDCl3) of N-(6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-
yl)butamide (100a) 
 






Figure A.23: 1H NMR (600 MHz, CDCl3) of N-(6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-
yl)butyramide (100b) 
 





Figure A.25: 1H NMR (500 MHz, CDCl3) of N-(6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-
yl)methanesulfonamide (101a) 
 





Figure A.27: 1H NMR (500 MHz, CDCl3) of N-(6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-
yl)methanesulfonamide (101b) 
 





Figure A.29: 1H NMR (500 MHz, CDCl3) of N,N,6-trimethyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-
10-amine (102a) 
 





Figure A.31: 1H NMR (500 MHz, CDCl3) of N,N-dimethyl-6-propyl-5,6,6a,7-tetrahydro-4H-
dibenzo[de,g]quinolin-10-amine (102b) 
 





Figure A.33: 1H NMR (500 MHz, CDCl3) of 1-(6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-
yl)urea (103a) 
 





Figure A.35: 1H NMR (500 MHz, CDCl3) of 1-(6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-
yl)urea (104b) 
 





Figure A.37: 1H NMR (600 MHz, CDCl3) of N-(6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-
yl)formamide (104a) 
 





Figure A.39: 1H NMR (600 MHz, CDCl3) of 2,2,2-trifluoro-N-(6-methyl-5,6,6a,7-tetrahydro-4H-
dibenzo[de,g]quinolin-10-yl)acetamide (105a) 
 





Figure A.41: 1H NMR (600 MHz, CDCl3) of 2,2,2-trifluoro-N-(6-propyl-5,6,6a,7-tetrahydro-4H-
dibenzo[de,g]quinolin-10-yl)acetamide (105b) 
 





Figure A.43: 1H NMR (600 MHz, CDCl3) of N-(6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-
yl)benzamide (106a)  
 
Figure A.44: :13C NMR (150 MHz, CDCl3)  of N-(6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-




Figure A.45:1H NMR (600 MHz, CDCl3) of N-(6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-
yl)benzamide (106b)  
 






Figure A.47: 1H NMR (500 MHz, CDCl3) of 7-methyl-6a,7,8,9-tetrahydro-6H-
benzo[de]thiazolo[4',5':5,6]benzo[1,2-g]quinolin-2-amine (107a) 
 





Figure A.49:1H NMR (500 MHz, CDCl3) of 7-propyl-6a,7,8,9-tetrahydro-6H-
benzo[de]thiazolo[4',5':5,6]benzo[1,2-g]quinolin-2-amine (107b) 
 





Figure A.51: 1H NMR (600 MHz, CDCl3) of 6-methyl-5,6,6a,7-tetrahydro-4H-
benzo[de]thiazolo[5',4':4,5]benzo[1,2-g]quinolin-10-amine (108a) 
 















Figure A.55: 1H NMR (500 MHz, CDCl3) of (R)-1-(6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-
10-yl)urea (R-103a)  
 






Figure A.57: 1H NMR (500 MHz, CDCl3) of (S)-1-(6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-
10-yl)urea (S-103a)  
 






Figure A.59: 1H NMR (500 MHz, CDCl3) of (R)-6-methyl-5,6,6a,7-tetrahydro-4H-
benzo[de]thiazolo[5',4':4,5]benzo[1,2-g]quinolin-10-amine (R-108a)  
 
 







Figure A.61: 1H NMR (500 MHz, CDCl3) of (S)-6-methyl-5,6,6a,7-tetrahydro-4H-
benzo[de]thiazolo[5',4':4,5]benzo[1,2-g]quinolin-10-amine (S-108a)  
 






Figure A.63: 1H NMR (500 MHz, CDCl3) of N-(6-methyl-9-nitro-5,6,6a,7-tetrahydro-4H-dibenzo[de,g] 
uinoline-10-yl)acetamide (112)  
 





Figure A.65: 1H NMR (500 MHz, CDCl3) of N-(6-methyl-11-nitro-5,6,6a,7-tetrahydro-4H-
dibenzo[de,g]quinolin-10-yl)acetamide (116)  
 





Figure A.67: 1H NMR (600 MHz, CDCl3) of 6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-9,10-
diamine (114)  
 






Figure A.69: 1H NMR (600 MHz, CDCl3) of N-(4-(benzyloxy)-3-methoxyphenethyl)-2-(2-bromo-4-
nitrophenyl)acetamide (121) 
 


















































































































































Figure A.99: 1H NMR (600 MHz, CDCl3) of N-(1-(cyclopropylmethoxy)-2-methoxy-6-methyl-5,6,6a,7-
tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)acetamide (128b)    
 
Figure A.100: 13C NMR (150 MHz, CDCl3) of N-(1-(cyclopropylmethoxy)-2-methoxy-6-methyl-5,6,6a,7-






















Figure A.105: 1H NMR (600 MHz, CDCl3) of N-(1,2-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-
dibenzo[de,g]quinolin-10-yl)butyramide (129a) 
 





Figure A.107: 1H NMR (500 MHz, CDCl3) of N-(1-(cyclopropylmethoxy)-2-methoxy-6-methyl-5,6,6a,7-
tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)butyramide (129b) 
 





Figure A.109:  1H NMR (500 MHz, CDCl3) of N-(1-(allyloxy)-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-
dibenzo[de,g]quinolin-10-yl)butyramide (129c)   
 
Figure A.110: 13C NMR (150 MHz, CDCl3) of N-(1-(allyloxy)-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-




Figure A.111: 1H NMR (500 MHz, CDCl3) of N-(2-methoxy-6-methyl-1-(prop-2-yn-1-yloxy)-5,6,6a,7-
tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)butyramide (129d) 
 





Figure A.113: 1H NMR (600 MHz, CDCl3) of N-(1,2-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-
dibenzo[de,g]quinolin-10-yl)methanesulfonamide (130a) 
 





Figure A.115: 1H NMR (500 MHz, CDCl3) of N-(1-(cyclopropylmethoxy)-2-methoxy-6-methyl-5,6,6a,7-
tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)methanesulfonamide (130b) 
 





Figure A.117: 1H NMR (500 MHz, CDCl3) of N-(1-(allyloxy)-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-
dibenzo[de,g]quinolin-10-yl)methanesulfonamide (130c) 
 





Figure A.119: 1H NMR (500 MHz, CDCl3) of N-(2-methoxy-6-methyl-1-(prop-2-yn-1-yloxy)-5,6,6a,7-
tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)methanesulfonamide (130d) 
 





Figure A.121: 1H NMR (600 MHz, CDCl3) of 1,2-dimethoxy-N,N,6-trimethyl-5,6,6a,7-tetrahydro-4H-
dibenzo[de,g]quinolin-10-amine (131a) 
 





Figure A.123: 1H NMR (500 MHz, CDCl3) of 1-(cyclopropylmethoxy)-2-methoxy-N,N,6-trimethyl-5,6,6a,7-
tetrahydro-4H-dibenzo[de,g]quinolin-10-amine (131b) 
 





Figure A.125: 1H NMR (600 MHz, CDCl3) of 1-(allyloxy)-2-methoxy-N,N,6-trimethyl-5,6,6a,7-tetrahydro-
4H-dibenzo[de,g]quinolin-10-amine (131c) 
 





Figure A.127: 1H NMR (600 MHz, CDCl3) of 1-(1,2-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-
dibenzo[de,g]quinolin-10-yl)urea (132a) 
 





Figure A.129: 1H NMR (600 MHz, CDCl3) of 1-(1-(cyclopropylmethoxy)-2-methoxy-6-methyl-5,6,6a,7-
tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)urea (132b) 
 





Figure A.131: 1H NMR (600 MHz, CDCl3) of 1-(2-methoxy-6-methyl-1-(prop-2-yn-1-yloxy)-5,6,6a,7-
tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)urea (132c) 
 





Figure A.133: 1H NMR (600 MHz, CDCl3) of N-(1,2-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-
dibenzo[de,g]quinolin-10-yl)formamide (133a) 
 





Figure A.135: 1H NMR (600 MHz, CDCl3) of N-(2-methoxy-6-methyl-1-(prop-2-yn-1-yloxy)-5,6,6a,7-
tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)formamide (133b)   
 
Figure A.136: 13C NMR (150 MHz, CDCl3)  of N-(2-methoxy-6-methyl-1-(prop-2-yn-1-yloxy)-5,6,6a,7-





Figure A.137: 1H NMR (600 MHz, CDCl3) of N-(1,2-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-
dibenzo[de,g]quinolin-10-yl)-2,2,2-trifluoroacetamide (134a) 
 





Figure A.139: 1H NMR (500 MHz, CDCl3) of N-(1-(allyloxy)-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-4H-
dibenzo[de,g]quinolin-10-yl)-2,2,2-trifluoroacetamide (134b) 
 





Figure A.141: 1H NMR (600 MHz, CDCl3) of 2,2,2-trifluoro-N-(2-methoxy-6-methyl-1-(prop-2-yn-1-yloxy)-
5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)acetamide (134c) 
 






Figure A.143: 1H NMR (600 MHz, CDCl3) of N-(1,2-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-
dibenzo[de,g]quinolin-10-yl)benzamide(135a) 
 






Figure A.145: 1H NMR (500 MHz, CDCl3) of N-(1-(cyclopropylmethoxy)-2-methoxy-6-methyl-5,6,6a,7-
tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)benzamide (135b)  
 
Figure A.146: 13C NMR (125 MHz, CDCl3)  of N-(1-(cyclopropylmethoxy)-2-methoxy-6-methyl-5,6,6a,7-




Figure A.147: 1H NMR (600 MHz, CDCl3) of N-(2-methoxy-6-methyl-1-(prop-2-yn-1-yloxy)-5,6,6a,7-
tetrahydro-4H-dibenzo[de,g]quinolin-10-yl)benzamide (135c)  
 
Figure A.148: 13C NMR (150 MHz, CDCl3) of N-(2-methoxy-6-methyl-1-(prop-2-yn-1-yloxy)-5,6,6a,7-





Figure A.149:1H NMR (500 MHz, CDCl3) of (S)-2-methoxy-6-methyl-1-(prop-2-yn-1-yloxy)-5,6,6a,7-
tetrahydro-4H-dibenzo[de,g]quinolin-10-amine ((S)-127d)  
 
 






Figure A.151: 1H NMR (500 MHz, CDCl3) of (S)-N-(1-(allyloxy)-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-
4H-dibenzo[de,g]quinolin-10-yl)acetamide ((S)-128c)  
 






Figure A.153:1H NMR (500 MHz, CDCl3) of (S)-N-(1-(allyloxy)-2-methoxy-6-methyl-5,6,6a,7-tetrahydro-
4H-dibenzo[de,g]quinolin-10-yl)butyramide ((S)-129c)  
 






























Figure A.159: Chromatogram of (S)- 94 
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